



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 22, 2022

Margaret M. Madden
Pfizer Inc.

Re: Pfizer Inc. (the "Company")
Incoming letter dated December 21, 2021

Dear Ms. Madden:

This letter is in response to your correspondence concerning the shareholder proposal (the "Proposal") submitted to the Company by Tara Health Foundation (the "Proponent") for inclusion in the Company's proxy materials for its upcoming annual meeting of security holders.

The Proposal requests that the Company publish an annual report analyzing the congruency of political, lobbying, and electioneering expenditures during the preceding year against publicly stated company values and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have led to a change in future expenditures or contributions.

There appears to be some basis for your view that the Company may exclude the Proposal under Rule 14a-8(i)(11). We also note that in the Proponent's view the Proposal is substantially duplicative of a previously submitted proposal that will be included in the Company's 2022 proxy materials. Accordingly, we will not recommend enforcement action to the Commission if the Company omits the Proposal from its proxy materials in reliance on Rule 14a-8(i)(11). In reaching this position, we have not found it necessary to address the alternative basis for omission upon which the Company relies.

Copies of all of the correspondence on which this response is based will be made available on our website at <https://www.sec.gov/corpfin/2021-2022-shareholder-proposals-no-action>.

Sincerely,

Rule 14a-8 Review Team

cc: Shelley Alpern
Rhia Ventures



Margaret M. Madden
Senior Vice President and Corporate Secretary
Chief Governance Counsel

Pfizer Inc. – Legal Division
235 East 42nd Street, New York, NY 10017
Tel 212 733 3451 Fax 646 563 9681
margaret.m.madden@pfizer.com

BY EMAIL (shareholderproposals@sec.gov)

December 21, 2021

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Chief Counsel
100 F Street, N.E.
Washington, D.C. 20549

RE: Pfizer Inc. – 2022 Annual Meeting
Omission of Shareholder Proposal of
Tara Health Foundation

Ladies and Gentlemen:

We are writing pursuant to Rule 14a-8(j) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to request that the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) concur with our view that, for the reasons stated below, Pfizer Inc., a Delaware corporation (“Pfizer”), may exclude the shareholder proposal and supporting statement (the “Proposal”) submitted by Tara Health Foundation (the “Proponent”) from the proxy materials to be distributed by Pfizer in connection with its 2022 annual meeting of shareholders (the “2022 proxy materials”).

In accordance with Section C of Staff Legal Bulletin No. 14D (Nov. 7, 2008) (“SLB 14D”), we are emailing this letter and its attachments to the Staff at shareholderproposals@sec.gov. In accordance with Rule 14a-8(j), we are simultaneously sending a copy of this letter and its attachments to the Proponent as notice of Pfizer’s intent to omit the Proposal from the 2022 proxy materials.

Rule 14a-8(k) and Section E of SLB 14D provide that shareholder proponents are required to send companies a copy of any correspondence that the shareholder proponents elect to submit to the Commission or the Staff. Accordingly, we are taking this opportunity to remind the Proponent that if the Proponent submits correspondence to the Commission or the Staff with respect to the Proposal, a copy of that correspondence should concurrently be furnished to the undersigned.

I. The Proposal

The text of the resolution contained in the Proposal is set forth below:

Shareholders request that Pfizer publish an annual report, at reasonable expense, analyzing the congruency of political, lobbying, and electioneering expenditures during the preceding year against publicly stated company values and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have led to a change in future expenditures or contributions.

II. Bases for Exclusion

We hereby respectfully request that the Staff concur with Pfizer's view that the Proposal may be excluded from the 2022 proxy materials pursuant to:

- Rule 14a-8(i)(10) because Pfizer has substantially implemented the Proposal; and
- Rule 14a-8(i)(11) because the Proposal substantially duplicates a shareholder proposal previously submitted to Pfizer that Pfizer intends to include in its 2022 proxy materials in the event that the Staff does not concur with the exclusion of the previously submitted proposal from Pfizer's 2022 proxy materials.

III. Background

Pfizer received an initial version of the Proposal via email on October 26, 2021, accompanied by a cover letter from the Proponent dated October 26, 2021, and a letter from Merrill Lynch, dated October 26, 2021, verifying the Proponent's continuous ownership of at least the requisite amount of Pfizer common stock for at least the requisite period preceding and including the date of submission of the Proposal. Pfizer received a revised version of the Proposal via email on November 8, 2021. Copies of the initial Proposal, cover letter and the revised Proposal are attached hereto as Exhibit A.

IV. The Proposal May be Excluded Pursuant to Rule 14a-8(i)(10) Because Pfizer Has Substantially Implemented the Proposal.

Rule 14a-8(i)(10) permits a company to exclude a shareholder proposal if the company has already substantially implemented the proposal. The Commission adopted the "substantially implemented" standard in 1983 after determining that the "previous formalistic application" of the rule defeated its purpose, which is to "avoid the possibility of shareholders having to consider matters which already have been favorably acted upon by the management." *See* Exchange Act Release No. 34-20091 (Aug. 16, 1983) (the "1983

Release”); Exchange Act Release No. 34-12598 (July 7, 1976). Accordingly, the actions requested by a proposal need not be “fully effected” provided that they have been “substantially implemented” by the company. *See* 1983 Release.

Applying this standard, the Staff has consistently permitted the exclusion of a proposal when it has determined that the company’s policies, practices and procedures or public disclosures compare favorably with the guidelines of the proposal. *See, e.g., Eli Lilly and Co.* (Feb. 26, 2021)*; *Devon Energy Corp.* (Apr. 1, 2020)*; *Johnson & Johnson* (Jan. 31, 2020)*; *Pfizer Inc.* (Jan. 31, 2020)*; *The Allstate Corp.* (Mar. 15, 2019); *Johnson & Johnson* (Feb. 6, 2019); *United Cont’l Holdings, Inc.* (Apr. 13, 2018); *eBay Inc.* (Mar. 29, 2018); *Kewaunee Scientific Corp.* (May 31, 2017); *Wal-Mart Stores, Inc.* (Mar. 16, 2017); *Dominion Resources, Inc.* (Feb. 9, 2016); *Ryder System, Inc.* (Feb. 11, 2015).

In addition, the Staff has permitted exclusion under Rule 14a-8(i)(10) where a company already addressed the underlying concerns and satisfied the essential objective of the proposal, even if the proposal had not been implemented exactly as proposed by the proponent. For example, in *PG&E Corp.* (Mar. 10, 2010), the Staff permitted exclusion under Rule 14a-8(i)(10) of a proposal requesting that the company provide a report disclosing, among other things, the company’s standards for choosing the organizations to which the company makes charitable contributions and specifically asked for disclosure of the “business rationale and purpose for each of the charitable contributions.” In arguing that the proposal had been substantially implemented, the company referred to a website where the company had described its policies and guidelines for determining the types of grants that it makes and the types of requests that the company typically does not fund. Although the proposal appeared to contemplate disclosure of each and every charitable contribution, the Staff concluded that the company had substantially implemented the proposal. *See also, e.g., The Wendy’s Co.* (Apr. 10, 2019) (permitting exclusion under Rule 14a-8(i)(10) of a proposal requesting a report assessing human rights risks of the company’s operations, including the principles and methodology used to make the assessment, the frequency of assessment and how the company would use the assessment’s results, where the company had a code of ethics and a code of conduct for suppliers and disclosed on its website the frequency and methodology of its human rights risk assessments); *MGM Resorts Int’l* (Feb. 28, 2012) (permitting exclusion under Rule 14a-8(i)(10) of a proposal requesting a report on the company’s sustainability policies and performance, including multiple objective statistical indicators, where the company published an annual sustainability report).

In particular, the Staff has permitted exclusion under Rule 14a-8(i)(10) where a company satisfied the essential objective of a proposal seeking disclosure relating to the company’s political expenditures even if the proposal had not been implemented exactly as proposed by the proponent. For example, in *Exelon Corp.* (Feb. 26, 2010), the Staff permitted exclusion under Rule 14a-8(i)(10) of a proposal requesting that the company prepare a report disclosing its policies and procedures for political contributions and its

* Citations marked with an asterisk indicate Staff decisions issued without a letter.

monetary and non-monetary political contributions. In arguing that the proposal had been substantially implemented, the company referenced its political contributions guidelines and report, which provided information regarding the company's political contributions policies and procedures and monetary and nonmonetary political contributions. Although the actions taken by the company may not have exactly aligned with the requests made by the proponent, the Staff concluded that the company had substantially implemented the proposal.

In this instance, Pfizer has substantially implemented the Proposal, the essential objective of which is to obtain a report from Pfizer on how its expenditures relating to its participation in the political process align with Pfizer's stated values and policies. In this respect, the Proposal's supporting statement explains that its request for disclosure is based on the view that "Pfizer's political expenditures appear to be misaligned with [Pfizer's] values and interests." As described below, Pfizer already publicly discloses how its expenditures relating to its participation in the political process – both to trade associations and to candidates and political committees – align with its stated values and policies.

In particular, Pfizer's website already contains extensive disclosure regarding Pfizer's support of trade associations. Specifically, Pfizer publishes on its "Political Partnership" webpage an Industry Associations – Report on Incongruencies (the "Congruency Report") that describes Pfizer's positions on important public policy matters and Pfizer's alignment with its "most significant trade association memberships" on each position.¹ The Congruency Report states that Pfizer "believe[s] that public policy engagement is an important and appropriate role for companies in open societies" and that "there is value in making sure [Pfizer's] positions on issues important to Pfizer and [its] industry are communicated and understood within those organizations."

In this respect, the Congruency Report includes the following summaries of Pfizer's alignment with its most significant trade association memberships, together with a detailed analysis of Pfizer's alignment with the associations "across six areas of key public policy and ESG significance for Pfizer: Climate Change; Patient Access to Healthcare; Trade; Tax; Diversity, Equity, and Inclusion; and Civic Integrity":

- **Biotechnology Innovation Organization.** "The policy goals of Pfizer and the Biotechnology Innovation Organization (BIO) are generally in alignment across the key areas reviewed. To the extent differences exist in the company and trade association's respective positions, such as on tax, they are largely because either Pfizer or BIO has taken a position on particular matters on which the other has not. Indeed, Pfizer has been more vocal than BIO on support of free trade, though both agree on the importance of intellectual property protections in trade agreements. On broad policy goals, Pfizer and BIO are well aligned. Pfizer engages with BIO on the following issues: (a) intellectual property/innovation protection; (b) vaccine policy

¹ See Pfizer's Industry Associations – Report on Incongruencies, available at <https://www.pfizer.com/about/programs-policies/political-partnerships> and attached hereto as Exhibit B.

and advocacy; (c) patient affordability solutions; and (d) FDA User Fee agreements (in partnership with PhRMA).”

- **Business Roundtable.** “The policy goals of Pfizer and the Business Roundtable (BRT) are generally in alignment across the key areas reviewed. To the extent there are differences in the company and trade association’s respective positions, they are because Pfizer and BRT are focusing on different specific aspects of the issue. However, on broad policy goals, Pfizer and BRT are well aligned. Pfizer engages with the BRT on the following issues: (a) U.S. tax competitiveness; (b) global tax debate; (c) free trade policies and intellectual property protection; (d) employer health care and health equity solutions; and (e) enhancing diversity and inclusion in the workforce.”
- **National Association of Manufacturers.** “The policy goals of Pfizer and the National Association of Manufacturers (NAM) are generally in alignment across the key areas reviewed. The alignment is less close in the areas of climate change and access to healthcare, largely because Pfizer and the NAM are focusing on different specific aspects of the issue. However, on broad policy goals, Pfizer and BRT are well aligned. Pfizer engages with NAM on the following issues: (a) high quality manufacturing; (b) international trade; and (c) to oppose governmental intervention in health care, including price controls in Medicare.”
- **Pharmaceutical Research and Manufacturers of America.** “Pfizer and Pharmaceutical Research and Manufacturers of America (PhRMA) are closely aligned on policy goals and specific positions. The only notable exception is in the area of climate change, where PhRMA has not taken a public position. Pfizer engages with PhRMA on the following issues: (a) lead industry efforts to advance pro-patient policies and defeat negative drug pricing proposals at the federal level; (b) advance rebate pass-through, copay accumulator bans and out of pocket caps at state level; (c) protect intellectual property rights globally; and (d) advance FDA User Fee agreements (in partnership with BIO).”
- **U.S. Chamber of Commerce.** “The policy goals of Pfizer and the U.S. Chamber of Commerce (Chamber) are generally in alignment across the key areas reviewed. To the extent there are differences in the company and trade association’s respective positions, they are generally because Pfizer and Chamber are focusing on different specific aspects of the issue. However, on broad policy goals, they are well aligned. Pfizer engages with the Chamber on the following issues: (a) promote and protect intellectual property/innovation through Global Innovation Policy Center; (b) drive narrative on counterfeits/product integrity; (c) lead on U.S. tax competitiveness; and (d) protect employer health care and drive policies to promote competition in health care.”

In explaining how Pfizer aligns its trade association memberships with Pfizer's stated values and policies, the Congruency Report notes that "support of these organizations is evaluated annually by [Pfizer's] U.S. Government Relations leaders based on these organizations' expertise in healthcare policy and advocacy and support of key issues of importance to Pfizer." The Congruency Report also notes that Pfizer "monitor[s] where and to what extent [Pfizer's] trade associations are misaligned" with Pfizer on issues important to Pfizer and "will advocate for the trade association to come into alignment, but if an organization's misalignment is egregious, and the membership benefits to Pfizer and its stakeholders are outweighed by the misalignments, [Pfizer] will reduce or end [its] involvement with the organization."

In addition, Pfizer publishes on its website an annual report titled the Pfizer PAC and Corporate Contributions Report (the "Political Contributions Report"), which lists the candidates and political committees supported by either Pfizer Inc. or the Pfizer political action committee (the "Pfizer PAC") and clearly explains Pfizer's rationale and motivation for making such political expenditures.² In this regard, the Political Contributions Report indicates that the driving force behind Pfizer's political and electioneering expenditures is to "support candidates of both political parties who support policies that impact [Pfizer's] purpose: Breakthroughs that change patients' lives." Pfizer also explains in the Political Contributions Report how its political and electioneering expenditures align with Pfizer's policy priorities, stating that in making the "decision to contribute to any elected official," Pfizer's "policy priorities include improving patient affordability and access, defending against threats to [Pfizer's] patents and intellectual property, protecting patients from dangerous insurance barriers and counterfeit medicines, ensuring patients continue to have robust access to innovative medicines in Medicare Part D and keeping an eye on burdensome tax policies." The Political Contributions Report, therefore, clearly describes the manner in which Pfizer's political expenditures are aligned with its stated values and policies.

Moreover, the Political Contributions Report acknowledges that politicians will have a range of views about policy that are both related and unrelated to Pfizer's business. While the Political Contributions Report identifies recipients of contributions who hold a diversity of political positions, it clearly states that contributions made to such recipients "[do] not imply an endorsement of a candidate's position on any social or religious issue." Instead of focusing on candidates' political views concerning matters unrelated to Pfizer's business, the Political Contributions Report states that Pfizer's "decision to contribute to any elected official is made based on ethical, responsible, and just policies that protect innovation incentives and patients' access to breakthrough medicines and vaccines."

The Political Contributions Report also describes Pfizer's corporate policy requiring "all PAC and corporate political contributions to be compiled and published annually in a

² See Pfizer's PAC and Corporate Political Contributions Report, available at https://cdn.pfizer.com/pfizercom/investors/corporate/2019-2020_Pfizer_PAC_and_Corporate_Political_Contributions_Report.pdf and attached hereto as Exhibit C.

report that is made available to employees, shareholders, and the public, and posted on [Pfizer's] website." In addition, the Political Contributions Report describes that Pfizer requests trade associations receiving \$100,000 or more from Pfizer in a given year to report to Pfizer the portion of Pfizer dues or payments used for certain non-deductible expenditures, which amounts Pfizer discloses in the Political Contributions Report. Further, the Political Contributions Report describes the PAC Steering Committee's process of "evaluat[ing] candidates on a basis of their views on the issues that impact Pfizer and its colleagues." In addition, the Political Contributions Report describes that Pfizer traditionally does not make contributions to 527 Issue Organizations and that to the extent Pfizer does make those expenditures, such expenditures "would have to be reviewed and approved by the Political Contributions Policy Committee and subsequently disclosed." The Political Contributions Report also notes that Pfizer "has determined that it will not make any direct independent expenditures."

Given the extensive disclosure in the Congruency Report and the Political Contributions Report, Pfizer has publicly disclosed how its expenditures relating to its participation in the political process align with its stated values and policies. Therefore, Pfizer has satisfied the Proposal's essential objective – obtaining a report from Pfizer on how its expenditures relating to its participation in the political process align with Pfizer's stated values and policies – and thus its public disclosures compare favorably with those requested by the Proposal.

Accordingly, Pfizer believes that the Proposal may be excluded from its 2022 proxy materials pursuant to Rule 14a-8(i)(10) as substantially implemented.

V. The Proposal May be Excluded Pursuant to Rule 14a-8(i)(11) Because the Proposal Substantially Duplicates Another Proposal Previously Submitted to Pfizer.

Under Rule 14a-8(i)(11), a company may exclude a shareholder proposal if it substantially duplicates another proposal previously submitted to the company by another proponent that will be included in the company's proxy materials for the same meeting. The Commission has stated that the purpose of Rule 14a-8(i)(11) is to eliminate the possibility of shareholders having to consider two or more substantially identical proposals submitted by proponents acting independently of each other. *See* Securities Exchange Act Release No. 34-12598 (July 7, 1976).

Two shareholder proposals need not be identical in order to provide a basis for exclusion under Rule 14a-8(i)(11). Proposals are substantially duplicative when the principal thrust or focus is substantially the same, even though the proposals differ in terms of the breadth and scope of the subject matter. In *Duke Energy Corp.* (Feb. 19, 2016), for example, the Staff granted the company's request to exclude a proposal asking the board to initiate a review of the organizations of which the company was a member or otherwise supported that may engage in lobbying activities and to provide a related report to shareholders. In that proposal, the supporting statement described the benefits received by the company from

limited government and relationships with pro-growth groups. In its no-action request, the company explained that the proposal shared the same principal thrust or focus as a previously-submitted proposal requesting a report on the company's direct and indirect lobbying activities, including grassroots lobbying activities, even though, unlike the other supporting statement, the previously-submitted proposal's supporting statement described the need for transparency and accountability concerning the company's role in influencing legislation and the use of corporate funds for lobbying activities. *See also, e.g., Exxon Mobil Corp.* (Mar. 13, 2020) (proposal requesting a report on how the company's lobbying activities align with the Paris Climate Agreement's goal may be excluded under Rule 14a-8(i)(11) because the proposal shared the same principal thrust or focus as a previously-submitted proposal seeking disclosure of lobbying expenditures that was broader in scope); *Danaher Corp.* (Jan. 19, 2017) (proposal to adopt goals for reducing greenhouse gas emissions, with a supporting statement describing four different reasons to do so, including a moral obligation, may be excluded under Rule 14a-8(i)(11) because the proposal shared the same principal thrust or focus as a previously-submitted proposal with a supporting statement describing the risks and opportunities provided by climate change); *Pfizer Inc.* (Feb. 17, 2012) (proposal requesting a lobbying priorities report, with a supporting statement describing the company's role in the passage of "ObamaCare," may be excluded under Rule 14a-8(i)(11) because the proposal shared the same principal thrust or focus as a previously-submitted proposal with a supporting statement calling for greater transparency of the company's lobbying expenditures).

Pfizer received a proposal (the "Prior Proposal") from the National Center for Public Policy Research, sent via FedEx, on September 3, 2021. A copy of the Prior Proposal is attached hereto as Exhibit D. Pfizer believes that the Proposal substantially duplicates the Prior Proposal and, as such, the Proposal may be excluded pursuant to Rule 14a-8(i)(11).

The text of the resolution contained in the Prior Proposal is set forth below:

Resolved: Pfizer publish an annual report, at reasonable expense, analyzing the congruency of political and electioneering expenditures during the preceding year against the company's fundamental purpose and publicly stated company values and policies.

The principal thrust and focus of the Proposal and the Prior Proposal are the same – an analysis of the congruency of Pfizer's political and electioneering expenditures during the preceding year against Pfizer's publicly stated values and policies. Specifically, the Proposal asks Pfizer to analyze "the congruency of [its] political, lobbying, and electioneering expenditures during the preceding year against publicly stated [Pfizer] values and policies." Likewise, the Prior Proposal asks Pfizer to analyze "the congruency of [its] political and electioneering expenditures during the preceding year against [Pfizer's] fundamental purpose and publicly stated [Pfizer] values and policies."

In addition, the supporting statement of each proposal demonstrates the proposals' shared focus on Pfizer's political and electioneering expenditures and their congruency with

Pfizer's stated values and policies. The Proposal's supporting statement asserts that "Pfizer's political expenditures appear to be misaligned with [its] values and interests," that "Pfizer should establish policies and reporting systems that minimize risk to [Pfizer's] reputation and brand by addressing possible missteps in corporate electioneering and political spending that contrast with its stated healthcare and environmental objectives" and that Pfizer analyze "risks to [its] brand, reputation, or shareholder value of expenditures in conflict with publicly stated [Pfizer] values." Similarly, the Prior Proposal's supporting statement asserts that "Pfizer's political expenditures appear to be misaligned with [its] purpose, values and interests," that "Pfizer should establish policies and reporting systems that minimize risk to [Pfizer's] reputation and brand by addressing possible missteps in corporate electioneering and political spending that contrast with its fundamental fiduciary purpose and stated policy objectives" and that Pfizer analyze "risks to [its] brand, reputation, or shareholder value of expenditures in conflict with publicly stated [Pfizer] values."

Although the breadth and scope of the Proposal and the Prior Proposal, as well as their respective supporting statements, may differ, with one emphasizing access to healthcare, birth control and greenhouse gas emissions and the other emphasizing discrimination, border security and pro-life policies, the Proposal and the Prior Proposal share the same thrust and focus – an analysis of the congruency of Pfizer's political and electioneering expenditures during the preceding year against Pfizer's publicly stated values and policies. Therefore, the inclusion of both proposals in Pfizer's 2022 proxy materials would be duplicative and would frustrate the policy concerns underlying the adoption of Rule 14a-8(i)(11).


Accordingly, because the Proposal substantially duplicates the Prior Proposal, which was previously submitted to Pfizer, the Proposal may be excluded pursuant to Rule 14a-8(i)(11) in the event that the Staff does not concur with the exclusion of the Prior Proposal from Pfizer's 2022 proxy materials.

VI. Conclusion

Based upon the foregoing analysis, we respectfully request that the Staff concur that it will take no action if Pfizer excludes the Proposal from its 2022 proxy materials.

Should the Staff disagree with the conclusions set forth in this letter, or should any additional information be desired in support of Pfizer's position, we would appreciate the opportunity to confer with the Staff concerning these matters prior to the issuance of the Staff's response. Please do not hesitate to contact me at (212) 733-3451 or Marc S. Gerber of Skadden, Arps, Slate, Meagher & Flom LLP at (202) 371-7233.

Very truly yours,

A handwritten signature in black ink, appearing to read "Margaret M. Madden". The signature is fluid and cursive, with a long horizontal flourish extending to the right.

Margaret M. Madden

Enclosures

cc: Shelley Alpern
Director of Corporate Engagement
Rhia Ventures

Elise Belusa
Acting Director
Tara Health Foundation

EXHIBIT A

(see attached)



October 26, 2021

Via email

Margaret M. Madden
Senior Vice President and Corporate Secretary, Chief Governance Counsel
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

Re: Shareholder proposal for 2022 Annual Shareholder Meeting

Dear Ms. Madden:

Tara Health Foundation is submitting the attached proposal (the "Proposal") pursuant to the Securities and Exchange Commission's Rule 14a-8 to be included in the proxy statement of Pfizer Inc. (the "Company") for its 2022 annual meeting of shareholders.

Tara Health Foundation has continuously beneficially owned, for at least three years as of the date hereof, more than \$25,000 worth of the Company's common stock. Verification of this ownership is attached. Tara Health Foundation intends to continue to hold such shares through the date of the Company's 2022 annual meeting of shareholders.

Tara Health Foundation is available to meet with the Company in person or via teleconference on the following dates:

Monday, Nov. 8, 4pm-4:45pm
Wednesday, Nov. 10th, 4pm-4:45pm
Wednesday, Nov. 24th, 1:15pm-2pm
Wednesday, Nov. 2pm-2:45pm

Please send future correspondence and communications regarding this proposal to my representative Shelley Alpern, director of corporate engagement at Rhia Ventures, who can be contacted at

Sincerely,

A handwritten signature in black ink that reads "Elise Belusa".

Elise Belusa
Acting Director
Tara Health Foundation

Shareholder Proposal for Pfizer 2022 Proxy Ballot re Political Contributions Misalignment
Submitted by Tara Health Foundation

POLITICAL CONTRIBUTIONS MISALIGNMENT

Whereas:

Pfizer policy states that “political contributions are made to support the election of candidates, political parties and committees that support public policies important to the industry, such as innovation and access to medicines.”

However, Pfizer’s political expenditures appear to be misaligned with the company’s values and interests.

- In January 2021, an internal Pfizer memo communicated that the company would not donate for at least 6 months to the 147 members of Congress who voted against certifying the election results. Following that period, Pfizer PAC has donated to at least six, none of whom has repudiated claims of election fraud.
- Pfizer has stated that “Expanded access to health insurance coverage will help ensure that patients with under-diagnosed and undertreated conditions are able to address them; and that those who will benefit from Pfizer medicines are better able to have access to them.” Yet in 2018, Pfizer was a top contributor to a 527 organization leading efforts to strike down the Affordable Care Act, which has made prescription drugs more accessible for millions, and contributes to PhRMA, which donates to numerous organizations opposing congressional efforts to reform drug pricing.
- Pfizer manufactures contraceptives and a drug commonly prescribed as an abortifacient. Yet Pfizer has been a top contributor to a 527 organization that funds state legislators’ efforts to implement extreme anti-abortion measures. The proponent estimates that in the 2016-2020 election cycles, Pfizer and its employee PACs have donated at least \$8.4 million to politicians and political organizations working to weaken women’s access to reproductive health care.
- Pfizer has set science-based greenhouse gas reduction targets yet is a member of the U.S. Chamber of Commerce, which has consistently lobbied to roll back specific US climate regulations and promote regulatory frameworks that would slow the transition towards a lower-carbon economy. This raises questions about whether Pfizer is also supporting electioneering efforts that conflict with its environmental commitments.

Proponents believe that Pfizer should establish policies and reporting systems that minimize risk to the firm's reputation and brand by addressing possible missteps in corporate electioneering and political spending that contrast with its stated healthcare and environmental objectives.

Shareholder Proposal for Pfizer 2022 Proxy Ballot re Political Contributions Misalignment
Submitted by Tara Health Foundation

Resolved:

Pfizer publish an annual report, at reasonable expense, analyzing the congruency of political, lobbying, and electioneering expenditures during the preceding year against publicly stated company values and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have led to a change in future expenditures or contributions.

Supporting Statement:

Proponents recommend that such report also contain management's analysis of risks to our company's brand, reputation, or shareholder value of expenditures in conflict with publicly stated company values. "Expenditures for electioneering communications" means spending, from the corporate treasury and from the PACs, directly or through a third party, at any time during the year, on printed, internet or broadcast communications, which are reasonably susceptible to interpretation as in support of or opposition to a specific candidate.

Subject: [EXTERNAL] Shareholder proposal for 2022 Annual Shareholder Meeting (Revised)
Attachments: PFE resolution 2022 - final with correction.docx

From: Elise Belusa [REDACTED]
Sent: Monday, November 8, 2021 12:31 PM
To: Madden, Margaret [REDACTED]
Cc: Shelley Alpern [REDACTED]
Subject: [EXTERNAL] Shareholder proposal for 2022 Annual Shareholder Meeting

Dear Ms. Madden:

Enclosed find an amendment to the shareholder proposal submitted by Tara Health on October 26, 2021. Please substitute the enclosed copy for the proposal. The only change in the proposal is the addition of the words "Shareholders request that" at the outset of the resolved clause.

Also, kindly confirm receipt of this email.

Best,

Elise Belusa, MSc
Acting Director
Tara Health Foundation
[REDACTED]

Shareholder Proposal for Pfizer 2022 Proxy Ballot re Political Contributions Misalignment
Submitted by Tara Health Foundation

POLITICAL CONTRIBUTIONS MISALIGNMENT

Whereas:

Pfizer policy states that “political contributions are made to support the election of candidates, political parties and committees that support public policies important to the industry, such as innovation and access to medicines.”

However, Pfizer’s political expenditures appear to be misaligned with the company’s values and interests.

- In January 2021, an internal Pfizer memo communicated that the company would not donate for at least 6 months to the 147 members of Congress who voted against certifying the election results. Following that period, Pfizer PAC has donated to at least six, none of whom has repudiated claims of election fraud.
- Pfizer has stated that “Expanded access to health insurance coverage will help ensure that patients with under-diagnosed and undertreated conditions are able to address them; and that those who will benefit from Pfizer medicines are better able to have access to them.” Yet in 2018, Pfizer was a top contributor to a 527 organization leading efforts to strike down the Affordable Care Act, which has made prescription drugs more accessible for millions, and contributes to PhRMA, which donates to numerous organizations opposing congressional efforts to reform drug pricing.
- Pfizer manufactures contraceptives and a drug commonly prescribed as an abortifacient. Yet Pfizer has been a top contributor to a 527 organization that funds state legislators’ efforts to implement extreme anti-abortion measures. The proponent estimates that in the 2016-2020 election cycles, Pfizer and its employee PACs have donated at least \$8.4 million to politicians and political organizations working to weaken women’s access to reproductive health care.
- Pfizer has set science-based greenhouse gas reduction targets yet is a member of the U.S. Chamber of Commerce, which has consistently lobbied to roll back specific US climate regulations and promote regulatory frameworks that would slow the transition towards a lower-carbon economy. This raises questions about whether Pfizer is also supporting electioneering efforts that conflict with its environmental commitments.

Proponents believe that Pfizer should establish policies and reporting systems that minimize risk to the firm's reputation and brand by addressing possible missteps in corporate electioneering and political spending that contrast with its stated healthcare and environmental objectives.

Shareholder Proposal for Pfizer 2022 Proxy Ballot re Political Contributions Misalignment
Submitted by Tara Health Foundation

Resolved:

Shareholders request that Pfizer publish an annual report, at reasonable expense, analyzing the congruency of political, lobbying, and electioneering expenditures during the preceding year against publicly stated company values and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have led to a change in future expenditures or contributions.

Supporting Statement:

Proponents recommend that such report also contain management's analysis of risks to our company's brand, reputation, or shareholder value of expenditures in conflict with publicly stated company values. "Expenditures for electioneering communications" means spending, from the corporate treasury and from the PACs, directly or through a third party, at any time during the year, on printed, internet or broadcast communications, which are reasonably susceptible to interpretation as in support of or opposition to a specific candidate.

EXHIBIT B

(see attached)



Industry Associations – Report on Incongruencies

Introduction

Pfizer Inc. (Pfizer) actively participates in the public policy arena because government policies affect our ability to meet patient needs and provide shareholder value. Barriers to access, counterfeit medicines, illegal importation and challenges to intellectual property protection challenge essential aspects of our business.. For this reason, we actively participate in public policy dialogues to explain our perspectives. We have extensive knowledge about health care and many ideas about improving its efficiency, as well as a global perspective on public health, disease prevention and health education. We believe that public policy engagement is an important and appropriate role for companies in open societies.

In furtherance of these goals, Pfizer is a member of various industry and trade groups that represent both the pharmaceutical industry and the business community at large to bring about consensus on broad policy issues that can impact Pfizer's business objectives and ability to serve patients. Our support of these organizations is evaluated annually by the company's U.S. Government Relations leaders based on these organizations' expertise in healthcare policy and advocacy and support of key issues of importance to Pfizer. In addition to their positions on health care policy issues, we realize these organizations may engage in a broad range of other issues that extend beyond the scope of what is of primary importance to Pfizer's business. If concerns arise about a particular issue, we convey our concerns, as appropriate, through our colleagues who serve on the boards and committees of these groups. We believe there is value in making sure our positions on issues important to Pfizer and our industry are communicated and understood within those organizations. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with each position taken by the larger organization and/or other members.

Our most significant trade association memberships are with the U.S. Chamber of Commerce (Chamber), the Business Roundtable (BRT), the National Association of Manufacturers (NAM), the Biotechnology Industry Association (BIO), and the Pharmaceutical Research and Manufacturers of America (PhRMA). We work closely and are proud of our collaboration with each of these trade associations on core issues of great importance to Pfizer's business and our stakeholders. PhRMA and BIO lead the industry in promoting pro-patient and pro-innovation health care policies while fighting against harmful government price control policies. The BRT, Chamber and NAM are leading voices on US tax competitiveness. All of these trade associations are vocal advocates for robust protections for intellectual property rights.

Of course, because these trade associations represent so many members with a diversity of interests, at times their positions and efforts on certain issues are not perfectly aligned with our own. Some misalignment is an unavoidable consequence of any collective endeavor. Nevertheless, we monitor where and to what extent our trade associations are misaligned with the company on such issues. Where possible, we will advocate for the trade association to come into alignment, but if an organization's misalignment is egregious, and the membership benefits to Pfizer and its stakeholders are outweighed by the misalignments, we will reduce or end our involvement with the organization.

In addition, the Governance & Sustainability Committee of the Board has oversight of the company's issues related to public policy, political spending policies and practices and our lobbying activities. At least annually, the Committee receives a report from the company's U.S. Government Relations leaders regarding our public policies activities, including an overview of the benefits derived from the company's association with certain trade and other organizations.

That said, the following report outlines the public policy positions of Pfizer and the five trade associations across six areas of key public policy and ESG significance for Pfizer: Climate Change; Patient Access to Healthcare; Trade; Tax; Diversity, Equity, and Inclusion; and Civic Integrity. The report also compares Pfizer and the trade associations' positions and describes the degree of alignment and areas of misalignment. Please note that while some of these issues, such as healthcare access, tax and trade are core to Pfizer's business, the other issues are nevertheless important to the company although they may not be core to the company's business

Biotechnology Innovation Organization

The policy goals of Pfizer and the Biotechnology Innovation Organization (BIO) are generally in alignment across the key areas reviewed. To the extent differences exist in the company and trade association’s respective positions, such as on tax, they are largely because either Pfizer or BIO has taken a position on particular matters on which the other has not. Indeed, Pfizer has been more vocal than BIO on support of free trade, though both agree on the importance of intellectual property protections in trade agreements. On broad policy goals, Pfizer and BIO are well aligned. Pfizer engages with BIO on the following issues: (a) intellectual property/innovation protection; (b) vaccine policy and advocacy; (c) patient affordability solutions; and (d) FDA User Fee agreements (in partnership with PhRMA).

	Pfizer	BIO	Gap Analysis
Climate Change	Pfizer understands and takes action to reduce the risks of adverse impacts from climate threats by recognizing that climate change is a defining issue of the times caused primarily by human activities. These values are illustrated through demonstrable policies and goals, supporting government efforts for market-based solutions aimed at achieving science-based emission reduction targets, while also taking steps at the company level, including becoming carbon neutral by 2030. The company also seeks to engage value chain partners to help them achieve target reductions in emissions.	BIO believes that climate change is one of the greatest public policy challenges facing this generation and that biotechnology has the potential to be a transformative asset in this struggle. It supports efforts to reduce greenhouse gas emissions as well as establishing a national low carbon fuels standard. BIO strongly supports the Growing Climate Solutions Act, including the establishment of a national carbon market, the U.S. rejoining the Paris Climate Accords, and the development of Sustainable Aviation Fuels. Lastly, BIO opposes the practice of granting small refinery hardship waivers under the Renewable Fuel Standard.	Pfizer and BIO are in close alignment on climate change, with both favoring market-based and scientific-evidence based solutions to climate change.
Access to Healthcare	Pfizer seeks to maximize the use of its medicines and vaccines for supporting global public health efforts. This includes permitting, as safely as possible, access to investigational drugs still in development in limited circumstances. As a global company, Pfizer attempts to	BIO believes that biotechnology can help provide healthcare solutions for a variety of problems, such as opioid addiction, vaccine access, and disease prevention. BIO member companies are committed to making innovative biotechnology medicines	Pfizer and BIO are in close alignment in expanding access to healthcare, including expanded access to investigational drugs and COVID vaccines.

	<p>ensure that underserved patients around the world have access to essential medicines and vaccines. In addition, Pfizer seeks to educate underserved patients on health literacy to further health equity.</p>	<p>available to patients who need them through the efficient development of approved, safe and effective products. However, BIO opposes global drug price control schemes such as those found in H.R. 3. BIO favors expanding access to investigational drugs as long as proper safeguards remain in place. Lastly, BIO and its members often work together with patient advocacy organizations to better understand the patients it serves in order to help raise awareness and understanding of disease and to advance patient-focused public policies.</p>	
Trade	<p>Pfizer balances the realities of encouraging trade, commerce, and patient access while protecting IP that is at the heart of the company’s innovation engine. As a company that engages heavily in R&D, it is imperative to the success of the company that products that are the result of costly research be given the appropriate market protections. This includes advocating for free trade agreements that provide legal certainty. Pfizer also emphasizes an ethical supply chain and following applicable antitrust laws, both in the U.S. and abroad.</p>	<p>BIO supports eliminating acute and systemic trade barriers to innovative biotechnology tools, particularly in important export markets, such as China, the European Union, and Mexico. It believes that to fully leverage the potential of biotechnology, a level-playing field at the global level is essential. BIO also favors robust intellectual property protections for biotechnology companies. It has criticized the World Trade Organization’s (WTO) proposed “TRIPS” waiver of intellectual property rights for technologies used to prevent, contain, or treat COVID-19. In addition, BIO supports pursuing biotechnology-specific outcomes in new trade agreements and modernizing older trade agreements to address biotechnology. It criticized the United States-Mexico-Canada Agreement (USMCA)</p>	<p>Pfizer and BIO are in close alignment on the importance of intellectual property protections in trade agreements, but Pfizer has spoken more favorably of free trade agreements generally than BIO has.</p>

		for failing to include enhanced intellectual property standards for American biopharmaceutical products.	
Tax	Pfizer opposes increasing the tax burden on U.S. companies through changes to the foreign minimum tax.	BIO supports a number of state-level tax credits, deductions, and exemptions. It supports seed capital tax credits and angel investor tax credits to encourage early-stage investment, tax credits to increase the availability of venture capital, tax credits for research and development, sales tax exemptions for equipment used in research and development and manufacturing, capital investment tax incentives, innovation investment tax incentives, tax credit transferability, the option to carry forward net operating losses (NOL), and capital gains deductions. At the federal level, it supports a number of biofuel tax incentives, particularly the Second Generation Biofuel Producer Tax Credit, the Special Depreciation Allowance for Second Generation Biofuel Plant Property, the Biodiesel and Renewable Diesel Fuels Credit, and the Alternative Fuel Vehicle Refueling Property Credit. It also supports reform of limitations on NOL carryforwards under Section 382 of the federal tax code.	Pfizer and BIO have different focuses in the area of tax policy. BIO does not appear to have taken a position on the foreign minimum tax issue of most interest to Pfizer, but holds a number of other positions on tax policy that Pfizer has not addressed. Thus, Pfizer and BIO's positions are misaligned in this area, though not in conflict.
Diversity Equity & Inclusion	Pfizer has numerous company policies and reports that emphasize the importance of diversity, equity, and inclusion to the company and provide metrics that reflect the priority that the company places on such efforts. This emphasis on	BIO supports increasing diversity, equity and inclusion (DE&I) in the biotechnology space. It has spearheaded several initiatives dedicated to improving diversity such as its BIOEquity Agenda and the Right Mix Matters campaign.	Pfizer and BIO are in close alignment on matters of DE&I, in terms of the corporate workforce, clinical trials and access to healthcare.

	<p>values related to DE&I is not illustrated only in policies addressing company personnel, but also related to patients, as the company seeks to overturn longstanding inequities in healthcare systems, such as through inclusive drug trials.</p>	<p>BIO also believes that it is imperative to increase diversity in clinical trials in order to best reflect the population that will ultimately be using the tested drugs. Lastly, BIO has committed to promoting health equity by enhancing clinical trial diversity, promoting access to vaccines and therapeutics for uninsured and underserved populations and fostering enhanced nutritional, environmental, and mental wellness opportunities in economically disadvantaged communities.</p>	
Civic Integrity	<p>Pfizer opposed the events at the Capitol on January 6, 2021 and paused Pfizer Political Action Committee (PAC) giving to the 147 Republicans who voted against certifying the election for the first half of 2021. Pfizer also supports ensuring every American citizen's right to vote, which is fundamental to our democracy.</p>	<p>BIO opposed the events that took place at the Capitol on January 6. As a result, it briefly paused all political giving in order to reassess the criteria it uses to make political donations.</p>	<p>Pfizer and BIO are in close alignment on civic integrity, with both condemning the events that took place at the Capitol on January 6, 2021.</p>

Business Roundtable

The policy goals of Pfizer and the Business Roundtable (BRT) are generally in alignment across the key areas reviewed. To the extent there are differences in the company and trade association’s respective positions, they are because Pfizer and BRT are focusing on different specific aspects of the issue. However, on broad policy goals, Pfizer and BRT are well aligned. Pfizer engages with the BRT on the following issues: (a) U.S. tax competitiveness; (b) global tax debate; (c) free trade policies and intellectual property protection; (d) employer health care and health equity solutions; and (e) enhancing diversity and inclusion in the workforce.

	Pfizer	Business Roundtable	Gap Analysis
Climate Change	<p>Pfizer understands and takes action to reduce the risks of adverse impacts from climate threats by recognizing that climate change is a defining issue of the times caused primarily by human activities. These values are illustrated through demonstrable policies and goals, supporting government efforts for market-based solutions aimed at achieving science-based emission reduction targets, while also taking steps at the company level, including becoming carbon neutral by 2030. The company also seeks to engage value chain partners to help them achieve target reductions in emissions.</p>	<p>The Business Roundtable believes corporations should lead by example, support sound public policies, and drive innovation in order to best address climate change. However, the BRT asserts that effective change will not happen in a vacuum, and that it is imperative for the U.S. government to act in tandem with corporations. In particular, the BRT calls on the U.S. government to adopt a more comprehensive, coordinated, and market-based approach to emissions reduction. This approach should also place a premium on fostering innovation, U.S. competitiveness, and compliance flexibility. The BRT identifies global cooperation and diplomacy as the keys to achieving the collective global action that is necessary to address the climate change challenge. However, the BRT has received criticism in the press for opposing the Biden administration’s Build Back Better legislation, despite its substantial investment in combating climate change.</p>	<p>Both Pfizer and BRT favor market-based and scientific-evidence based solutions to climate change. Pfizer is committed to taking responsible climate action and reducing environmental impact; BRT also advocates for corporations to take such actions. BRT has been criticized in the press in recent months for opposing the Biden administration’s Build Back Better legislation, despite its substantial investment in combating climate change. But this opposition is due to the onerous tax provisions included in the legislation; BRT has called for separate legislative action on climate change.</p>

<p>Access to Healthcare</p>	<p>Pfizer seeks to maximize the use of its medicines and vaccines for supporting global public health efforts. This includes permitting, as safely as possible, access to investigational drugs still in development in limited circumstances. As a global company, Pfizer attempts to ensure that underserved patients around the world have access to essential medicines and vaccines. In addition, Pfizer seeks to educate underserved patients on health literacy to further health equity.</p>	<p>The BRT believes that an affordable, innovative and efficient healthcare system is an essential factor in ensuring a better quality of life for all Americans as well as a more productive and competitive U.S. workforce. The BRT has established its own Health & Retirement committee to bring about its goals. The committee’s purpose is to support health policy initiatives and the U.S. retirement system. The BRT also supports policies that will improve the affordability and quality of U.S. healthcare and is particularly interested in the intersection of racial equity and health. The BRT believes that by focusing on effective and inclusive healthcare and retirement policies, the U.S. will become a more attractive location for skilled workers and businesses. BRT has also actively promoted use of COVID vaccines.</p>	<p>Pfizer and BRT are both focused on expanding access to healthcare. Pfizer largely focuses on expanding access to medicines and vaccines, including investigational drugs. BRT does not appear to have taken a position on these specific initiatives, except that it has been promoting access to COVID vaccines, and is instead focused on reducing the cost of, and expanding access to, health insurance. Both Pfizer and BRT support efforts to promote equity in access to healthcare.</p>
<p>Trade</p>	<p>Pfizer balances the realities of encouraging trade, commerce, and patient access while protecting IP that is at the heart of the company’s innovation engine. As a company that engages heavily in R&D, it is imperative to the success of the company that products that are the result of costly research be given the appropriate market protections. This includes advocating for free trade agreements that provide legal certainty. Pfizer also emphasizes an ethical supply chain and following applicable antitrust laws, both in the U.S. and abroad.</p>	<p>The BRT believes that every sector of the U.S. economy benefits from free trade, and that future economic growth and jobs in the U.S. depend on expanding U.S. trade and investment opportunities around the world. In this same vein, the BRT is very supportive of friendly trade relations with Canada and Mexico. However, the BRT takes issue with China’s trade and investment practices and supports the preservation of the Phase Agreement as well as working with U.S. allies and trading partners to press for further structural reforms in China such as stronger intellectual property</p>	<p>Pfizer and BRT are in close alignment on trade policy. Both favor free trade agreements and the protection of intellectual property rights through such agreements.</p>

		protections. Lastly, the BRT opposes the Section 232 tariffs on steel and aluminum imports.	
Tax	Pfizer opposes increasing the tax burden on U.S. companies through changes to the foreign minimum tax.	The BRT supports tax and fiscal policies that promote innovation and create more opportunity for America’s workers, communities and job creators. It strongly supports the 2017 tax reform and believe that it has aligned the U.S. corporate tax rate with global competitors thereby allowing for low unemployment, better-than-expected growth in GDP, and the fastest two-year wage growth in 20 years (prior to the pandemic). Furthermore, the BRT believes that any U.S. minimum tax should be agreed upon at a global level instead of just applying to U.S. companies. Lastly, the BRT opposes an increase in corporate taxes being bundled into an infrastructure bill.	Pfizer and BRT are in close alignment on opposition to changes to the foreign minimum tax that would increase the tax burden on U.S. companies relative to foreign companies. BRT has positions on numerous other tax issues on which Pfizer has not taken a public position.
Diversity Equity & Inclusion	Pfizer has numerous company policies and reports that emphasize the importance of diversity, equity, and inclusion to the company and provide metrics that reflect the priority that the company places on such efforts. This emphasis on values related to DE&I is not illustrated only in policies addressing company personnel, but also related to patients, as the company seeks to overturn longstanding inequities in healthcare systems, such as through inclusive drug trials.	The BRT strongly supports the DE&I efforts of its member companies. It also recommends that member companies increase transparency on corporate diversity by voluntarily disclosing their diversity metrics, including hiring and leadership. Furthermore, the BRT has taken a multi-faceted approach to DE&I initiatives and has created substantive policies that address DE&I issues in employment, finance, education, health, housing, and the justice system.	Pfizer and BRT are in close alignment on matters of DE&I, both in terms of the corporate workforce and access to healthcare.
Civic Integrity	Pfizer opposed the events at the Capitol on January 6,	The BRT strongly opposed claims that the results of the	Pfizer and BRT are in close alignment on civic

	<p>2021 and paused Pfizer Political Action Committee (PAC) giving to the 147 Republicans who voted against certifying the election for the first half of 2021. Pfizer also supports ensuring every American citizen's right to vote, which is fundamental to our democracy.</p>	<p>2020 Presidential election were the product of fraud before, during, and after the events that took place at the Capitol on January 6, 2021. The BRT also supports greater access to voting and encourages broad voter participation. In the same vein, the BRT encourages its member companies to allow their employees to take the day off of work in order to vote.</p>	<p>integrity, with both condemning the events that took place at the Capitol on January 6, 2021, and supporting access to voting.</p>
--	---	---	---

National Association of Manufacturers

The policy goals of Pfizer and the National Association of Manufacturers (NAM) are generally in alignment across the key areas reviewed. The alignment is less close in the areas of climate change and access to healthcare, largely because Pfizer and the NAM are focusing on different specific aspects of the issue. However, on broad policy goals, Pfizer and BRT are well aligned. Pfizer engages with NAM on the following issues: (a) high quality manufacturing; (b) international trade; and (c) to oppose governmental intervention in health care, including price controls in Medicare.

	Pfizer	NAM	Gap Analysis
Climate Change	<p>Pfizer understands and takes action to reduce the risks of adverse impacts from climate threats by recognizing that climate change is a defining issue of the times caused primarily by human activities. These values are illustrated through demonstrable policies and goals, supporting government efforts for market-based solutions aimed at achieving science-based emission reduction targets, while also taking steps at the company level, including becoming carbon neutral by 2030. The company also seeks to engage value chain partners to help them achieve target reductions in emissions.</p>	<p>The NAM recognizes that climate change poses a serious threat to the planet. It has called for a clear and unified federal climate policy that is based on science-based metrics and that preempts conflicting and duplicative regulations. It supports increasing investments in public- and private-sector energy and water efficiency, scaling up the adoption of energy- and water-efficient products and technologies, and developing pathways for the deployment of new technologies like carbon capture, utilization, and storage. It believes that any federal policy must be part of a broader global</p>	<p>Both Pfizer and the NAM favor scientific evidence based solutions to climate change. There is some misalignment in how to achieve these solutions, with Pfizer focused on market-based mechanisms while the NAM supports greater regulatory clarity and consistency that supports innovation and a global approach to climate change.</p>

		<p>solution and has encouraged the U.S. to reengage with the international community in order to reduce greenhouse gas emissions collectively, rather than in isolation. The NAM is opposed to measures, such as the Green New Deal, that it believes would too quickly transition the U.S. from fossil fuels and would put U.S. manufacturers at a competitive disadvantage.</p>	
<p>Access to Healthcare</p>	<p>Pfizer seeks to maximize the use of its medicines and vaccines for supporting global public health efforts. This includes permitting, as safely as possible, access to investigational drugs still in development in limited circumstances. As a global company, Pfizer attempts to ensure that underserved patients around the world have access to essential medicines and vaccines. In addition, Pfizer seeks to educate underserved patients on health literacy to further health equity.</p>	<p>The NAM supports market-based solutions to lower healthcare costs. In particular, it supports moving the U.S. from a fee-for-service or volume-based healthcare system to a value-based healthcare system; enacting policies that allow employers to use innovative approaches to providing coverage for their employees, such as wellness programs, association health plans, and direct primary care; improving health savings accounts to reduce patient out-of-pocket costs; reducing Affordable Care Act–mandated reporting requirements; and maintaining the tax-exempt status of employee health benefits to avoid higher premiums for workers and families. The NAM is opposed to government price controls, which it argues will chill innovation and expose consumers to unsafe medicines.</p>	<p>Pfizer and the NAM are in broad alignment on minimizing government intervention between patients and the drugs and vaccines they need. Pfizer largely focuses on expanding access to medicines and vaccines, including investigational drugs. The NAM does not appear to have taken a position on these specific initiatives, except that it has been promoting access to COVID vaccines, and is instead focused on reducing the cost of healthcare and health insurance, while combating government price controls.</p>
<p>Trade</p>	<p>Pfizer balances the realities of encouraging trade, commerce, and patient access while protecting IP that is at the heart of the company’s innovation engine. As a company that engages heavily in R&D, it is imperative to the</p>	<p>The NAM supports free trade agreements to provide certainty in the global marketplace, open markets for U.S.-manufactured goods, and eliminate unfair barriers to trade. It believes that the U.S. needs to work with allies</p>	<p>Pfizer and the NAM are in close alignment on trade policy. Both favor free trade agreements and the protection of intellectual property rights through such agreements.</p>

	<p>success of the company that products that are the result of costly research be given the appropriate market protections. This includes advocating for free trade agreements that provide legal certainty. Pfizer also emphasizes an ethical supply chain and following applicable antitrust laws, both in the U.S. and abroad.</p>	<p>to shape the global rules for trade. It supports vigorous protection of intellectual property rights at home and abroad and targeted policies directed at China to reverse the country’s illegal subsidies, intellectual property theft, and discriminatory industrial policies. It also supports modernizing U.S. and foreign customs operations to cut red tape and expedite legitimate trade in the U.S. and across foreign borders and implementing U.S. export control and investment review policies that promote the leadership, competitiveness, and strength of the U.S. manufacturing industry. The NAM is opposed to tariffs, which it argues undermine economic growth by restricting trade.</p>	
Tax	<p>Pfizer opposes increasing the tax burden on U.S. companies through changes to the foreign minimum tax.</p>	<p>The NAM supports a competitive tax code that promotes economic growth and incentivizes investment in infrastructure, research and development, and human capital. It is opposed to increasing taxes, particularly the corporate tax and foreign minimum tax, and to limiting tax deductions, such as the business interest expense deduction.</p>	<p>Pfizer and the NAM are in close alignment on opposition to changes to the foreign minimum tax that would increase the tax burden on U.S. companies relative to foreign companies. The NAM has positions on numerous other tax issues on which Pfizer has not taken a public position.</p>
Diversity Equity & Inclusion	<p>Pfizer has numerous company policies and reports that emphasize the importance of diversity, equity, and inclusion to the company and provide metrics that reflect the priority that the company places on such efforts. This emphasis on values related to DE&I is not illustrated only in policies addressing company</p>	<p>The NAM supports diversity, equity, and inclusion policies. It encourages manufacturers to take proactive measures to hire more women, people of color, and members of the LGBT community and to make their workplaces more open and accepting.</p>	<p>Pfizer and the NAM are in close alignment on DE&I, matters in the corporate workforce, although the NAM does not appear to have focused on inequities in healthcare systems specifically.</p>

	<p>personnel, but also related to patients, as the company seeks to overturn longstanding inequities in healthcare systems, such as through inclusive drug trials.</p>		
<p>Civic Integrity</p>	<p>Pfizer opposed the events at the Capitol on January 6, 2021 and paused Pfizer Political Action Committee (PAC) giving to the 147 Republicans who voted against certifying the election for the first half of 2021. Pfizer also supports ensuring every American citizen's right to vote, which is fundamental to our democracy.</p>	<p>The NAM encourages people to vote and spoke out against efforts after the 2020 general election to undermine the presidential election results.</p>	<p>Pfizer and the NAM are in close alignment on civic integrity, with both condemning the events that took place following the 2020 election.</p>

Pharmaceutical Research and Manufacturers of America

Pfizer and Pharmaceutical Research and Manufacturers of America (PhRMA) are closely aligned on policy goals and specific positions. The only notable exception is in the area of climate change, where PhRMA has not taken a public position. Pfizer engages with PhRMA on the following issues: (a) lead industry efforts to advance pro-patient policies and defeat negative drug pricing proposals at the federal level; (b) advance rebate pass-through, copay accumulator bans and out of pocket caps at state level; (c) protect intellectual property rights globally; and (d) advance FDA User Fee agreements (in partnership with BIO).

	Pfizer	PhRMA	Gap Analysis
Climate Change	Pfizer understands and takes action to reduce the risks of adverse impacts from climate threats by recognizing that climate change is a defining issue of the times caused primarily by human activities. These values are illustrated through demonstrable policies and goals, supporting government efforts for market-based solutions aimed at achieving science-based emission reduction targets, while also taking steps at the company level, including becoming carbon neutral by 2030. The company also seeks to engage value chain partners to help them achieve target reductions in emissions.	No public policy or position identified.	PhRMA does not have public positions on climate change, so there is no material misalignment between Pfizer and PhRMA on this topic.
Access to Healthcare	Pfizer seeks to maximize the use of its medicines and vaccines for supporting global public health efforts. This includes permitting, as safely as possible, access to investigational drugs still in development in limited circumstances. As a global company, Pfizer attempts to ensure that underserved patients around the world have access to essential medicines and vaccines. In addition, Pfizer seeks to	PhRMA is willing to work with all stakeholders to deliver a more resilient, stronger, affordable and equitable healthcare system for all. However, it believes that the current price setting proposals in Congress threaten Americans' access to crucial, breakthrough medicines, and that there should instead be a cap on out-of-pocket costs for seniors. It also focuses on lower cost sharing and	Pfizer and PhRMA are in close alignment on expanding access to healthcare, including through greater access to investigational drugs.

	educate underserved patients on health literacy to further health equity.	making drugs prices more predictable. PhRMA wants to ensure that billions of dollars in rebates and discounts get passed on to patients – not kept by the insurance companies, hospitals and middlemen. PhRMA also supports expanded access to investigational drugs.	
Trade	Pfizer balances the realities of encouraging trade, commerce, and patient access while protecting IP that is at the heart of the company’s innovation engine. As a company that engages heavily in R&D, it is imperative to the success of the company that products that are the result of costly research be given the appropriate market protections. This includes advocating for free trade agreements that provide legal certainty. Pfizer also emphasizes an ethical supply chain and following applicable antitrust laws, both in the U.S. and abroad.	PhRMA supports free and fair trade and believes that through trade agreements with other countries, medicines developed in the U.S. are able to reach patients around the world who otherwise would not be able to access the latest treatments and cures. However, it argues that some countries artificially limit the price of innovative U.S. pharmaceuticals, and fail to adequately protect intellectual property, thereby hampering access to new treatments in foreign countries and reducing investment in research and development. PhRMA argues that this ultimately harms patients and health systems. Therefore, PhRMA supports strong IP protection policies.	Pfizer and PhRMA are in close alignment on trade policy, with both favoring free trade and strong intellectual property protections.
Tax	Pfizer opposes increasing the tax burden on U.S. companies through changes to the foreign minimum tax.	PhRMA believes that increased taxes limit the ability of pharmaceutical companies to provide new treatments abroad and disincentivizes research and development for lifesaving cures. It engaged an outside auditor to estimate the effects of the Biden administration’s federal income tax payment plan on the pharmaceutical industry. The analysis showed that the administration’s tax proposals	Pfizer and PhRMA are in close alignment on opposition to changes to the foreign minimum tax that would increase the tax burden on U.S. companies relative to foreign companies.

		would increase tax payments on the pharmaceutical industry by more than \$95 billion because of revisions to the global minimum tax regime and related proposals. This coupled, with the increase in the corporate income tax rate to 28%, would raise the pharmaceutical industry's taxes by an estimated \$40.7 billion.	
Diversity Equity & Inclusion	Pfizer has numerous company policies and reports that emphasize the importance of diversity, equity, and inclusion to the company and provide metrics that reflect the priority that the company places on such efforts. This emphasis on values related to DE&I is not illustrated only in policies addressing company personnel, but also related to patients, as the company seeks to overturn longstanding inequities in healthcare systems, such as through inclusive drug trials.	PhRMA is committed to enhancing diversity, equity and inclusion in the pharmaceutical industry. It published the first ever industry-wide principles on clinical trial diversity. Further, it has consistently responded to government requests for information on diversity initiatives. PhRMA has also created a grant program that awards money to community-based projects to address inequities in diagnosis, treatment, and adherence. Lastly, PhRMA has published an open letter on equity, noting that systemic racism is as real as any disease and commits PhRMA to pursuing various measures in order to improve its diversity, equity and inclusion efforts.	Pfizer and PhRMA are in close alignment on matters of DE&I, both in terms of the corporate workforce, access to healthcare and participation in clinical trials.
Civic Integrity	Pfizer opposed the events at the Capitol on January 6, 2021 and paused Pfizer Political Action Committee (PAC) giving to the 147 Republicans who voted against certifying the election for the first half of 2021. Pfizer also supports ensuring every American citizen's right to vote, which is fundamental to our democracy.	PhRMA's CEO issued a strong rebuke of the events at the Capitol on January 6. Soon after, PhRMA paused all political giving to those who voted to reject the outcome of the 2020 presidential election.	Pfizer and PhRMA are in close alignment on civic integrity, with both condemning the events that took place at the Capitol on January 6, 2021.

U.S. Chamber of Commerce

The policy goals of Pfizer and the U.S. Chamber of Commerce (Chamber) are generally in alignment across the key areas reviewed. To the extent there are differences in the company and trade association’s respective positions, they are generally because Pfizer and Chamber are focusing on different specific aspects of the issue. However, on broad policy goals, they are well aligned. Pfizer engages with the Chamber on the following issues: (a) promote and protect intellectual property/innovation through Global Innovation Policy Center; (b) drive narrative on counterfeits/product integrity; (c) lead on U.S. tax competitiveness; and (d) protect employer health care and drive policies to promote competition in health care.

	Pfizer	Chamber	Gap Analysis
Climate Change	Pfizer understands and takes action to reduce the risks of adverse impacts from climate threats by recognizing that climate change is a defining issue of the times caused primarily by human activities. These values are illustrated through demonstrable policies and goals, supporting government efforts for market-based solutions aimed at achieving science-based emission reduction targets, while also taking steps at the company level, including becoming carbon neutral by 2030. The company also seeks to engage value chain partners to help them achieve target reductions in emissions.	The Chamber acknowledges the severity of the climate threat, that humans are contributing, and that steps needs to be taken to address the crisis. The organization recognizes the role that business and market-driven solutions can play in slowing the effects of climate change. In addition, governments and technological solutions should be leveraged but solutions must be realistic, durable, and reinforce U.S. economic competitiveness.	On climate change, both Pfizer and the Chamber favor market-based and technology-based solutions. Pfizer is committed to taking responsible climate action and reducing environmental impact; the Chamber also advocates for corporations to take such actions. The Chamber has been criticized for its history of opposition to legislation targeting climate change and opposing the Biden administration’s Build Back Better legislation, which includes climate provisions. The Chamber testified before Congress in October and noted that combating climate change requires citizens, governments, and businesses to work together – and that inaction is not an option..
Access to Healthcare	Pfizer seeks to maximize the use of its medicines and vaccines for supporting global public health efforts. This includes permitting, as safely as possible, access to investigational drugs still in	The Chamber believes private business is a significant factor in what makes America the leader in healthcare in the world. American innovation leads to better outcomes for both domestic and	Pfizer and the Chamber are in alignment on expanding access to healthcare. Pfizer largely focuses on expanding access to medicines and vaccines, including

	<p>development in limited circumstances. As a global company, Pfizer attempts to ensure that underserved patients around the world have access to essential medicines and vaccines. In addition, Pfizer seeks to educate underserved patients on health literacy to further health equity.</p>	<p>international patients and companies must be provided proper incentives and protection to allow research and development to continue. These protections should be balanced to increase affordability and optimize access for all patients. Employer-sponsored healthcare provides the best option for many Americans.</p>	<p>investigational drugs. The Chamber does not appear to have taken a position on these specific initiatives, except that it has been promoting access to COVID vaccines, and is instead focused on reducing the cost of, and expanding access to, health insurance.</p>
Trade	<p>Pfizer balances the realities of encouraging trade, commerce, and patient access while protecting costly IP that is at the heart of the company's profitability. As a company that engages heavily in R&D, it is imperative to the success of the company that products that are the result of costly research be given the appropriate market protections. This includes advocating for free trade agreements that provide legal certainty. Pfizer also emphasizes an ethical supply chain and following applicable antitrust laws, both in the U.S. and abroad.</p>	<p>The Chamber emphasizes free trade and opposes tariffs, providing American companies the opportunity to participate in the global marketplace. In addition to agreements that open the marketplace, it's important that these agreements also provide intellectual property protections that protect and encourage innovation.</p>	<p>Pfizer and the Chamber are in close alignment on trade policy. Both favor free trade agreements and the protection of intellectual property rights through such agreements.</p>
Tax	<p>Pfizer opposes increasing the tax burden on U.S. companies through changes to the foreign minimum tax.</p>	<p>The Chamber believes in tax policies that support business and promote the growth the economy. This generally means lower and stable tax rates for business that spurs job growth and investment. In addition, the Chamber supports repealing taxes on certain aspects of healthcare. Internationally, the Chamber supports tax agreements that establish fair systems by which American companies can compete globally, and opposes an increase to the</p>	<p>Pfizer and the Chamber are in close alignment on opposition to changes to the foreign minimum tax that would increase the tax burden on U.S. companies relative to foreign companies. The Chamber has positions on numerous other tax issues on which Pfizer has not taken a public position.</p>

		global minimum tax for U.S. companies.	
Diversity Equity & Inclusion	Pfizer has numerous company policies and reports that emphasize the importance of diversity, equity, and inclusion to the company and provide metrics that reflect the priority that the company places on such efforts. This emphasis on values related to DE&I is not illustrated only in policies addressing company personnel, but also related to patients, as the company seeks to overturn longstanding inequities in healthcare systems, such as through inclusive drug trials.	The Chamber supports and understands the role that diversity, equity, and inclusion play in creating a vibrant and dynamic economy. This includes by supporting member efforts, instituting programs, and creating studies that illustrate that diversity is a strength in America. The organization believes that DE&I efforts will be central to a growing economy in the future.	Pfizer and the Chamber are in close alignment on matters of DE&I, with respect to promoting diversity in the corporate workforce.
Civic Integrity	Pfizer opposed the events at the Capitol on January 6, 2021 and paused Pfizer Political Action Committee (PAC) giving to the 147 Republicans who voted against certifying the election for the first half of 2021. Pfizer also supports ensuring every American citizen's right to vote, which is fundamental to our democracy.	The Chamber condemned the attacks against the Capitol on January 6 and believes the 2020 presidential electoral college was won by Joe Biden. After the attacks, the organization announced that it would holistically consider future contributions to candidates, including their positions on issues related to democracy, but did not say it would categorically withhold funds from those who voted against certifying the electoral college. The Chamber opposes the For the People Act of 2021, Democrats' signature voting rights bill this session, taking the position that it would silence voices from the political process.	Pfizer and the Chamber both condemned the events of January 6, 2021. The Chamber has taken a position against the For the People Act of 2021; although Pfizer has indicated its support for voting rights, it has not taken a public position on this bill.

Methodology

This report surveys the public policy positions of Pfizer and five national trade associations of which Pfizer is a member: the Biotechnology Innovation Organization, the Business Roundtable, the National Association of Manufacturers, the Pharmaceutical Research and Manufacturers of America, and the U.S. Chamber of Commerce (collectively the “Trade Associations”). The review included the notable written policies of Pfizer and the Trade Associations generally addressing six issues: Climate Change; Patient Access to Healthcare; Trade; Tax; Diversity, Equity, and Inclusion; and Civic Integrity.

The report draws from the policies maintained on the websites of Pfizer and the Trade Associations. The policies were identified through a review of the respective websites and targeted keyword searches of the websites. In addition, we compiled recent notable criticism of the Trade Associations’ positions featured in media outlets through keyword searches of media databases. Please note, this report is focused on current Pfizer and Trade Association policies as of Fall 2021 and we omitted policies and criticism that we could determine were written prior to 2019.

December 2021

EXHIBIT C

(see attached)



Pfizer PAC

Political Action Committee

Leading the Conversation

Pfizer PAC and Corporate Political Contributions Report

January 2019–December 2020

U.S. Government Relations & Pfizer PAC

Leading the Conversation and Making an Impact

A Message from Sally Susman & Rady Johnson, Co-Chairs, Pfizer PAC

We are pleased to share our 2020 election cycle political contributions report, which includes a list of candidates and political committees supported either by Pfizer Inc. or the Pfizer PAC from January 1, 2019 through December 31, 2020.

It has been a year like no other, and we are proud of the all the hard work and long hours our colleagues dedicated and continue to dedicate to develop and deliver the first COVID-19 vaccine. As if COVID wasn't enough, 2020 was also a big election year and Pfizer and the Pfizer PAC continued to support candidates of both political parties who support policies that impact our purpose: Breakthroughs that change patients' lives. We do not contribute to Presidential candidates or super PACs. In the 2020 cycle, Pfizer PAC and Pfizer Inc. supported 1,842 candidates and multiple political committees at all levels of the government. Forty-nine percent of the Pfizer PAC disbursements in the 2019-2020 cycle went to Republicans and 46% went to Democrats. We continue to advance our purpose to discover and deliver breakthroughs that change patients' lives, thanks to our PAC members and our Pfizer U.S. Government Relations team, who are on the ground educating and engaging elected officials about Pfizer's purpose.



As Pfizer's Chief Compliance & Corporate Affairs Officers, we can tell you unequivocally that our decision to contribute to any elected official is made based on ethical, responsible, and just policies that support innovation incentives and patients' access to breakthrough medicines and vaccines. Our PAC support does not imply an endorsement of a candidate's position on any social or religious issue.

We consider our support of the PAC a vote for Pfizer; we make this vote with the same pride that we do when we show up at the voting booth and vote for candidates who we believe are best for our profession and our families. No breakthrough can get to patients without a favorable regulatory and legislative framework. The Pfizer PAC helps ensure that framework is strong.

We hope you will take some time to review the report to see which candidates the PAC supported in your state and community. Our priority in 2021 is to help build a constructive discourse in the political and regulatory environment while supporting policies – and policymakers – who share these same ideals. Those policy priorities include improving patient affordability and access, defending against threats to our patents and intellectual property, protecting patients from dangerous insurance barriers and counterfeit medicines, ensuring patients continue to have robust access to innovative medicines in Medicare Part D and keeping an eye on burdensome tax policies. As Pfizer's PAC Co-Chairs, and through our interactions with elected officials, we see first-hand how decisions are made that impact our ability to bring breakthrough medicines and vaccines to patients and physicians who rely on us every day. We must ensure our voice is heard so that patients can continue to be first in everything we do.

Thank you for your support,

A handwritten signature in black ink that reads "Sally Susman".

Sally Susman
Executive Vice President
Chief Corporate Affairs Officer
Co-Chair, Pfizer PAC

A handwritten signature in black ink that reads "Rady Johnson".

Rady Johnson
Executive Vice President
Chief Compliance, Quality & Risk Officer
Co-Chair, Pfizer PAC



PFIZER PAC

Leading the Conversation.

What is a PAC?

PAC stands for Political Action Committee. A political action committee is a government-regulated organization that anyone can form to raise money for political campaign donations. PACs are formed by individuals, non-profits, and even many major corporations.

How Does Pfizer PAC Work?

The Pfizer political action committee, Pfizer PAC, is a nonpartisan organization that provides opportunities for employees to participate in the American political process. The Pfizer PAC is an employee-run organization with a Steering Committee made up of Pfizer employees from different divisions of the company. All corporate PACs are funded by voluntary employee contributions. Pfizer PAC is no different; it relies on the participation of Pfizer colleagues.

Who Receives Pfizer PAC Contributions?

Pfizer PAC is nonpartisan. It supports Democrats and Republicans who support policies that impact our purpose: Breakthroughs that change patients' lives. From January 2019 through December 2020, Pfizer PAC supported 950 candidates.

When choosing to make a contribution to a candidate, our Government Relations colleagues consider candidates' views and voting record on policy issues that impact patient access to breakthrough medicines and vaccines as well as the impact on our employees and Pfizer facilities in the candidate's district or state. A complete list of Pfizer PAC and state corporate political contributions for January 2019 – December 2020 is included in this report.



PFIZER PAC & POLITICAL CONTRIBUTIONS GOVERNANCE POLICY

Pfizer complies fully with all federal, state, and local laws and reporting requirements governing PAC and corporate political contributions.

Pfizer has a Corporate Policy Procedure (#802a) that requires all PAC and corporate political contributions to be compiled and published annually in a report that is made available to employees, shareholders, and the public, and posted on the Company's website at www.pfizer.com in "Lobbying and Political Contributions" under the "About Pfizer" tab within the "Corporate Governance" section. At the end of each Federal cycle (every two years), the Pfizer PAC is audited by Withum, a certified public accounting and advisory firm.

Pfizer also requests that trade associations receiving total payments of \$100,000 or more from Pfizer in a given year report the portion of Pfizer dues or payments used for expenditures or contributions that, if made directly by Pfizer, would not be deductible under section 162(e)(1)(B) of the Internal Revenue Code. We are disclosing such information received from our trade associations in this report.

Pfizer has a PAC Steering Committee comprised of five colleagues who review and approve all PAC and corporate political contributions on a monthly basis. To ensure adequate representation, Steering Committee members represent different divisions within the Pfizer organization. The PAC Steering Committee evaluates candidates on a basis of their views on issues that impact Pfizer and its colleagues. It also takes note of whether Pfizer facilities or colleagues reside in a candidate's district or state. In addition, all PAC and corporate contribution requests are shared with the Pfizer Political Contributions Policy Committee for review. The Political Contributions Policy Committee is responsible for governing the Pfizer PAC.

Pfizer does not traditionally make contributions to 527 Issue Organizations. If we were asked to make such a contribution, it would have to be reviewed and approved by the Political Contributions Policy Committee and subsequently disclosed in our semi-annual report.

Finally, in light of the Supreme Court decision in the Citizens United case, Pfizer has determined that it will not make any direct independent expenditures, a decision which has been discussed at the executive level as well as with the Corporate Governance Committee of our Board.

Political Contributions Policy Committee

CO CHAIR

[Sally Susman](#)

Executive Vice President
Chief Corporate Affairs Officer

[David Blackwell](#)

Senior Director
Global General Toxicology
Research & Development

[Rod MacKenzie](#)

Executive Vice President
Chief Development Officer
Global Product Development
Group

CO CHAIR

[Rady Johnson](#)

Executive Vice President
Chief Compliance, Quality
& Risk Officer

[Josh Brown](#)

Vice President
State Government Relations
Corporate Affairs

[Margaret Madden](#)

Senior Vice President
& Corporate Secretary
Chief Governance Counsel

TREASURER

[Matthew Meehan](#)

Director
U.S. Government Relations

[Sheryl Colyer](#)

Vice President
Human Resources

[Ed Nowicki](#)

Senior Vice President
Deputy Chief Compliance Officer
Corporate Compliance

SECRETARY

[Barbara Bonfiglio](#)

Assistant General Counsel
Corporate Governance

[Navin Katyal](#)

Regional President
Hospital Business Unit
Pfizer Biopharma Group

[Andrew Schmeltz](#)

Global President
Pfizer Oncology
Pfizer Biopharma Group

[John Kelly](#)

Vice President
Quality Operations & EHS
Pfizer Global Supply

[Jennifer Walton](#)

Vice President
U.S. Government Relations
Corporate Affairs

[Nick Lagunowich](#)

Global President
Internal Medicine
Pfizer Biopharma Group

[John Young](#)

Group President
Chief Business Officer

Pfizer PAC Steering Committee

[Leslie Black, DBA](#)

Senior Manager
Oncology Training

[Sam Gonzalez](#)

Business/Scientific
Operations Lead
Global Products Development
Pfizer Oncology

[Dezarie Mayers](#)

Senior Manager
Global Health & Social Impact

[Jim Cafone](#)

Vice President
Pfizer Global Supply

[Mike Hoffman](#)

Vice President
Global Procurement

[Dennis Ryan](#)

Key Account Manager
Pfizer Internal Medicine

[Richard Dudek](#)

Vice President
National Sales
Pfizer Oncology



Pfizer PAC

Political Action Committee

Leading the Conversation

Political Contributions Recipients

January 2019 – December 2020



Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
ALABAMA									
US SENATE									
		Doug Jones	▲			D			\$10,000.00
		Sen. Thomas H. Tuberville	▲		Up in '26	R			\$2,500.00
US HOUSE									
	W	Rep. Robert Brown Aderholt				R	004		\$1,000.00
		Bradley Roberts Byrne				R	001		\$2,500.00
	W	Rep. Terri Andrea Sewell				D	007		\$6,000.00
STATE ATTORNEY GENERAL									
		AG Steve T. Marshall	▲	●		R		\$5,000.00	
ALASKA									
US SENATE									
	W	Sen. Daniel Scott Sullivan	▲			R			\$5,000.00
ARIZONA									
US SENATE									
		Martha Elizabeth McSally	▲			R			\$7,500.00
		Sen. Kyrsten Sinema	▲		Up in '24	D			\$2,500.00
US HOUSE									
	W	Rep. Ruben M. Gallego	▲			D	007		\$2,000.00
	W	Rep. Ann L. Kirkpatrick				D	002		\$2,000.00
	W	Rep. Tom O'Halleran				D	001		\$4,000.00
	W	Rep. David Schweikert				R	006		\$2,000.00
STATE SENATE									
		Sylvia Tenney Allen				R	006		\$600.00
	W	Sen. Lela Alston	▲			D	024		\$600.00
	W	Sen. Nancy K. Barto				R	015		\$400.00
	W	Sen. Sean Bowie				D	018		\$650.00
	W	Sen. Paul Boyer				R	020		\$600.00
		David T. Bradley				D	010		\$350.00
		Kate Brophy McGee				R	028		\$650.00
		Heather Carter				R	015		\$900.00
	W	Sen. Lupe Chavira Contreras				D	019		\$650.00
	W	Sen. Karen Elizabeth Fann				R	001		\$750.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Sen. David M. Gowan, Sr.				R	014		\$600.00
	W	Sen. Rick Gray				R	021		\$650.00
	W	Sen. Sine Kerr				R	013		\$600.00
	W	Sen. Venden Leach				R	011		\$600.00
	W	Sen. David Livingston				R	022		\$600.00
	W	Sen. Javan D. Mesnard				R	017		\$650.00
	W	Sen. Otoniel Navarrete				D	030		\$600.00
	W	Sen. Lisa Anne Otondo				D	004		\$600.00
	W	Sen. Tyler Pace				R	025		\$750.00
	W	Sen. Warren Petersen				R	012		\$600.00
	W	Sen. Rebecca Rios				D	027		\$600.00
	W	Sen. Thomas Shope				R	008		\$600.00
	W	Sen. Michelle Ugenti-Rita				R	023		\$500.00
STATE HOUSE									
		Sen. Nancy K. Barto				R	015		\$500.00
	W	Rep. Leo Biasiucci				R	005		\$550.00
	W	Rep. Walter Blackman				R	006		\$400.00
	W	Rep. Reginald Bolding				D	027		\$500.00
	W	Rep. Shawna Bolick				R	020		\$400.00
	W	Rep. Russell W. Bowers				R	025		\$750.00
	W	Rep. Judy M. Burges				R	001		\$250.00
	W	Rep. Kelli Butler				D	028		\$500.00
	W	Rep. Cesar Chavez				D	029		\$600.00
	W	Rep. Regina E. Cobb				R	005		\$900.00
	W	Rep. David Cook				R	008		\$600.00
	W	Rep. Domingo DeGrazia				D	010		\$200.00
	W	Rep. J. Diego Espinoza				D	019		\$650.00
	W	Rep. Charlene R. Fernandez				D	004		\$600.00
	W	Rep. Mark W. Finchem				R	011		\$650.00
	W	Rep. Randall S. Friese				D	009		\$600.00
	W	Rep. Travis W. Grantham				R	012		\$600.00
	W	Rep. Alma Hernandez				D	003		\$650.00
	W	Rep. Daniel Hernandez, Jr.				D	002		\$650.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Jake Hoffman				R	012		\$200.00
	W	Rep. Jennifer Jermaine				D	018		\$200.00
	W	Rep. John Kavanagh				R	023		\$400.00
		Anthony T. Kern				R	020		\$550.00
		Jay Lawrence				R	023		\$600.00
	W	Rep. Aaron Lieberman				D	028		\$550.00
	W	Rep. Jennifer Longdon	▲			D	024		\$200.00
	W	Rep. Robert Meza				D	030		\$600.00
	W	Rep. Becky Ann Nutt				R	014		\$600.00
	W	Rep. Joanne Osborne				R	013		\$550.00
	W	Rep. Jennifer Pawlik				D	017		\$500.00
	W	Rep. Kevin Payne				R	021		\$500.00
	W	Rep. Frank M. Pratt				R	008		\$600.00
	W	Rep. Bret Roberts				R	011		\$550.00
		Bob Robson				R	018		\$200.00
	W	Rep. Lorenzo Sierra				D	019		\$200.00
	W	Rep. Stephanie Stahl Hamilton				D	010		\$200.00
	W	Rep. Ben Toma				R	022		\$600.00
	W	Rep. Michelle Udall				R	025		\$550.00
	W	Rep. Jeff Weninger				R	017		\$600.00
ARKANSAS									
US HOUSE									
	W	Rep. J. French Hill	▲			R	002		\$2,500.00
STATE SENATE									
		Sen. Cecile Bledsoe			Up in '22	R	003		\$500.00
		John R. Cooper				R	021		\$500.00
	W	Sen. Breanne Davis				R	016		\$500.00
	W	Sen. Jimmy Hickey, Jr.				R	011		\$500.00
		Sen. Missy Thomas Irvin			Up in '22	R	018		\$500.00
		Sen. Mark Johnson			Up in '22	R	015		\$500.00
		Sen. Bill Sample			Up in '22	R	014		\$500.00
STATE HOUSE									
	W	Rep. Justin Boyd				R	077		\$1,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Deborah Ferguson				D	051		\$1,000.00
	W	Rep. Denise Garner				D	084		\$500.00
	W	Rep. Michelle Gray				R	062		\$500.00
	W	Rep. Lee Johnson				R	075		\$500.00
	W	Rep. Fredrick J. Love				D	029		\$500.00
	W	Rep. Stephen Magie				D	072		\$1,000.00
	W	Rep. Reginald Murdock				D	048		\$500.00
		Chris Richey				D	012		\$500.00

CALIFORNIA

US HOUSE

	W	Rep. Peter Ray Aguilar				D	031		\$3,000.00
	W	Rep. Nanette Diaz Barragan				D	044		\$2,000.00
	W	Rep. Karen Ruth Bass				D	037		\$1,000.00
	W	Rep. Amerish B. Bera				D	007		\$4,000.00
	W	Rep. Kenneth S. Calvert				R	042		\$1,000.00
	W	Rep. Tony Cardenas				D	029		\$7,000.00
		Paul Joseph Cook				R	008		\$1,000.00
	W	Rep. J. Luis Correa				D	046		\$4,000.00
	W	Rep. Anna G. Eshoo	▲			D	018		\$7,000.00
	W	Rep. Jimmy Gomez				D	034		\$5,000.00
	W	Rep. Barbara Jean Lee				D	013		\$5,000.00
	W	Rep. Ted W. Lieu				D	033		\$1,000.00
	W	Rep. Doris O. Matsui	▲			D	006		\$2,000.00
	W	Rep. Kevin Owen McCarthy				R	023		\$10,000.00
	W	Rep. Devin G. Nunes				R	022		\$8,500.00
	W	Rep. James V. Panetta				D	020		\$5,500.00
	W	Rep. Nancy Pelosi	▲			D	012		\$5,000.00
	W	Rep. Scott H. Peters	▲			D	052		\$6,500.00
	W	Rep. Raul Ruiz				R	036		\$5,500.00
	W	Rep. Linda T. Sanchez	▲			D	038		\$7,000.00
	W	Rep. Eric Michael Swalwell, Jr.				D	015		\$2,000.00
	W	Rep. Michael C. Thompson				D	005		\$1,000.00
	W	Rep. Norma Judith Torres				D	035		\$3,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Juan Carlos Vargas				D	051		\$2,000.00
	W	Rep. Maxine Waters				D	043		\$1,000.00
STATE TREASURER									
		Hon. Fiona Ma	▲		Up in '22	D			\$1,500.00
STATE CONTROLLER									
		Cathleen Galgiani			Up in '22	D			\$1,500.00
		Sen. Bob M. Hertzberg			Up in '22	D			\$1,500.00
STATE SENATE									
	W	Sen. Toni G. Atkins	▲			D	039		\$4,000.00
	W	Sen. Josh Becker	▲			D	013		\$2,500.00
		Sen. Anna Marie Caballero			Up in '22	D	012		\$5,000.00
		Ling-Ling Chang				R	029		\$2,000.00
	W	Sen. Bill Dodd				D	003		\$3,100.00
		Sen. Maria Elena Durazo			Up in '22	D	024		\$1,500.00
	W	Sen. Steven M. Glazer				D	007		\$2,500.00
	W	Sen. Lena A. Gonzalez		●		D	033		\$1,500.00
		Sen. Shannon L. Grove			Up in '22	R	016		\$3,500.00
		Sen. Melissa Hurtado			Up in '22	D	014		\$3,500.00
	W	Sen. John Laird	▲			D	017		\$500.00
	W	Sen. Monique Limon				D	019		\$1,500.00
	W	Sen. Anthony J. Portantino				D	025		\$3,500.00
		Sen. Susan Rubio			Up in '22	D	022		\$3,000.00
		Sen. Thomas J. Umberg		●		D	034		\$2,000.00
					Up in '22	D	034		\$2,000.00
	W	Sen. Scott Wiener	▲			D	011		\$1,500.00
	W	Sen. Scott Thomas Wilk				R	021		\$1,500.00
STATE HOUSE									
	W	Assm. Cecilia M. Aguiar-Curry				D	004		\$3,000.00
	W	Assm. Joaquin Arambula				D	031		\$4,000.00
	W	Assm. Frank Bigelow				R	005		\$3,000.00
	W	Assm. Tasha Boerner Horvath				D	076		\$4,000.00
	W	Assm. Rob Bonta				D	018		\$4,000.00
		William P. Brough	▲	●		R	073		\$1,500.00

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
						R	073	\$1,500.00	
	W	Assm. Autumn R. Burke				D	062	\$1,500.00	
	W	Assm. Lisa Calderon	▲			D	057	\$1,500.00	
	W	Assm. Wendy Carrillo				D	051	\$2,000.00	
	W	Assm. Jim Cooper				D	009	\$5,500.00	
	W	Assm. Jordan Cunningham				R	035	\$2,500.00	
	W	Assm. Tom Daly				D	069	\$8,900.00	
	W	Assm. Heath Flora				R	012	\$4,500.00	
	W	Assm. Vince Fong				R	034	\$4,000.00	
	W	Assm. Jim Frazier				D	011	\$3,000.00	
	W	Assm. Mike A. Gipson				D	064	\$3,000.00	
	W	Assm. Lorena Gonzalez				D	080	\$5,000.00	
	W	Assm. Adam C. Gray				D	021	\$3,000.00	
	W	Assm. Timothy S. Grayson				D	014	\$4,000.00	
	W	Assm. Jacqui Irwin				D	044	\$1,500.00	
	W	Assm. Sydney K. Kamlager				D	054	\$1,500.00	
	W	Assm. Marc Levine				D	010	\$4,000.00	
		Sen. Monique Limon				D	037	\$1,500.00	
	W	Assm. Evan Low				D	028	\$1,500.00	
	W	Assm. Brian Maienschein	▲			R	077	\$4,000.00	
		Efren Martinez				D	059	\$1,500.00	
	W	Assm. Chad Mayes				R	042	\$3,500.00	
	W	Assm. Jose Medina				D	061	\$3,500.00	
	W	Assm. Kevin Mullin	▲			D	022	\$4,000.00	
	W	Assm. Adrin Nazarian				D	046	\$8,000.00	
	W	Assm. Cottie Petrie-Norris	▲			D	074	\$1,500.00	
	W	Assm. James C. Ramos				D	040	\$4,000.00	
	W	Assm. Robert Rivas				D	030	\$3,000.00	
	W	Assm. Freddie Rodriguez				D	052	\$4,000.00	
	W	Assm. Blanca E. Rubio				D	048	\$3,500.00	
		Sylvia Rubio	▲	●		D	057	\$1,500.00	
	W	Assm. Rudy Salas				D	032	\$5,000.00	
	W	Assm. Miguel Santiago				D	053	\$3,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Assm. Marie Waldron				R	075	\$4,000.00	
	W	Assm. Chris Ward	▲			D	078	\$1,500.00	
	W	Assm. Jim Wood				D	002	\$1,000.00	
MAYOR (Sacramento)									
	W	May. Darrell S. Steinberg				D		\$200.00	
COLORADO									
US SENATE									
		Cory Gardner	▲			R			\$6,000.00
US HOUSE									
	W	Rep. Diana L. DeGette	▲			D	001		\$6,000.00
STATE SENATE									
	W	Sen. Jeff Bridges				D	026		\$400.00
	W	Sen. Janet P. Buckner				D	028		\$400.00
	W	Sen. James Rashad Coleman				D	033		\$400.00
	W	Sen. Steven Fenberg	▲			D	018		\$200.00
	W	Sen. Rhonda Fields				D	029		\$400.00
	W	Sen. Bob Gardner				R	012		\$200.00
	W	Sen. Chris Hansen	▲			D	031		\$400.00
		Sen. Dennis Hisey			Up in '22	R	002		\$200.00
	W	Sen. Barbara Kirkmeyer				R	023		\$200.00
	W	Sen. Larry G. Liston				R	010		\$200.00
	W	Sen. Dominick Moreno				D	021		\$400.00
		Sen. Brittany L. Pettersen			Up in '22	D	022		\$200.00
	W	Sen. Bob Rankin				R	008		\$200.00
	W	Sen. Cleave Simpson, Jr.				R	035		\$200.00
	W	Sen. Jim Smallwood				R	004		\$200.00
		Sen. Rob Woodward			Up in '22	R	015		\$200.00
	W	Sen. Rachel Zenzinger	▲			D	019		\$200.00
STATE HOUSE									
	W	Rep. Judith Amabile				D	013		\$200.00
	W	Rep. Mark Baisley				R	039		\$400.00
		K.C. Becker				D	013		\$200.00
	W	Rep. Shannon K. Bird				D	035		\$400.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Mary Bradfield				R	021		\$200.00
	W	Rep. Yadira Caraveo				D	031		\$200.00
	W	Rep. Daneya Esgar				D	046		\$400.00
	W	Rep. Alec Garnett				D	002		\$400.00
	W	Rep. Matt Gray				D	033		\$200.00
	W	Rep. Leslie Herod				D	008		\$200.00
	W	Rep. Dominique Jackson				D	042		\$200.00
	W	Rep. Julie McCluskie				D	061		\$400.00
	W	Rep. Dafna Michaelson Jenet				D	030		\$400.00
	W	Rep. Kim Ransom				R	044		\$200.00
	W	Rep. Naquetta Ricks				D	040		\$200.00
	W	Rep. Dylan Roberts				D	026		\$400.00
	W	Rep. Matt Soper				R	054		\$400.00
	W	Rep. Kerry Tipper				D	028		\$200.00
CONNECTICUT									
US SENATE									
		Sen. Richard Blumenthal	▲		Up in '22	D			\$4,800.00
US HOUSE									
	W	Rep. Joseph D. Courtney	▲			D	002		\$5,500.00
	W	Rep. James Andrew Himes	▲			D	004		\$4,500.00
	W	Rep. John Barry Larson	▲			D	001		\$6,000.00
DELAWARE									
US SENATE									
	W	Sen. Christopher Andrew Coons	▲			D			\$4,000.00
US HOUSE									
	W	Rep. Lisa Blunt Rochester	▲			D	001		\$5,000.00
GOVERNOR									
	W	Gov. John Charles Carney, Jr.	▲			D		\$1,000.00	
LIEUTENANT GOVERNOR									
	W	Hon. Bethany A. Hall-Long	▲			D		\$1,000.00	
STATE TREASURER									
		Hon. Colleen C. Davis	▲		Up in '22	D		\$400.00	

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
INSURANCE COMMISSIONER									
	W	Hon. Trinidad Navarro	▲			D		\$900.00	
STATE SENATE									
		Sen. Darius J. Brown			Up in '22	D	002	\$300.00	
		Catherine L. Cloutier				R	005	\$600.00	
		Anthony Delcollo				R	007	\$300.00	
	W	Sen. Bruce C. Ennis				D	014	\$600.00	
		Jacqueline Hugg				D	015	\$300.00	
		Sen. S. Elizabeth Lockman			Up in '22	D	003	\$300.00	
	W	Sen. Marie Pinkney				D	013	\$400.00	
	W	Sen. Nicole Poore	▲			D	012	\$200.00	
	W	Sen. John Walsh				D	009	\$200.00	
STATE HOUSE									
	W	Rep. Andria L. Bennett				D	032	\$300.00	
	W	Rep. William Bush				D	029	\$600.00	
	W	Rep. Nnamdi O. Chukwuocha				D	001	\$200.00	
	W	Rep. Krista Griffith				D	012	\$500.00	
		Earl G. Jaques, Jr.				D	027	\$200.00	
	W	Rep. Kendra L. Johnson				D	005	\$300.00	
		Rachael King				D	033	\$100.00	
	W	Rep. Larry D. Lambert, Jr.				D	007	\$300.00	
	W	Rep. Valerie J. Longhurst	▲			D	015	\$200.00	
	W	Rep. Sean M. Lynn				D	031	\$300.00	
	W	Rep. Sean Matthews				D	010	\$200.00	
	W	Rep. Melissa Minor-Brown				D	017	\$200.00	
	W	Rep. Sherae'a Moore				D	008	\$300.00	
	W	Rep. Bryan W. Shupe				R	036	\$300.00	
	W	Rep. Michael F. Smith				R	022	\$400.00	
DISTRICT OF COLUMBIA									
CITY COUNCILPERSON (DC)									
		Brandon Todd				D	004	\$500.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
FLORIDA									
US SENATE									
		Sen. Marco Antonio Rubio	▲		Up in '22	R			\$7,500.00
US HOUSE									
	W	Rep. Gus Michael Bilirakis				R	012		\$1,000.00
		Rep. Gus Michael Bilirakis			Up in '22	R	012		\$2,500.00
	W	Rep. Vernon Gale Buchanan				R	016		\$4,000.00
	W	Rep. Val Butler Demings				D	010		\$4,500.00
	W	Rep. Mario Rafael Diaz-Balart				R	025		\$2,000.00
	W	Rep. Lois Jane Frankel				D	021		\$1,000.00
	W	Rep. Stephanie N. Murphy				D	007		\$4,500.00
		Donna E. Shalala				D	027		\$2,000.00
	W	Rep. Darren Michael Soto				D	009		\$5,000.00
	W	Rep. Debbie Wasserman Schultz				D	023		\$2,500.00
STATE SENATE									
	W	Sen. Danny W. Burgess				R	020	\$1,000.00	
	W	Sen. Gayle B. Harrell				R	025	\$1,000.00	
	W	Sen. Shevrin D. Jones				D	035	\$1,000.00	
STATE HOUSE									
	W	Rep. Vance Arthur Aloupis, Jr.				R	115	\$2,000.00	
	W	Rep. James Vernon Buchanan				R	074	\$1,000.00	
	W	Rep. Colleen Burton				R	040	\$2,000.00	
	W	Rep. Michael A. Caruso				R	089	\$1,000.00	
	W	Rep. Charles Wesley Clemons, Sr.				R	021	\$1,000.00	
	W	Rep. Ben Diamond				D	068	\$1,000.00	
	W	Rep. Nick DiCeglie				R	066	\$1,000.00	
	W	Rep. Nicholas X. Duran				D	112	\$1,000.00	
	W	Rep. Juan Alfonso Fernandez-Barquin				R	119	\$1,000.00	
	W	Rep. Elizabeth Anne Fetterhoff				R	026	\$2,000.00	
	W	Rep. Christopher John Latvala				R	067	\$1,000.00	
	W	Rep. Ralph E. Massullo, Jr.				R	034	\$1,000.00	
	W	Rep. Lawrence McClure				R	058	\$1,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Anthony Rodriguez				R	118	\$1,000.00	
		Alexandria Suarez				R	120	\$500.00	
	W	Rep. Allison Tant				D	009	\$1,000.00	
	W	Rep. Jackie Toledo				R	060	\$1,000.00	
	W	Rep. Clay E. Yarborough				R	012	\$1,000.00	
GEORGIA									
US SENATE									
		Kelly Loeffler	▲			R			\$10,000.00
		David Alfred Perdue, Jr.	▲			R			\$6,500.00
US HOUSE									
	W	Rep. Sanford D. Bishop, Jr.	▲			D	002		\$1,000.00
	W	Rep. Earl L. B. Carter				R	001		\$5,500.00
		Douglas Allen Collins				R	009		\$1,000.00
	W	Rep. A. Drew Ferguson, IV				R	003		\$9,000.00
		Tom Graves				R	014		\$3,000.00
	W	Rep. Henry C. Johnson, Jr.	▲			D	004		\$2,000.00
LIEUTENANT GOVERNOR									
		Hon. Geoffrey L. Duncan	▲		Up in '22	R			\$7,000.00
STATE SENATE									
	W	Sen. Matthew Freeman Brass				R	028		\$1,000.00
	W	Sen. Dean Burke				R	011		\$1,000.00
	W	Sen. Gloria Singleton Butler				D	055		\$2,000.00
	W	Sen. Gail Davenport				D	044		\$2,000.00
	W	Sen. Michael Dugan				R	030		\$1,500.00
	W	Sen. Ed Harbison				D	015		\$500.00
		Steve Henson	▲			D	041		\$500.00
	W	Sen. Chuck Hufstetler				R	052		\$1,000.00
	W	Sen. Lester G. Jackson, III.				D	002		\$500.00
	W	Sen. John F. Kennedy				R	018		\$1,000.00
	W	Sen. Kay Kirkpatrick	▲			R	032		\$1,000.00
		P.K. Martin				R	009		\$1,000.00
	W	Sen. Cecil Terrell Miller				R	049		\$1,700.00
	W	Sen. Nancy Grogan Orrock	▲			D	036		\$500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Sen. Valencia M. Seay				D	034	\$300.00	
		Jesse Collins Stone				R	023	\$500.00	
	W	Sen. Horacena Tate				D	038	\$500.00	
	W	Sen. Blake Tillery				R	019	\$500.00	
	W	Sen. Ben L. Watson				R	001	\$1,500.00	
		Rep. Nikema Williams				D	039	\$500.00	
STATE HOUSE									
		Sharon Beasley-Teague		DR		D	065	\$500.00	
	W	Rep. Patty J. Bentley				D	139	\$500.00	
	W	Rep. Shaw Blackmon				R	146	\$500.00	
	W	Rep. Jon G. Burns				R	159	\$2,000.00	
	W	Rep. Sharon M. Cooper				R	043	\$2,000.00	
	W	Rep. Katie M. Dempsey				R	013	\$1,000.00	
		Pamela Dickerson				D	113	\$250.00	
	W	Rep. Winfred J. Dukes				D	154	\$250.00	
	W	Rep. Chuck Efstrotation				R	104	\$1,000.00	
	W	Rep. Terry England				R	116	\$1,500.00	
	W	Rep. Barry A. Fleming				R	121	\$1,500.00	
	W	Rep. Gloria J. Frazier				D	126	\$300.00	
		Patricia Park Gardner				D	057	\$300.00	
		Brett Harrell				R	106	\$1,000.00	
	W	Rep. Matthew Hatchett				R	150	\$1,000.00	
		Michele Henson				D	086	\$2,000.00	
	W	Rep. Carolyn Hugley				D	136	\$750.00	
	W	Rep. Sheila Jones				D	053	\$300.00	
	W	Rep. Angelika Kausche				D	050	\$500.00	
	W	Rep. Trey Kelley				R	016	\$1,500.00	
	W	Rep. Pedro R. Marin				D	096	\$500.00	
	W	Rep. William W. Mitchell	FA			D	088	\$1,750.00	
	W	Rep. W. Mark Newton				R	123	\$1,500.00	
	W	Rep. Mary Margaret Oliver				D	082	\$300.00	
	W	Rep. Larry J. Parrish				R	158	\$1,000.00	
	W	Rep. Alan T. Powell				R	032	\$1,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Jay Powell				R	171	\$500.00	
	W	Rep. David Ralston				R	007	\$2,000.00	
	W	Rep. Richard H. Smith				R	134	\$1,500.00	
	W	Rep. Calvin Smyre				D	135	\$3,300.00	
		Kevin Kermit Tanner				R	009	\$250.00	
		Robert T. Trammell, Jr				D	132	\$1,000.00	
	W	Rep. Cyril Algernon Williams				D	168	\$500.00	
	W	Rep. Bruce Williamson				R	115	\$1,000.00	
HAWAII									
US SENATE									
		Sen. Mazie Keiko Hirono	▲		Up in '24	D			\$5,000.00
LIEUTENANT GOVERNOR									
		Hon. Joshua B. Green	▲		Up in '22	D		\$2,300.00	
STATE SENATE									
		Sen. Rosalyn H. Baker			Up in '22	D	006	\$1,000.00	
	W	Sen. Donovan M. Dela Cruz				D	022	\$800.00	
		Sen. J. Kalani English			Up in '22	D	007	\$800.00	
	W	Sen. Gilbert S.C. Keith-Agaran				D	005	\$500.00	
		Sen. Michelle N. Kidani			Up in '22	D	018	\$500.00	
	W	Sen. Ronald D. Kouchi				D	008	\$1,000.00	
		Sen. Clarence K. Nishihara			Up in '22	D	017	\$300.00	
	W	Sen. Joy A. San Buenaventura				D	002	\$200.00	
	W	Sen. Brian T. Taniguchi				D	011	\$300.00	
STATE HOUSE									
	W	Rep. Henry James C. Aquino				D	038	\$100.00	
	W	Rep. Della Au Belatti				D	024	\$1,000.00	
		Rida Cabanilla Arakawa				D	041	\$200.00	
	W	Rep. Ty Diaz Cullen				D	039	\$500.00	
	W	Rep. Lynn DeCoite				D	013	\$100.00	
	W	Rep. Linda E. Ichiyama				D	032	\$500.00	
	W	Rep. Bertrand Kobayashi				D	019	\$300.00	
	W	Rep. Nicole E. Lowen				D	006	\$100.00	
	W	Rep. Sylvia J. Luke				D	025	\$1,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. John M. Mizuno				D	028	\$1,000.00	
	W	Rep. Daynette Morikawa				D	016	\$500.00	
	W	Rep. Nadine K. Nakamura				D	014	\$200.00	
	W	Rep. Scott Y. Nishimoto				D	021	\$800.00	
	W	Rep. Richard H.K. Onishi				D	003	\$200.00	
	W	Rep. Scott K. Saiki				D	026	\$1,000.00	
		Calvin K. Y. Say				D	020	\$100.00	
	W	Rep. Roy M. Takumi				D	035	\$450.00	
	W	Rep. Justin H. Woodson				D	009	\$250.00	

IDAHO

US SENATE									
		Sen. Michael Dean Crapo	▲		Up in '22	R			\$2,500.00
	W	Sen. James E. Risch	▲			R			\$2,000.00

STATE SENATE

	W	Sen. Jeff C. Agenbroad				R	013	\$300.00	
	W	Sen. Grant Burgoyne				D	016	\$500.00	
	W	Sen. Van T. Burtenshaw				R	035	\$500.00	
	W	Sen. Lori Den Hartog				R	022	\$300.00	
	W	Sen. Jim Guthrie				R	028	\$300.00	
	W	Sen. Mark R. Harris				R	032	\$1,000.00	
		Brent Hill				R	034	\$500.00	
		Maryanne Jordan				D	017	\$200.00	
	W	Sen. Todd M. Lakey				R	012	\$500.00	
	W	Sen. Abby Lee				R	009	\$300.00	
	W	Sen. Fred S. Martin				R	015	\$1,400.00	
	W	Sen. James L. Patrick				R	025	\$500.00	
	W	Sen. Doug Ricks				R	034	\$300.00	
	W	Sen. Peter J. Riggs				R	003	\$500.00	
	W	Sen. Mary Souza				R	004	\$600.00	
	W	Sen. Janie Ward-Engelking				D	018	\$300.00	
	W	Sen. Chuck Winder				R	020	\$900.00	

STATE HOUSE

	W	Rep. Scott C. Bedke				R	027	\$1,000.00	
--	---	---------------------	--	--	--	---	-----	------------	--



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Megan C. Blanksma				R	023	\$500.00	
	W	Rep. Matthew Bundy				R	023	\$300.00	
	W	Rep. Greg Chaney				R	010	\$300.00	
	W	Rep. Susan B. Chew				D	017	\$200.00	
		Mathew Erpelding	▲			D	019	\$500.00	
	W	Rep. Marc Gibbs				R	032	\$500.00	
	W	Rep. Laurie Lickley				R	025	\$600.00	
		Britt Raybould				R	034	\$300.00	
	W	Rep. Ilana S. Rubel				D	018	\$700.00	
	W	Rep. John Vander Woude				R	022	\$600.00	
		Jarom Wagoner				R	010	\$300.00	
	W	Rep. Fred Wood				R	027	\$1,000.00	
	W	Rep. Rick D. Youngblood				R	012	\$300.00	
ILLINOIS									
US SENATE									
		Sen. L. Tammy Duckworth	▲		Up in '22	D			\$5,000.00
US HOUSE									
	W	Rep. Michael J. Bost				R	012		\$3,000.00
	W	Rep. Cheryl L. Bustos				D	017		\$5,000.00
	W	Rep. Sean Casten				D	006		\$2,000.00
	W	Rep. Rodney Lee Davis	▲			R	013		\$5,000.00
	W	Rep. Bill Foster				D	011		\$1,000.00
	W	Rep. Robin Lynne Kelly				D	002		\$7,000.00
	W	Rep. Adam Daniel Kinzinger				R	016		\$5,000.00
	W	Rep. Darin M. LaHood				R	018		\$4,000.00
	W	Rep. Bradley Scott Schneider	▲			D	010		\$5,000.00
		John M. Shimkus				R	015		\$2,500.00
STATE SENATE									
		Sen. Omar Aquino			Up in '22	D	002	\$500.00	
		William E. Brady, Jr.			Up in '22	R	044	\$2,500.00	
		Sen. William Cunningham			Up in '22	D	018	\$750.00	
		Sen. Donald P. DeWitte			Up in '22	R	033	\$250.00	
	W	Sen. Sara Feigenholtz				D	006	\$1,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Laura Fine			Up in '22	D	009	\$1,500.00	
		Sen. Don Harmon			Up in '22	D	039	\$7,500.00	
		Sen. Napoleon B. Harris, III			Up in '22	D	015	\$2,000.00	
	W	Sen. Michael E. Hastings				D	019	\$750.00	
		Sen. Linda Holmes			Up in '22	D	042	\$500.00	
		Sen. Mattie Hunter			Up in '22	D	003	\$2,250.00	
		Sen. Emil Jones, III			Up in '22	D	014	\$750.00	
		Sen. Steven M. Landek			Up in '22	D	012	\$1,000.00	
	W	Sen. Kimberly A. Lightford				D	004	\$1,000.00	
		Terry Link			Up in '22	D	030	\$1,000.00	
		Iris Y. Martinez			Up in '22	D	020	\$250.00	
	W	Sen. Robert F. Martwick, Jr.				D	010	\$250.00	
		Sen. Dan McConchie			Up in '22	R	026	\$1,500.00	
		Pat McGuire				D	043	\$250.00	
		Sen. Julie A. Morrison	▲		Up in '22	D	029	\$1,500.00	
	W	Sen. Antonio Munoz				D	001	\$4,000.00	
	W	Sen. Laura M. Murphy				D	028	\$250.00	
	W	Sen. Steven Stadelman				D	034	\$250.00	
		Heather A. Steans			Up in '22	D	007	\$500.00	
		Sen. Dave Syverson			Up in '22	R	035	\$500.00	
	W	Sen. Celina Villanueva				D	011	\$250.00	
		Sen. Craig Wilcox			Up in '22	R	032	\$250.00	
STATE HOUSE									
	W	Rep. Jaime M. Andrade, Jr.				D	040	\$750.00	
		Luis Arroyo				D	003	\$500.00	
	W	Rep. Dan E. Brady				R	105	\$500.00	
	W	Rep. Kelly M. Burke				D	036	\$500.00	
		John M. Cabello				R	068	\$500.00	
		Rep. Kelly M. Cassidy			Up in '22	D	014	\$250.00	
	W	Rep. Dan Caulkins				R	101	\$250.00	
	W	Rep. Deborah O'Keefe Conroy				D	046	\$500.00	
	W	Rep. Fred Crespo				D	044	\$500.00	
	W	Rep. William Davis				D	030	\$500.00	

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Anthony DeLuca				D	080	\$1,000.00	
	W	Rep. Tom Demmer				R	090	\$1,000.00	
	W	Rep. Daniel Didech				D	059	\$500.00	
	W	Rep. Jim Durkin				R	082	\$2,250.00	
	W	Rep. Marcus C. Evans, Jr.				D	033	\$500.00	
	W	Rep. Mary E. Flowers				D	031	\$1,500.00	
	W	Rep. La Shawn K. Ford				D	008	\$500.00	
	W	Rep. Robyn Gabel				D	018	\$2,000.00	
	W	Rep. Jehan A. Gordon-Booth				D	092	\$500.00	
	W	Rep. Latoya N. Greenwood				D	114	\$500.00	
	W	Rep. Norine K. Hammond				R	093	\$250.00	
	W	Rep. Gregory Harris				D	013	\$2,500.00	
	W	Rep. Elizabeth Hernandez				D	024	\$250.00	
	W	Rep. Jay C. Hoffman				D	113	\$1,000.00	
	W	Rep. Frances Ann Hurley				D	035	\$250.00	
		Yehiel Kalish				D	016	\$1,500.00	
	W	Rep. Camille Lilly				D	078	\$500.00	
	W	Rep. Michael J. Madigan				D	022	\$3,500.00	
	W	Rep. Natalie A. Manley				D	098	\$500.00	
	W	Rep. Rita Mayfield				D	060	\$750.00	
		Rep. Rita Mayfield			Up in '22	D	060	\$1,000.00	
	W	Rep. Deanne Marie Mazzochi				R	047	\$750.00	
	W	Rep. Bob Morgan	▲			D	058	\$500.00	
	W	Rep. Martin J. Moylan				D	055	\$250.00	
		Diane Pappas	▲			D	045	\$250.00	
	W	Rep. Robert Rita				D	028	\$750.00	
		Rep. Robert Rita			Up in '22	D	028	\$250.00	
	W	Rep. Lamont J. Robinson, Jr.				D	005	\$750.00	
	W	Rep. Nicholas K. Smith				D	034	\$2,000.00	
	W	Rep. Ryan Spain				R	073	\$250.00	
	W	Rep. Bradley Stephens				R	020	\$500.00	
	W	Rep. Andre M. Thapedi				D	032	\$500.00	
		Arthur Turner, Jr.				D	009	\$250.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Mark L. Walker				D	053	\$250.00	
	W	Rep. Lawrence M. Walsh, Jr.				D	086	\$1,500.00	
	W	Rep. Emanuel Chris Welch				D	007	\$750.00	
	W	Rep. Keith R. Wheeler				R	050	\$500.00	
	W	Rep. Ann M. Williams				D	011	\$500.00	
	W	Rep. Kathleen Willis				D	077	\$250.00	
	W	Rep. Michael J. Zalewski				D	023	\$2,000.00	
CITY COUNCILPERSON (Chicago)									
		Ald. Howard B. Brookins, Jr.			Up in '23	D	021	\$250.00	
		Ald. Brian Hopkins			Up in '23	NP	002	\$250.00	
		Ald. Brendan Reilly			Up in '23	D	042	\$250.00	
		Ald. Thomas M. Tunney			Up in '23	D	044	\$250.00	
		Ald. Gilbert Villegas			Up in '23	D	036	\$250.00	
INDIANA									
US SENATE									
		Sen. Michael K. Braun	▲		Up in '24	R			\$1,000.00
		Sen. Todd Christopher Young	▲		Up in '22	R			\$3,500.00
US HOUSE									
	W	Rep. James E. Banks				R	003		\$1,500.00
	W	Rep. Larry Dean Bucshon	▲			R	008		\$4,500.00
	W	Rep. Andre D. Carson	▲			D	007		\$1,000.00
	W	Rep. Gregory J. Pence				R	006		\$2,500.00
	W	Rep. Jacqueline Walorski				R	002		\$8,000.00
STATE SENATE									
	W	Sen. Rodric D. Bray				R	037		\$500.00
	W	Sen. Jean D. Breaux				D	034		\$500.00
		Sen. Elizabeth Brown			Up in '22	R	015		\$250.00
	W	Sen. Edward E. Charbonneau				R	005		\$500.00
	W	Sen. Michael R. Crider				R	028		\$250.00
		Sen. James D. Ford			Up in '22	D	029		\$250.00
		Sen. Ronald T. Grooms			Up in '22	R	046		\$250.00
		Sen. Travis Holdman			Up in '22	R	019		\$250.00
		Sen. Erin Houchin			Up in '22	R	047		\$250.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Timothy S. Lanane			Up in '22	D	025		\$250.00
	W	Sen. Jean Leising				R	042		\$250.00
	W	Sen. Ryan D. Mishler				R	009		\$250.00
STATE HOUSE									
		Ronald Bacon				R	075		\$250.00
	W	Rep. Bradford J. Barrett				R	056		\$250.00
		Brian C. Bosma				R	088		\$500.00
	W	Rep. Timothy N. Brown				R	041		\$250.00
	W	Rep. Martin J. Carbaugh				R	081		\$500.00
	W	Rep. Steven Joseph Davisson				R	073		\$250.00
	W	Rep. Philip Kelly GiaQuinta				D	080		\$250.00
	W	Rep. Dave Allen Heine				R	085		\$250.00
	W	Rep. Todd Michael Huston				R	037		\$1,000.00
		Cindy Lynn Kirchhofer				R	089		\$500.00
	W	Rep. Donald Joseph Lehe				R	025		\$250.00
	W	Rep. Shane Michael Lindauer				R	063		\$250.00
	W	Rep. Ethan E. Manning				R	023		\$250.00
	W	Rep. Gregory W. Porter				D	096		\$250.00
	W	Rep. Robin Cheri Shackelford				D	098		\$500.00
	W	Rep. Dennis James Zent				R	051		\$250.00
	W	Rep. Cindy Meyer Ziemke				R	055		\$250.00
IOWA									
US SENATE									
	W	Sen. Joni Kay Ernst	▲			R			\$10,000.00
GOVERNOR									
		Gov. Kimberly Reynolds	▲		Up in '22	R			\$1,000.00
STATE SENATE									
		Sen. Tony Bisignano			Up in '22	D	017		\$1,000.00
	W	Sen. Dan Dawson				R	008		\$250.00
	W	Sen. Pam Jochum				D	014		\$500.00
		Sen. Kevin Kinney			Up in '22	D	039		\$500.00
		Sen. Jim Lykam			Up in '22	D	045		\$250.00
	W	Sen. Liz Mathis				D	034		\$500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Amanda Ragan			Up in '22	D	027		\$500.00
	W	Sen. Ken Rozenboom				R	040		\$250.00
		Sen. Jason Schultz			Up in '22	R	009		\$500.00
	W	Sen. Amy Sinclair				R	014		\$250.00
		Sen. Annette Sweeney			Up in '22	R	025		\$750.00
		Sen. Todd E. Taylor			Up in '22	D	035		\$250.00
		Sen. Jack Whitver			Up in '22	R	019		\$1,750.00

STATE HOUSE

	W	Rep. Marti Anderson				D	036		\$250.00
	W	Rep. Brian Best				R	012		\$500.00
	W	Rep. Jane E. Bloomingdale				R	051		\$250.00
	W	Rep. Wesley C. Breckenridge				D	029		\$500.00
	W	Rep. Holly Brink				R	080		\$250.00
	W	Rep. Joel Fry				R	027		\$500.00
	W	Rep. Pat Grassley				R	050		\$1,250.00
		Chris Hagenow				R	043		\$1,000.00
	W	Rep. Bruce L. Hunter				D	034		\$250.00
	W	Rep. Megan Hess Jones				R	002		\$1,250.00
	W	Rep. Kenan Judge				D	044		\$250.00
	W	Rep. Bobby Kaufmann				R	073		\$500.00
	W	Rep. Jarad Klein				R	078		\$500.00
	W	Rep. Brian K. Lohse				R	030		\$1,250.00
	W	Rep. Shannon Lundgren				R	057		\$1,000.00
	W	Rep. Mary S. Mascher				D	086		\$500.00
		Andy McKean				D	058		\$250.00
	W	Rep. Ann Meyer				R	009		\$250.00
	W	Rep. Brian Meyer				D	033		\$250.00
	W	Rep. Joe Mitchell				R	084		\$500.00
	W	Rep. Jo Oldson				D	041		\$250.00
	W	Rep. Rick L. Olson				D	031		\$250.00
		Scott Ourth				D	026		\$250.00
	W	Rep. Todd Prichard				D	052		\$4,000.00
	W	Rep. Kristin Sunde				D	042		\$500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Jon Thorup				R	028		\$500.00
		Linda L. Upmeyer				R	054		\$1,000.00
	W	Rep. Matt W. Windschitl				R	017		\$1,500.00
KANSAS									
US SENATE									
	W	Sen. Roger W. Marshall	▲			R			\$5,000.00
		Sen. Jerry W. Moran	▲		Up in '22	R			\$9,500.00
US HOUSE									
	W	Rep. Ron Estes	▲			R	004		\$5,000.00
STATE SENATE									
		Edward E. Berger				R	034	\$1,000.00	
		Sen. Ethan Corson			Up in '24	D	007	\$500.00	
		Sen. Brenda S. Dietrich			Up in '24	R	020	\$500.00	
		Sen. Renee Erickson			Up in '24	R	030	\$500.00	
		Sen. Beverly Gossage			Up in '24	R	009	\$500.00	
		Sen. Richard Kloos			Up in '24	R	019	\$500.00	
		Sen. Kristen O'Shea			Up in '24	R	018	\$500.00	
		Sen. Jeff Pittman			Up in '24	D	005	\$500.00	
		Sen. Mark Steffen			Up in '24	R	034	\$500.00	
	W	Sen. Gene Suellentrop				R	027	\$2,000.00	
		Sen. Mike Thompson			Up in '24	R	010	\$500.00	
		Sen. Kellie Warren			Up in '24	R	011	\$500.00	
STATE HOUSE									
	W	Rep. John R. Eplee				R	063	\$1,000.00	
	W	Rep. Daniel R. Hawkins				R	100	\$1,000.00	
	W	Rep. Brenda K. Landwehr				R	105	\$1,000.00	
		Monica Murnan				D	003	\$1,000.00	
	W	Rep. Tom Sawyer				D	095	\$500.00	
KENTUCKY									
US SENATE									
	W	Sen. Mitch McConnell	▲			R			\$386.11
US HOUSE									
	W	Rep. Andy H. Barr, IV				R	006		\$2,500.00

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. S. Brett Guthrie				R	002		\$3,500.00
GOVERNOR									
		Matthew Griswold Bevin	▲			R			\$4,000.00
STATE SENATE									
	W	Sen. David P. Givens				R	009		\$1,000.00
	W	Sen. Christian McDaniel				R	023		\$1,500.00
	W	Sen. Bertram Robert Stivers				R	025		\$3,000.00
	W	Sen. Damon Thayer				R	017		\$2,000.00
STATE HOUSE									
	W	Rep. John Carney				R	051		\$1,000.00
	W	Rep. David Meade				R	080		\$1,000.00
	W	Rep. Kimberly Poore Moser				R	064		\$1,000.00
	W	Rep. Jason Michael Nemes				R	033		\$500.00
	W	Rep. David W. Osborne				R	059		\$2,000.00
	W	Rep. Bart T. Rowland				R	053		\$1,000.00
LOUISIANA									
US SENATE									
	W	Sen. William Cassidy	▲			R			\$4,000.00
		Sen. John Neely Kennedy	▲		Up in '22	R			\$3,500.00
US HOUSE									
	W	Rep. Garret Neal Graves	▲			R	006		\$1,000.00
	W	Cedric Levon Richmond				D	002		\$5,500.00
	W	Rep. Stephen Joseph Scalise				R	001		\$10,000.00
SECRETARY OF STATE (STATE LEVEL)									
	W	Hon. R. Kyle Ardoin	▲			R			\$500.00
STATE SENATE									
	W	Sen. R.L. Allain, II				R	021		\$500.00
	W	Sen. Regina Ashford Barrow				D	015		\$500.00
	W	Sen. Gerald Boudreaux				D	024		\$500.00
		Sen. Gerald Boudreaux			Up in '23	D	024		\$1,000.00
		Sen. Joseph Bouie, Jr.			Up in '23	D	003		\$500.00
	W	Sen. Troy A. Carter				D	007		\$500.00
		Sen. Troy A. Carter			Up in '23	D	007		\$500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Stewart Cathey, Jr.			Up in '23	R	033	\$500.00	
		Sen. Heather Cloud			Up in '23	R	028	\$500.00	
	W	Sen. Patrick Page Cortez				R	023	\$500.00	
		Sen. Patrick Page Cortez			Up in '23	R	023	\$1,000.00	
		Reid Falconer				R	011	\$500.00	
		James Roy Fannin				R	035	\$500.00	
		Sen. Michael Fesi, Sr.			Up in '23	R	020	\$500.00	
	W	Sen. Jimmy Harris				D	004	\$500.00	
		Sen. Jimmy Harris			Up in '23	D	004	\$500.00	
	W	Sen. Bob Hensgens				R	026	\$500.00	
		Sen. Bob Hensgens			Up in '23	R	026	\$1,000.00	
	W	Sen. Sharon W. Hewitt				R	001	\$500.00	
	W	Sen. Katrina R. Jackson				D	034	\$500.00	
	W	Sen. Ronnie Johns				R	027	\$500.00	
	W	Sen. Jay Luneau				D	029	\$500.00	
		Sen. Jay Luneau			Up in '23	D	029	\$500.00	
		Sen. Patrick McMath			Up in '23	R	011	\$500.00	
	W	Sen. Fred H. Mills, Jr.				R	022	\$500.00	
		Sen. Fred H. Mills, Jr.			Up in '23	R	022	\$1,000.00	
		Sen. Robert Mills			Up in '23	R	036	\$500.00	
		Sen. Beth Mizell			Up in '23	R	012	\$500.00	
		Sen. Jay Morris			Up in '23	R	035	\$500.00	
	W	Sen. Barrow Peacock				R	037	\$500.00	
		Sen. J. Rogers Pope			Up in '23	R	013	\$500.00	
	W	Sen. Edward J. Price				D	002	\$500.00	
	W	Sen. Gary L. Smith, Jr.				D	019	\$500.00	
		Patricia Haynes Smith	▲			D	014	\$500.00	
	W	Sen. Gregory W. Tarver, Sr.				D	039	\$500.00	
	W	Sen. Rick Ward, III				R	017	\$500.00	
	W	Sen. Mack A. White, Jr.				R	006	\$500.00	
		Sen. Glen D. Womack			Up in '23	R	032	\$500.00	
STATE HOUSE									
	W	Rep. Tony Bacala				R	059	\$250.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Lawrence A. Bagley				R	007	\$250.00	
		Rep. Lawrence A. Bagley			Up in '23	R	007	\$1,000.00	
		Rep. Stuart J. Bishop			Up in '23	R	043	\$500.00	
	W	Rep. Ken Brass				D	058	\$250.00	
	W	Rep. Chad Brown				D	060	\$250.00	
		Rep. Chad Brown			Up in '23	D	060	\$250.00	
		Rep. Marcus Anthony Bryant			Up in '23	D	096	\$500.00	
		Rep. Barbara West Carpenter			Up in '23	D	063	\$250.00	
	W	Rep. Gary M. Carter, Jr.				D	102	\$250.00	
		Rep. Gary M. Carter, Jr.			Up in '23	D	102	\$250.00	
	W	Rep. Jean-Paul Coussan				R	045	\$250.00	
	W	Rep. Kenny Ray Cox				D	023	\$250.00	
		Rep. Raymond Crews			Up in '23	R	008	\$250.00	
	W	Rep. Paula Davis				R	069	\$250.00	
		Rep. Paula Davis			Up in '23	R	069	\$500.00	
	W	Rep. Phillip DeVillier				R	041	\$250.00	
	W	Rep. Mary DuBuisson				R	090	\$250.00	
	W	Rep. Royce Duplessis				D	093	\$250.00	
	W	Stephen Dwight				R	035	\$250.00	
		Rep. Michael C. Echols			Up in '23	R	014	\$250.00	
	W	Rep. Rick Edmonds				R	066	\$250.00	
	W	Rep. Julie Emerson				R	039	\$250.00	
		Rep. Gabe Firment			Up in '23	R	022	\$250.00	
		Rep. Larry Frieman			Up in '23	R	074	\$250.00	
	W	Rep. Randal L. Gaines				D	057	\$250.00	
	W	Rep. Raymond E. Garofalo, Jr.				R	103	\$250.00	
		Rep. Kyle M. Green, Jr.			Up in '23	D	083	\$250.00	
	W	Rep. Lance Harris				R	025	\$250.00	
	W	Rep. Stephanie Hilferty				R	094	\$250.00	
		Rep. Jason Hughes			Up in '23	D	100	\$250.00	
		Rep. Mike Huval			Up in '23	R	046	\$1,000.00	
		Rep. John R. Illg, Jr.			Up in '23	R	078	\$250.00	
	W	Rep. Barry Ivey				R	065	\$250.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Edward C. James				D	101	\$250.00	
		Rep. Edmond Jordan			Up in '23	D	029	\$250.00	
		Christopher J. Leopold				R	105	\$250.00	
	W	Rep. Sherman Q. Mack				R	095	\$250.00	
		Rep. Sherman Q. Mack			Up in '23	R	095	\$250.00	
	W	Rep. Tanner Magee				R	053	\$250.00	
		Rep. Tanner Magee			Up in '23	R	053	\$500.00	
	W	Rep. Jack G. McFarland				R	013	\$250.00	
	W	Rep. Wayne McMahan				R	010	\$250.00	
		Rep. Wayne McMahan			Up in '23	R	010	\$250.00	
	W	Rep. Blake Miguez				R	049	\$250.00	
		Rep. Blake Miguez			Up in '23	R	049	\$500.00	
	W	Rep. Dustin Miller				D	040	\$250.00	
	W	Rep. Gregory A. Miller				R	056	\$250.00	
		Rep. Dustin Miller			Up in '23	D	040	\$250.00	
	W	Rep. Nicholas Muscarello, Jr.				R	086	\$250.00	
		Rep. Robert S. Owen			Up in '23	R	076	\$250.00	
	W	Rep. Vincent J. Pierre				D	044	\$250.00	
		Rep. Vincent J. Pierre			Up in '23	D	044	\$500.00	
		Rep. Thomas Alexander Pressly, IV			Up in '23	R	006	\$250.00	
		Rep. Clay Schexnayder			Up in '23	R	081	\$500.00	
		Rep. Larry Selders	▲		Up in '23	D	067	\$250.00	
	W	Rep. Joseph A. Stagni				R	092	\$250.00	
	W	Rep. Polly J. Thomas				R	080	\$250.00	
	W	Rep. Christopher Turner				R	012	\$250.00	
		Rep. Christopher Turner			Up in '23	R	012	\$500.00	
		Rep. Matthew Willard			Up in '23	D	097	\$250.00	
	W	Rep. Mark Wright				R	077	\$250.00	
	W	Rep. Jerome Zeringue				R	052	\$250.00	

MAINE

STATE SENATE

W	Sen. G. William Diamond	D	026	\$650.00
---	-------------------------	---	-----	----------



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
STATE HOUSE									
	W	Rep. Susan M. W. Austin				R	109	\$250.00	
	W	Rep. Beth A. O'Connor	▲			R	005	\$250.00	
MARYLAND									
US HOUSE									
	W	Rep. Anthony Gregory Brown				D	004		\$5,500.00
	W	Rep. Steny Hamilton Hoyer	▲			D	005		\$10,000.00
	W	Rep. Kweisi Mfume				D	007		\$1,000.00
	W	Rep. Jamie Ben Raskin	▲			D	008		\$2,000.00
STATE SENATE									
		Sen. Malcolm L. Augustine			Up in '22	D	047	\$500.00	
		Sen. Jack Daniel Bailey			Up in '22	R	029	\$500.00	
		Sen. Pamela G. Beidle			Up in '22	D	032	\$500.00	
		Sen. Joanne Claybon Benson			Up in '22	D	024	\$500.00	
		Sen. Mary Beth Carozza			Up in '22	R	038	\$500.00	
		Sen. Arthur Carr Ellis			Up in '22	D	028	\$500.00	
		Sen. Brian Jeffrey Feldman			Up in '22	D	015	\$1,000.00	
		Sen. Bill Ferguson			Up in '22	D	046	\$4,000.00	
		Sen. Jason Charles Gallion			Up in '22	R	035	\$500.00	
		Sen. Antonio L. Hayes			Up in '22	D	040	\$1,000.00	
		Sen. Stephen S. Hershey, Jr.			Up in '22	R	036	\$1,250.00	
		Sen. Katie Fry Hester			Up in '22	D	009	\$250.00	
		Sen. Michael Joseph Hough			Up in '22	R	004	\$250.00	
		Sen. J. B. Jennings			Up in '22	R	007	\$1,250.00	
		Sen. Cheryl Corinne Kagan			Up in '22	D	017	\$750.00	
		Sen. Delores G. Kelley			Up in '22	D	010	\$1,750.00	
		Sen. Katherine Klausmeier			Up in '22	D	008	\$500.00	
		Sen. Benjamin F. Kramer			Up in '22	D	019	\$500.00	
		Sen. Clarence K. Lam			Up in '22	D	012	\$500.00	
		Thomas V. Miller, Jr.			Up in '22	D	027	\$1,000.00	
		Shirley Nathan-Pulliam			Up in '22	D	044	\$250.00	
		Sen. Obie Patterson			Up in '22	D	026	\$500.00	
		Sen. Paul G. Pinsky			Up in '22	D	022	\$750.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Edward Robert Reilly			Up in '22	R	033	\$500.00	
		Sen. Bryan W. Simonaire			Up in '22	R	031	\$500.00	
		Sen. Mary L. Washington			Up in '22	D	043	\$250.00	
		Sen. Ronald Nelson Young			Up in '22	D	003	\$250.00	
STATE HOUSE									
		Del. Ereik L. Barron			Up in '22	D	024	\$250.00	
		Del. Lisa Belcastro			Up in '22	D	011	\$125.00	
		Del. Harry Bhandari			Up in '22	D	008	\$225.00	
		Del. Alfred Clinton Carr, Jr			Up in '22	D	018	\$200.00	
		Del. Nick Charles			Up in '22	D	025	\$225.00	
		Del. Brian A. Chisholm			Up in '22	R	31B	\$250.00	
		Del. Bonnie L. Cullison			Up in '22	D	019	\$1,000.00	
		Del. Terri L. Hill			Up in '22	D	012	\$250.00	
		Del. Steve C. Johnson			Up in '22	D	34A	\$250.00	
		Del. Adrienne A. Jones			Up in '22	D	010	\$3,000.00	
		Del. Ariana Brannigan Kelly			Up in '22	D	016	\$375.00	
		Del. Ken Kerr			Up in '22	D	03B	\$250.00	
		Del. Nicholas R. Kipke			Up in '22	R	31B	\$1,050.00	
		Del. Susan W. Krebs			Up in '22	R	09B	\$500.00	
		Del. Robbyn Lewis			Up in '22	D	046	\$250.00	
		Del. Richard W. Metzgar			Up in '22	R	006	\$100.00	
		Del. James Matthew Morgan			Up in '22	R	29A	\$575.00	
		Del. Joseline A. Pena-Melnyk			Up in '22	D	021	\$1,000.00	
		Del. Shane E. Pendergrass	▲		Up in '22	D	013	\$1,750.00	
		Del. Teresa Reilly			Up in '22	R	35B	\$125.00	
		Del. Samuel I. Rosenberg			Up in '22	D	042	\$500.00	
		Del. Sid Saab			Up in '22	R	033	\$500.00	
		Del. Sheree Sample-Hughes			Up in '22	D	37A	\$375.00	
		Del. Kathryn Y. Szeliga			Up in '22	R	007	\$1,050.00	
		Del. Karen Lewis Young			Up in '22	D	03A	\$500.00	
MASSACHUSETTS									
US HOUSE									
	W	Rep. Katherine M. Clark	▲			D	005		\$3,500.00
W			NP						



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. William Richard Keating				D	009		\$2,000.00
	W	Rep. Richard Edmund Neal	▲			D	001		\$7,500.00
US SENATE									
	W	Sen. Gary Charles Peters	▲			D			\$5,000.00
US HOUSE									
	W	Rep. Deborah Ann Dingell	▲			D	012		\$2,000.00
	W	Rep. Daniel Timothy Kildee				D	005		\$3,000.00
	W	Rep. Brenda L. Lawrence				D	014		\$1,000.00
	W	Rep. Frederick Stephen Upton	▲			R	006		\$10,000.00
	W	Rep. Timothy L. Walberg				R	007		\$1,000.00
STATE SENATE									
		Sen. John Bizon			Up in '22	R	019		\$500.00
		Sen. Curtis Hertel, Jr.	▲		Up in '22	D	023		\$1,500.00
		Peter MacGregor			Up in '22	R	028		\$1,000.00
		Sen. Sean A. McCann	▲		Up in '22	D	020		\$500.00
		Sen. Jim Stamas			Up in '22	R	036		\$1,000.00
		Sen. Lana L. Theis			Up in '22	R	022		\$500.00
		Sen. Curt VanderWall			Up in '22	R	035		\$1,000.00
STATE HOUSE									
	W	Rep. Julie Calley				R	087		\$500.00
	W	Rep. Matthew Hall				R	063		\$500.00
	W	Rep. Roger Hauck				R	099		\$1,000.00
	W	Rep. Mark E. Huizenga				R	074		\$500.00
		Brandt Iden	▲			R	061		\$2,000.00
	W	Rep. Sarah L. Lightner				R	065		\$500.00
	W	Rep. Jim Lilly				R	089		\$500.00
	W	Rep. Brad Paquette				R	078		\$500.00
		Jason M. Sheppard				R	056		\$1,000.00
		Hank Vaupel				R	047		\$500.00
		Rebekah Warren				D	053		\$500.00
	W	Rep. Jason Wentworth				R	097		\$1,000.00
	W	Rep. Mary Whiteford				R	080		\$500.00

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
MINNESOTA									
US HOUSE									
	W	Rep. Thomas Earl Emmer, Jr.				R	006		\$1,000.00
MISSISSIPPI									
US HOUSE									
	W	Rep. Bennie G. Thompson				D	002		\$4,500.00
GOVERNOR									
	W	Gov. Tate Reeves	▲			R		\$1,000.00	
		Gov. Tate Reeves	▲		Up in '23	R		\$1,000.00	
LIEUTENANT GOVERNOR									
	W	Hon. Delbert Hosemann	▲			R		\$1,000.00	
		Hon. Delbert Hosemann	▲		Up in '23	R		\$1,000.00	
INSURANCE COMMISSIONER									
	W	Hon. Mike Chaney	▲			R		\$1,000.00	
		Hon. Mike Chaney	▲		Up in '23	R		\$1,000.00	
STATE SENATE									
	W	Sen. Kevin Blackwell				R	019	\$500.00	
		Sen. Kevin Blackwell			Up in '23	R	019	\$500.00	
	W	Sen. Hob Bryan				D	007	\$250.00	
		Sen. Hob Bryan			Up in '23	D	007	\$500.00	
	W	Sen. Joel R. Carter, Jr.				R	049	\$500.00	
		Sen. Dennis DeBar, Jr.			Up in '23	R	043	\$250.00	
	W	Sen. Joey Fillingane				R	041	\$250.00	
		Sen. Joey Fillingane			Up in '23	R	041	\$250.00	
	W	Sen. Josh Harkins				R	020	\$750.00	
		Sen. Josh Harkins			Up in '23	R	020	\$500.00	
	W	Sen. Angela Burks Hill				R	040	\$500.00	
	W	Sen. John A. Horhn				D	026	\$250.00	
		Sen. John A. Horhn			Up in '23	D	026	\$250.00	
		Sen. Chris Johnson			Up in '23	R	045	\$500.00	
	W	Sen. M. Dean Kirby				R	030	\$250.00	
		Sen. M. Dean Kirby			Up in '23	R	030	\$500.00	
	W	Sen. Chad McMahan				R	006	\$500.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Sen. J. Walter Michel				R	025	\$750.00	
		Sen. J. Walter Michel			Up in '23	R	025	\$500.00	
	W	Sen. Rita Potts Parks				R	004	\$500.00	
		Sen. Rita Potts Parks			Up in '23	R	004	\$500.00	
	W	Sen. John A. Polk				R	044	\$250.00	
		Sen. John A. Polk			Up in '23	R	044	\$500.00	
	W	Sen. Brice Wiggins				R	052	\$500.00	
		Sen. Brice Wiggins			Up in '23	R	052	\$250.00	
		Sen. Tammy Felder Witherspoon			Up in '23	D	038	\$250.00	
STATE HOUSE									
	W	Rep. Richard Bennett				R	120	\$250.00	
		Rep. Richard Bennett			Up in '23	R	120	\$250.00	
	W	Rep. C. Scott Bounds				R	044	\$500.00	
	W	Rep. Chris Brown				R	020	\$250.00	
	W	Rep. Charles T. Busby				R	111	\$250.00	
	W	Gary Alan Chism				R	037	\$500.00	
		William C. Denny, Jr.				R	064	\$500.00	
	W	Rep. Philip Gunn				R	056	\$1,000.00	
		Rep. Philip Gunn			Up in '23	R	056	\$1,000.00	
	W	Rep. John Wesley Hines, Sr.				D	050	\$250.00	
	W	Rep. Joey Hood				R	035	\$500.00	
		Rep. Joey Hood			Up in '23	R	035	\$500.00	
	W	Rep. Elton Mac Huddleston				R	015	\$250.00	
	W	Rep. John Thomas Lamar				R	008	\$500.00	
		Rep. John Thomas Lamar			Up in '23	R	008	\$500.00	
	W	Rep. Missy Warren McGee				R	102	\$500.00	
	W	Rep. Sam C. Mims, V				R	097	\$500.00	
		Rep. Sam C. Mims, V			Up in '23	R	097	\$500.00	
	W	Rep. John O. Read				R	112	\$500.00	
		Rep. John O. Read			Up in '23	R	112	\$500.00	
		Jeffrey C. Smith				R	039	\$1,000.00	
	W	Rep. Percy W. Watson				D	103	\$250.00	
	W	Rep. Jason M. White				R	048	\$500.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Rep. Jason M. White			Up in '23	R	048	\$500.00	
	W	Rep. Lee Yancey				R	074	\$250.00	
MISSOURI									
US SENATE									
		Sen. Roy Dean Blunt	▲		Up in '22	R			\$5,000.00
US HOUSE									
		William Lacy Clay, Jr.	▲			D	001		\$1,000.00
	W	Rep. Emanuel Cleaver, II	▲			D	005		\$1,000.00
	W	Rep. Samuel Bruce Graves, Jr.				R	006		\$2,000.00
	W	Rep. William H. Long, II				R	007		\$7,500.00
	W	Rep. Jason Thomas Smith				R	008		\$9,500.00
	W	Rep. Ann Louise Wagner	▲			R	002		\$9,000.00
LIEUTENANT GOVERNOR									
	W	Hon. Mike Kehoe	▲			R			\$2,600.00
SECRETARY OF STATE (STATE LEVEL)									
	W	Hon. John R. Ashcroft	▲			R			\$1,000.00
STATE TREASURER									
	W	Hon. Scott Fitzpatrick	▲			R			\$2,000.00
STATE AUDITOR GENERAL									
		Hon. Nicole Galloway			Up in '22	D			\$2,600.00
STATEWIDE									
		Sen. Dan Hegeman			Up in '22	R			\$1,000.00
STATE SENATE									
	W	Sen. Lauren Arthur				D	017		\$1,000.00
	W	Sen. Jason Bean				R	025		\$1,200.00
	W	Sen. Doug Beck	▲			D	001		\$1,200.00
		Sen. Mike Bernskoetter			Up in '22	R	006		\$1,000.00
		Jack Bondon, Jr.				R	031		\$1,000.00
		Sen. Justin Dan Brown			Up in '22	R	016		\$1,000.00
		David Cole				R	029		\$1,000.00
		Sen. Lincoln Hough			Up in '22	R	020		\$1,500.00
		Sen. Tony Luetkemeyer			Up in '22	R	034		\$2,500.00
	W	Sen. Angela Mosley				D	013		\$1,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Tommie Pierson, Jr.				D	013		\$1,000.00
	W	Sen. Holly Rehder				R	027		\$1,000.00
	W	Sen. John Joseph Rizzo				D	011		\$2,000.00
		Robert Ross				R	033		\$1,000.00
	W	Sen. Caleb Rowden				R	019		\$3,059.00
STATE HOUSE									
	W	Rep. LaDonna Appelbaum	▲			D	071		\$500.00
	W	Rep. LaKeySha Bosley				D	079		\$500.00
	W	Rep. Doug Clemens				D	072		\$500.00
	W	Rep. Mary Elizabeth Coleman				R	097		\$750.00
	W	Rep. Dirk E. Deaton				R	159		\$750.00
	W	Rep. Aaron D. Griesheimer				R	061		\$500.00
		Elijah Haahr				R	134		\$1,000.00
		Kip Kendrick				D	045		\$1,000.00
	W	Rep. Michael A. O'Donnell				R	095		\$750.00
	W	Rep. Jonathan Patterson				R	030		\$1,000.00
	W	Rep. Louis Riggs				R	005		\$750.00
	W	Rep. Brenda Shields				R	011		\$500.00
	W	Rep. Cody Smith				R	163		\$1,000.00
	W	Rep. Curtis D. Trent				R	133		\$1,000.00
	W	Rep. Rob Vescovo				R	112		\$1,700.00
	W	Rep. John D. Wiemann				R	103		\$1,000.00
COUNTY EXECUTIVE (St. Louis)									
	W	Sam Page				D			\$1,000.00
MONTANA									
US SENATE									
	W	Sen. Steve David Daines	▲			R			\$10,000.00
GOVERNOR									
		Tim Fox	▲			R			\$680.00
INSURANCE COMMISSIONER									
		Sen. Shane A. Morigeau	▲			D			\$340.00
STATE SENATE									
		Nancy Ballance				R	044		\$180.00



Winner



Non-Partisan



Debt-Retirement



Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Sen. Terry J. Gauthier				R	040		\$180.00
	W	Sen. Greg Hertz				R	006		\$180.00
STATE HOUSE									
		Barbara Bessette				D	024		\$180.00
	W	Rep. Ed Buttrey				R	021		\$180.00
	W	Rep. Llewelyn E. Jones				R	018		\$180.00
	W	Rep. Connie Keogh				D	091		\$180.00
NEBRASKA									
US SENATE									
		Sen. Debra S. Fischer	▲		Up in '24	R			\$7,000.00
	W	Sen. Benjamin Eric Sasse	▲			R			\$3,500.00
US HOUSE									
	W	Rep. Jeffrey Lane Fortenberry	▲			R	001		\$3,500.00
	W	Rep. Adrian Michael Smith				R	003		\$7,500.00
GOVERNOR									
		Gov. Pete Ricketts	▲		Up in '22	R			\$4,600.00
STATE SENATE									
	W	Sen. Joni Albrecht				R	017		\$300.00
		Sen. John Arch			Up in '22	R	014		\$600.00
	W	Sen. Bruce Bostelman	▲			R	023		\$300.00
		Sen. Machaela Cavanaugh			Up in '22	D	006		\$300.00
		Sen. Myron Dorn			Up in '22	R	030		\$300.00
	W	Sen. Michael Flood				NP	019		\$300.00
	W	Sen. Suzanne Geist				R	025		\$600.00
		Sen. Ben Hansen			Up in '22	R	016		\$300.00
	W	Sen. Mike Hilgers	▲			R	021		\$600.00
		Sen. Mark A. Kolterman			Up in '22	R	024		\$600.00
		Andrew La Grone				R	049		\$600.00
		Sen. Steve Lathrop			Up in '22	NP	012		\$600.00
		Sen. Brett Lindstrom			Up in '22	R	018		\$600.00
	W	Sen. Lou Ann Linehan				R	039		\$600.00
	W	Sen. John S. Lowe, Sr.				R	037		\$600.00
	W	Sen. Mike McDonnell				D	005		\$600.00



Winner



Non-Partisan



Debt-Retirement



Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Mike Moser			Up in '22	R	022	\$300.00	
		Sen. Dave Murman			Up in '22	R	038	\$300.00	
		Dan Quick				D	035	\$600.00	
	W	Sen. Julie Slama				R	001	\$300.00	
	W	Sen. Tony Vargas				D	007	\$600.00	
	W	Sen. Lynne M. Walz				D	015	\$300.00	
		Sen. Matt Williams			Up in '22	R	036	\$600.00	
	W	Sen. Anna Wishart	▲			D	027	\$600.00	
NEVADA									
US SENATE									
		Sen. Jacky Rosen	▲		Up in '24	D			\$2,500.00
US HOUSE									
	W	Rep. Steven Alexzander Horsford				D	004		\$3,500.00
	W	Rep. Susie Lee	▲			D	003		\$2,000.00
GOVERNOR									
		Gov. Stephen F. Sisolak	▲		Up in '22	D		\$5,000.00	
STATE SENATE									
	W	Sen. Christopher Lee Brooks				D	003	\$1,000.00	
	W	Sen. Nicole Jeanette Cannizzaro				D	006	\$4,000.00	
		Sen. Marilyn Dondero Loop			Up in '22	D	008	\$1,000.00	
	W	Sen. Peter J. Goicoechea				R	019	\$1,000.00	
	W	Sen. Scott Thomas Hammond				R	018	\$2,000.00	
		Sen. Joseph Paul Hardy, M.D.			Up in '22	R	012	\$2,500.00	
	W	Sen. Dina A. Neal				D	004	\$2,000.00	
	W	Sen. Heidi Seevers Gansert				R	015	\$3,000.00	
		Sen. James Arnold Settlemeyer			Up in '22	R	017	\$2,500.00	
	W	Sen. Patricia Ann Spearman				D	001	\$2,000.00	
		Ellen B. Spiegel				D	007	\$1,000.00	
STATE HOUSE									
		Alexander Assefa				D	042	\$750.00	
		Shea Backus				D	037	\$750.00	
	W	Assm. Teresa Benitez-Thompson				D	027	\$2,000.00	

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Assm. Shannon Mary Bilbray-Axelrod				D	034	\$2,000.00	
	W	Assm. Lesley E. Cohen				D	029	\$1,500.00	
		Christopher Thomas Edwards				R	019	\$1,000.00	
	W	Assm. John Ellison				R	033	\$500.00	
	W	Assm. Jason M. Frierson				D	008	\$2,000.00	
	W	Assm. Gregory Hafen				R	036	\$1,000.00	
	W	Assm. Alexis M. Hansen				R	032	\$500.00	
	W	Assm. Melissa Hardy				R	022	\$2,000.00	
	W	Assm. Sandra Jauregui				D	041	\$750.00	
	W	Assm. Glen Kaimi Leavitt				R	023	\$1,250.00	
	W	Assm. Daniele Monroe-Moreno				D	001	\$1,000.00	
		Connie S. Munk				D	004	\$1,000.00	
	W	Assm. Rochelle T. Nguyen				D	010	\$1,750.00	
	W	Assm. Thomas A. Roberts				R	013	\$1,500.00	
	W	Assm. Robin L. Titus, M.D.				R	038	\$1,000.00	
	W	Assm. Jill Tolles				R	025	\$3,000.00	
	W	Assm. Howard Watts				D	015	\$1,000.00	
	W	Assm. Steven James Yeager				D	009	\$2,500.00	
NEW HAMPSHIRE									
US SENATE									
	W	Sen. Jeanne Shaheen	▲			D			\$5,000.00
US HOUSE									
	W	Rep. Ann McLane Kuster	▲			D	002		\$3,500.00
GOVERNOR									
	W	Gov. Chris Sununu	▲			R		\$7,000.00	
STATE SENATE									
	W	Sen. Kevin A. Avard				R	012	\$500.00	
	W	Sen. Regina M. Birdsell				R	019	\$1,500.00	
	W	Sen. Joseph E. Bradley, III				R	003	\$1,500.00	
	W	Sen. Sharon M. Carson				R	014	\$1,500.00	
	W	Sen. Kevin J. Cavanaugh				D	016	\$2,500.00	
		Shannon E. Chandley	▲			D	011	\$1,500.00	

W Winner

NP Non-Partisan

● Debt-Retirement

▲ Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Sen. Lou D'Allesandro				D	020	\$1,000.00	
	W	Sen. Harold F. French				R	007	\$2,000.00	
	W	Sen. William M. Gannon				R	023	\$1,000.00	
	W	Sen. Robert J. Giuda				R	002	\$1,500.00	
	W	Sen. James P. Gray				R	006	\$1,500.00	
	W	Sen. Jay Kahn				D	010	\$1,500.00	
	W	Sen. Rebecca Perkins Kwoka				D	021	\$500.00	
		Jon Morgan				D	023	\$3,000.00	
	W	Sen. Charles W. Morse				R	022	\$1,500.00	
	W	Sen. Suzanne M. Prentiss				D	005	\$500.00	
	W	Sen. John M. Reagan				R	017	\$1,500.00	
	W	Sen. Denise Ricciardi				R	009	\$500.00	
	W	Sen. Donna M. Soucy				D	018	\$2,000.00	
	W	Sen. Ruth B. Ward				R	008	\$1,000.00	
	W	Sen. David H. Watters				D	004	\$1,500.00	
	W	Sen. Becky Whitley				D	015	\$500.00	
NEW JERSEY									
US SENATE									
		Sen. Robert Menendez	▲		Up in '24	D			\$2,500.00
US HOUSE									
	W	Rep. Joshua S. Gottheimer				D	005		\$5,000.00
	W	Rep. Frank Pallone, Jr.	▲			D	006		\$4,500.00
	W	Rep. William James Pascrell, Jr.				D	009		\$1,000.00
	W	Rep. Donald Milford Payne, Jr.				D	010		\$1,000.00
	W	Rep. Mikie Sherrill	▲			D	011		\$7,500.00
	W	Rep. Jeff Van Drew, D.D.S.				R	002		\$3,000.00
	W	Rep. Bonnie Watson Coleman	▲			D	012		\$2,000.00
STATE SENATE									
		Sen. Dawn Marie Addiego			Up in '21	R	008	\$500.00	
		Sen. Christopher Bateman			Up in '21	R	016	\$500.00	
	W	Sen. Anthony M. Bucco				R	025	\$1,000.00	
		Anthony R. Bucco			Up in '21	R	025	\$500.00	
		Sen. Richard J. Codey	▲		Up in '21	D	027	\$1,500.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Kristin M. Corrado			Up in '21	R	040	\$500.00	
		Sen. Joseph P. Cryan			Up in '21	D	020	\$1,500.00	
		Sen. Sandra Bolden Cunningham			Up in '21	D	031	\$1,200.00	
		Sen. Vin Gopal			Up in '21	D	011	\$1,000.00	
		Sen. Linda R. Greenstein			Up in '21	D	014	\$500.00	
		Sen. Joseph A. Lagana			Up in '21	D	038	\$500.00	
		Sen. Fred H. Madden			Up in '21	D	004	\$1,000.00	
		Sen. Steven V. Oroho			Up in '21	R	024	\$1,600.00	
		Sen. Declan Joseph O'Scanlon, Jr.			Up in '21	R	013	\$1,000.00	
		Sen. Nelida Pou			Up in '21	D	035	\$1,600.00	
		Sen. M. Teresa Ruiz			Up in '21	D	029	\$1,000.00	
		Sen. Paul A. Sarlo			Up in '21	D	036	\$1,100.00	
		Sen. Robert W. Singer			Up in '21	R	030	\$1,000.00	
		Sen. Troy Singleton			Up in '21	D	007	\$1,000.00	
		Sen. Stephen M. Sweeney			Up in '21	D	003	\$1,500.00	
		Sen. Joseph F. Vitale			Up in '21	D	019	\$1,500.00	
		Sen. Loretta Weinberg			Up in '21	D	037	\$1,000.00	
STATE HOUSE									
	W	Assm. Daniel R. Benson				D	014	\$1,500.00	
		Assm. Daniel R. Benson			Up in '21	D	014	\$1,000.00	
	W	Assm. Jon M. Bramnick				R	021	\$2,000.00	
		Assm. Jon M. Bramnick			Up in '21	R	021	\$1,500.00	
		Sen. Anthony M. Bucco				R	025	\$1,500.00	
	W	Assm. John J. Burzichelli				D	003	\$500.00	
		Assm. John J. Burzichelli			Up in '21	D	003	\$1,500.00	
		Assm. Nicholas A. Chiaravalloti			Up in '21	D	031	\$500.00	
	W	Assm. Herbert Conaway				D	007	\$1,000.00	
		Assm. Herbert Conaway			Up in '21	D	007	\$1,500.00	
	W	Assm. Craig J. Coughlin				D	019	\$2,000.00	
		Assm. Craig J. Coughlin			Up in '21	D	019	\$2,500.00	
	W	Assm. Joseph F. Danielsen	▲			D	017	\$500.00	
		Assm. Joseph F. Danielsen	▲		Up in '21	D	017	\$500.00	
	W	Assm. BettyLou DeCroce	▲			R	026	\$1,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Assm. BettyLou DeCroce	▲		Up in '21	R	026	\$1,000.00	
	W	Assm. Christopher P. DePhillips				R	040	\$750.00	
		Assm. Christopher P. DePhillips			Up in '21	R	040	\$750.00	
	W	Assm. John DiMaio	▲			R	023	\$500.00	
		Assm. John DiMaio	▲		Up in '21	R	023	\$500.00	
	W	Assm. Joann Downey				D	011	\$750.00	
		Assm. Joann Downey			Up in '21	D	011	\$500.00	
	W	Assm. Aura Kenny Dunn				R	025	\$500.00	
	W	Assm. Roy Freiman				D	016	\$750.00	
		Assm. Roy Freiman			Up in '21	D	016	\$500.00	
	W	Assm. Louis D. Greenwald				D	006	\$1,500.00	
		Assm. Louis D. Greenwald			Up in '21	D	006	\$2,000.00	
	W	Assm. Jamel C. Holley				D	020	\$500.00	
	W	Assm. Mila M. Jasey	▲			D	027	\$500.00	
		Assm. Mila M. Jasey	▲		Up in '21	D	027	\$900.00	
		Assm. Angelica M. Jimenez			Up in '21	D	032	\$500.00	
	W	Assm. Gordon M. Johnson				D	037	\$500.00	
		Assm. Gordon M. Johnson			Up in '21	D	037	\$500.00	
	W	Assm. Pamela Rosen Lampitt				D	006	\$1,000.00	
		Assm. Pamela Rosen Lampitt			Up in '21	D	006	\$800.00	
	W	Assm. Yvonne M. Lopez				D	019	\$300.00	
		Assm. Yvonne M. Lopez			Up in '21	D	019	\$500.00	
	W	Assm. John Francis McKeon	▲			D	027	\$1,000.00	
		Assm. John Francis McKeon	▲		Up in '21	D	027	\$1,000.00	
	W	Assm. Paul D. Moriarty				D	004	\$700.00	
		Assm. Paul D. Moriarty			Up in '21	D	004	\$500.00	
	W	Assm. Gabriela M. Mosquera				D	004	\$500.00	
		Assm. Gabriela M. Mosquera			Up in '21	D	004	\$500.00	
	W	Assm. Raj Mukherji				D	033	\$500.00	
		Assm. Raj Mukherji			Up in '21	D	033	\$500.00	
	W	Assm. Nancy F. Munoz				R	021	\$1,000.00	
		Assm. Nancy F. Munoz			Up in '21	R	021	\$1,000.00	
	W	Assm. Carol Murphy				D	007	\$350.00	



Winner



Non-Partisan



Debt-Retirement



Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Assm. Carol Murphy			Up in '21	D	007	\$500.00	
	W	Assm. Erik Peterson	▲			R	023	\$1,000.00	
		Assm. Erik Peterson	▲		Up in '21	R	023	\$500.00	
	W	Nancy Pinkin				D	018	\$800.00	
	W	Assm. Eliana Pintor Marin				D	029	\$1,500.00	
		Assm. Eliana Pintor Marin			Up in '21	D	029	\$2,000.00	
	W	Assm. Annette Quijano				D	020	\$500.00	
		Assm. Annette Quijano			Up in '21	D	020	\$500.00	
	W	Assm. Kevin J. Rooney				R	040	\$500.00	
		Assm. Kevin J. Rooney			Up in '21	R	040	\$500.00	
	W	Assm. Gary S. Schaer				D	036	\$750.00	
		Assm. Gary S. Schaer			Up in '21	D	036	\$1,000.00	
	W	Assm. Holly T. Schepisi				R	039	\$500.00	
		Assm. Holly T. Schepisi			Up in '21	R	039	\$500.00	
	W	Assm. Shavonda E. Sumter				D	035	\$500.00	
		Assm. Shavonda E. Sumter			Up in '21	D	035	\$500.00	
		Assm. Lisa Swain			Up in '21	D	038	\$500.00	
	W	Assm. Adam J. Taliaferro				D	003	\$500.00	
		Assm. Adam J. Taliaferro			Up in '21	D	003	\$500.00	
		Assm. P. Christopher Tully			Up in '21	D	038	\$500.00	
	W	Assm. Anthony S. Verrelli	▲			D	015	\$350.00	
		Assm. Anthony S. Verrelli	▲		Up in '21	D	015	\$500.00	
	W	Assm. Jay Webber	▲			R	026	\$500.00	
	W	Assm. Benjie E. Wimberly				D	035	\$500.00	
		Assm. Benjie E. Wimberly			Up in '21	D	035	\$500.00	
		Assm. Harold J. Wirths			Up in '21	R	024	\$500.00	
	W	Assm. Andrew Zwicker				D	016	\$800.00	
		Assm. Andrew Zwicker			Up in '21	D	016	\$750.00	

NEW MEXICO

US SENATE

		Sen. Martin Heinrich	▲		Up in '24	D			\$5,000.00
	W	Sen. Ben Ray Lujan	▲			D			\$10,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
GOVERNOR									
		Gov. Michelle Lujan Grisham	▲		Up in '22	D		\$8,400.00	
LIEUTENANT GOVERNOR									
		Hon. Howie C. Morales	▲		Up in '22	D		\$3,400.00	
STATE SENATE									
	W	Sen. Gregory A. Baca				R	029	\$500.00	
	W	Sen. Craig W. Brandt				R	040	\$1,000.00	
	W	Sen. William F. Burt				R	033	\$500.00	
	W	Sen. Pete Campos				D	008	\$400.00	
	W	Sen. Jacob R. Candelaria				D	026	\$1,000.00	
	W	Sen. Joseph Cervantes, Joe				D	031	\$1,000.00	
		Candace Thompson Gould				R	010	\$1,000.00	
	W	Sen. Ron Griggs				R	034	\$500.00	
	W	Sen. Daniel A. Ivey-Soto				D	015	\$1,000.00	
	W	Sen. Gay G. Kernan				R	042	\$1,000.00	
		Richard C. Martinez				D	005	\$500.00	
	W	Sen. Mark D. Moores				R	021	\$500.00	
	W	Sen. Bill B. O'Neill				D	013	\$500.00	
	W	Sen. Michael Padilla				D	014	\$1,000.00	
		Mary Kay Papen				D	038	\$500.00	
	W	Sen. Cliff R. Pirtle				R	032	\$500.00	
		Sander Rue				R	023	\$1,000.00	
		Clemente Sanchez				D	030	\$500.00	
		John M. Sapien				D	009	\$500.00	
	W	Sen. Gregg William Schmedes				R	019	\$500.00	
		John Arthur Smith				D	035	\$500.00	
	W	Sen. Elizabeth Stefanics				D	039	\$1,000.00	
	W	Sen. Pat Woods				R	007	\$400.00	
STATE HOUSE									
	W	Rep. Deborah A. Armstrong				D	017	\$1,500.00	
	W	Rep. Gail Armstrong				R	049	\$1,000.00	
	W	Rep. Alonzo Baldonado				R	008	\$500.00	
	W	Rep. Zachary J. Cook				R	056	\$1,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Rebecca L. Dow				R	038	\$500.00	
	W	Rep. Brian F. Egolf, Jr.				D	047	\$1,250.00	
	W	Rep. Damon B. Ely				D	023	\$500.00	
	W	Rep. Candy Spence Ezzell				R	058	\$400.00	
	W	Rep. Kelly K. Fajardo				R	007	\$1,000.00	
	W	Rep. Natalie R. Figueroa				D	030	\$500.00	
	W	Rep. Doreen Yvonne Gallegos				D	052	\$400.00	
	W	Rep. Jason Carl Harper				R	057	\$900.00	
	W	Rep. Dayan M. Hochman-Vigil				D	015	\$400.00	
	W	Rep. Georgene Louis				D	026	\$200.00	
	W	Rep. Patricia A. Lundstrom				D	009	\$1,000.00	
	W	Rep. Antonio Maestas				D	016	\$500.00	
	W	Rep. Javier I. Martinez				D	011	\$500.00	
	W	Rep. Rodney D. Montoya				R	001	\$500.00	
	W	Rep. William R. Rehm				R	031	\$500.00	
		Patricio R. Ruiloba				D	012	\$250.00	
	W	Rep. Sheryl Williams Stapleton				D	019	\$500.00	
	W	Rep. Candie G. Sweetser				D	032	\$500.00	
	W	Rep. Elizabeth L. Thomson				D	024	\$1,000.00	
NEW YORK									
US HOUSE									
	W	Rep. Yvette Diana Clarke				D	009		\$3,000.00
		Eliot Lance Engel	▲			D	016		\$1,000.00
	W	Rep. Adriano Espaillat				D	013		\$3,000.00
	W	Rep. Brian M. Higgins				D	026		\$1,000.00
	W	Rep. John Michael Katko				R	024		\$7,500.00
	W	Rep. Carolyn B. Maloney	▲			D	012		\$1,000.00
	W	Rep. Sean Patrick Maloney				D	018		\$3,500.00
	W	Rep. Gregory Weldon Meeks				D	005		\$5,000.00
	W	Rep. Grace Meng				D	006		\$1,000.00
	W	Rep. Joseph D. Morelle				D	025		\$1,000.00
	W	Rep. Jerrold Lewis Nadler				D	010		\$2,000.00
	W	Rep. Thomas W. Reed, II.				R	023		\$7,500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Thomas R. Suozzi				D	003		\$1,000.00
	W	Rep. Paul David Tonko	▲			D	020		\$1,000.00
	W	Rep. Lee M. Zeldin				R	001		\$3,500.00
STATE SENATE									
	W	Sen. Neil D. Breslin	▲			D	044		\$1,000.00
		David S. Carlucci	▲			D	038		\$500.00
	W	Sen. Leroy G. Comrie, Jr.				D	014		\$1,000.00
		John J. Flanagan, Jr.				R	002		\$1,000.00
	W	Sen. Patrick M. Gallivan				R	059		\$1,000.00
	W	Sen. Michael N. Gianaris				D	012		\$2,000.00
	W	Sen. Andrew S. Gounardes				D	022		\$500.00
	W	Sen. Joseph A. Griffo				R	047		\$1,000.00
	W	Sen. Peter B. Harckham				D	040		\$500.00
	W	Sen. Brad M. Hoylman	▲			D	027		\$2,000.00
	W	Sen. Todd D. Kaminsky				D	009		\$500.00
	W	Sen. Timothy M. Kennedy				D	063		\$1,500.00
	W	Sen. Andrew J. Lanza				R	024		\$1,000.00
		Elizabeth O'Connor Little	▲			R	045		\$500.00
	W	Sen. Shelley B. Mayer				D	037		\$1,000.00
	W	Sen. Robert G. Ort				R	062		\$1,000.00
	W	Sen. Kevin S. Parker				D	021		\$1,000.00
	W	Sen. J. Gustavo Rivera				D	033		\$2,000.00
		Joseph E. Robach				R	056		\$500.00
	W	Sen. Diane J. Savino				D	023		\$1,000.00
	W	Sen. James G. Skoufis				D	039		\$1,000.00
	W	Sen. Toby Ann Stavisky				D	016		\$1,000.00
	W	Sen. Andrea Stewart-Cousins				D	035		\$3,200.00
STATE HOUSE									
	W	Assm. Peter J. Abbate, Jr.				D	049		\$1,000.00
	W	Assm. Thomas J. Abinanti				D	092		\$800.00
	W	Assm. Jeffrion L. Aubry				D	035		\$500.00
	W	Assm. William A. Barclay				R	120		\$1,000.00
	W	Assm. Rodneyse Bichotte Hermelyn				D	042		\$500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Assm. Edward C. Braunstein				D	026		\$1,000.00
	W	Assm. Kevin M. Byrne				R	094		\$500.00
	W	Assm. Kevin A. Cahill				D	103		\$1,000.00
		Marcos A. Crespo				D	085		\$1,000.00
	W	Assm. Michael J. Cusick				D	063		\$1,000.00
	W	Assm. Steven H. Cymbrowitz				D	045		\$1,000.00
	W	Assm. Maritza Davila				D	053		\$500.00
	W	Assm. Erik Martin Dilan				D	054		\$1,000.00
	W	Assm. Jeffrey Dinowitz				D	081		\$1,000.00
	W	Rep. Andrew R. Garbarino				R	007		\$500.00
	W	Assm. Richard N. Gottfried				D	075		\$2,000.00
	W	Assm. Aileen M. Gunther				D	100		\$1,000.00
	W	Assm. Andrew D. Hevesi				D	028		\$1,000.00
	W	Assm. Alicia L. Hyndman				D	029		\$1,000.00
		Ellen C. Jaffee				D	097		\$1,000.00
		Brian M. Kolb				R	131		\$500.00
	W	Assm. Charles D. Lavine				D	013		\$1,000.00
		Joseph R. Lentol				D	050		\$1,000.00
	W	Assm. William B. Magnarelli				D	129		\$1,000.00
	W	Assm. John T. McDonald, III				D	108		\$1,000.00
	W	Assm. Catherine T. Nolan				D	037		\$500.00
	W	Assm. Daniel J. O'Donnell				D	069		\$500.00
	W	Assm. Amy R. Paulin				D	088		\$1,000.00
	W	Assm. Crystal D. Peoples-Stokes				D	141		\$2,500.00
	W	Assm. N. Nick Perry				D	058		\$1,000.00
	W	Assm. Stacey G. Pheffer Amato				D	023		\$1,000.00
	W	Assm. Victor M. Pichardo				D	086		\$1,000.00
	W	Assm. J. Gary Pretlow				D	089		\$1,000.00
	W	Assm. Dan Quart	▲			D	073		\$2,000.00
		Andrew P. Raia				R	012		\$500.00
	W	Assm. Karines Reyes				D	087		\$500.00
	W	Assm. Robert J. Rodriguez				D	068		\$1,500.00
		Robin Schimminger				D	140		\$500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Assm. Colin J. Schmitt				R	099		\$500.00
	W	Assm. Rebecca A. Seawright				D	076		\$500.00
		Aravella Simotas				D	036		\$1,000.00
	W	Assm. Michaelle C. Solages				D	022		\$500.00
	W	Assm. Phillip G. Steck				D	110		\$500.00
	W	Assm. Helene E. Weinstein				D	041		\$1,000.00
	W	Assm. David I. Weprin				D	024		\$1,000.00
	W	Assm. Kenneth Paul Zebrowski				D	096		\$1,000.00
CITY COUNCILPERSON (NYC)									
		Cnclm Alicka Ampry-Samuel			Up in '21	D	041		\$500.00
		Cnclm Diana Ayala			Up in '21	D	008		\$500.00
		Cnclm Andrew Cohen			Up in '21	D	011		\$500.00
		Cnclm Robert Cornegy			Up in '21	D	036		\$500.00
		Cnclm Mathieu Eugene			Up in '21	D	040		\$500.00
		Cnclm Robert Holden			Up in '21	D	030		\$500.00
		Cnclm Mark Levine			Up in '21	D	007		\$1,000.00
		Cnclm Alan N. Maisel			Up in '21	D	046		\$500.00
		Cnclm Keith Powers			Up in '21	D	004		\$1,000.00
		Cnclm Carlina Rivera			Up in '21	D	002		\$200.00
		Cnclm Paul Vallone			Up in '21	D	019		\$700.00
NORTH CAROLINA									
US SENATE									
	W	Sen. Thomas Roland Tillis	▲			R			\$2,500.00
US HOUSE									
	W	Rep. Theodore Paul Budd				R	013		\$1,000.00
		Rep. Theodore Paul Budd			Up in '22	R	013		\$2,500.00
	W	Rep. George Kenneth Butterfield, Jr.	▲			D	001		\$5,000.00
		George E. Holding	▲			R	002		\$3,500.00
	W	Rep. Richard Lane Hudson, Jr.	▲			R	008		\$7,500.00
	W	Rep. Patrick Timothy McHenry				R	010		\$5,000.00
		Mark Randall Meadows				R	011		\$3,500.00
	W	Rep. David Cheston Rouzer	▲			R	007		\$1,000.00

W Winner

NP Non-Partisan

● Debt-Retirement

▲ Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Bradley Mark Walker	▲			R			\$1,000.00
GOVERNOR									
	W	Gov. Roy Cooper	▲			D			\$10,800.00
STATE SENATE									
	W	Sen. Philip Edward Berger, Sr.				R	026		\$4,000.00
	W	Sen. Daniel T. Blue, Jr	▲			D	014		\$1,000.00
	W	Sen. Jay Jyoti Chaudhuri				D	015		\$1,000.00
	W	Sen. Donald Gene Davis				D	005		\$1,000.00
	W	Sen. Kathy Gray Harrington				R	043		\$2,000.00
	W	Sen. Ralph Edward Hise, Jr.				R	047		\$2,000.00
	W	Sen. Brent Jackson				R	010		\$2,000.00
	W	Sen. Joyce Riley Krawiec				R	031		\$1,000.00
	W	Sen. Paul Robert Newton				R	036		\$1,000.00
	W	Sen. Jim Allen Perry				R	007		\$1,000.00
	W	Sen. William Peter Rabon				R	008		\$1,000.00
		Jerry W. Tillman				R	029		\$1,000.00
STATE HOUSE									
	W	Rep. Gale B. Adcock	▲			D	041		\$1,000.00
	W	Rep. Kristin Dutrow Baker				R	082		\$700.00
	W	Rep. John Richard Bell				R	010		\$1,000.00
		Darren G. Jackson				D	039		\$1,000.00
		Perrin Wayne Jones, M.D.				R	009		\$500.00
		David Ray Lewis				R	053		\$1,000.00
	W	Rep. Timothy Keith Moore				R	111		\$4,000.00
	W	Rep. Larry Wayne Potts				R	081		\$1,000.00
	W	Rep. Robert Tyrone Reives, II	▲			D	054		\$2,000.00
	W	Rep. Jason Ray Saine				R	097		\$500.00
	W	Rep. Wayne Sasser				R	067		\$1,000.00
	W	Rep. Sarah Suzanne Stevens				R	090		\$1,000.00
	W	Rep. Donna McDowell White	▲			R	026		\$1,000.00
NORTH DAKOTA									
US SENATE									
		Sen. Kevin John Cramer	▲		Up in '24	R			\$1,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. John Henry Hoeven, III	▲		Up in '22	R			\$5,000.00
US HOUSE									
	W	Rep. Kelly M. Armstrong	▲			R	001		\$2,500.00
GOVERNOR									
	W	Gov. Doug Burgum	▲			R			\$1,500.00
INSURANCE COMMISSIONER									
	W	Hon. Jon Godfread	▲			R			\$1,250.00
STATE SENATE									
		Sen. Joan M. Heckaman			Up in '22	D	023		\$200.00
	W	Sen. Jerry Klein				R	014		\$200.00
		Sen. Oley Larsen			Up in '22	R	003		\$200.00
		Sen. Judith Lee			Up in '22	R	013		\$700.00
		Sen. Rich Wardner			Up in '22	R	037		\$200.00
STATE HOUSE									
		Rep. Pamela Anderson			Up in '22	D	041		\$200.00
		Rep. George J. Keiser			Up in '22	R	047		\$200.00
		Rep. Chet Pollert			Up in '22	R	029		\$200.00
		Rep. Karen M. Rohr			Up in '22	R	031		\$200.00
	W	Rep. Robin Weisz				R	014		\$700.00
OHIO									
US SENATE									
		Sen. Rob J. Portman	▲		Up in '22	R			\$5,000.00
US HOUSE									
	W	Rep. Joyce Beatty				D	003		\$2,500.00
	W	Rep. Marcia Louise Fudge	▲			D	011		\$3,000.00
	W	Rep. Robert Brian Gibbs				R	007		\$1,000.00
	W	Rep. William L. Johnson				R	006		\$2,500.00
	W	Rep. James Daniel Jordan				R	004		\$10,000.00
	W	Rep. Robert E. Latta	▲			R	005		\$2,000.00
	W	Rep. Steve Stivers				R	015		\$2,000.00
	W	Rep. Brad R. Wenstrup				R	002		\$2,500.00
STATE SUPREME COURT JUSTICE									
		Judith French				R			\$2,500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Hon. Sharon Kennedy				R			\$2,500.00
STATE SENATE									
	W	Sen. Niraj J. Antani				R	006		\$700.00
		Sen. Nickie J. Antonio			Up in '22	D	023		\$350.00
	W	Sen. Louis W. Blessing, III				R	008		\$350.00
		Sen. Andrew O. Brenner			Up in '22	R	019		\$350.00
		David E. Burke				R	026		\$350.00
	W	Sen. Jerry Cirino				R	018		\$250.00
		Sen. Hearcel Ford Craig			Up in '22	D	015		\$300.00
	W	Sen. Matthew J. Dolan				R	024		\$1,000.00
	W	Sen. Theresa A. Gavarone	▲			R	002		\$700.00
	W	Sen. Robert D. Hackett				R	010		\$700.00
	W	Sen. Frank Hoagland				R	030		\$350.00
		Sen. Jay Hottinger	▲		Up in '22	R	031		\$350.00
	W	Sen. Matt Huffman				R	012		\$1,350.00
		Sen. Stephen A. Huffman			Up in '22	R	005		\$350.00
	W	Sen. Terry A. Johnson				R	014		\$700.00
	W	Sen. Stephanie L. Kunze	▲			R	016		\$700.00
	W	Sen. George F. Lang	▲			R	004		\$700.00
		Peggy Lehner				R	006		\$350.00
		Larry J. Obhof				R	022		\$1,000.00
		Sean J. O'Brien				D	032		\$350.00
		Sen. Bob Peterson			Up in '22	R	017		\$500.00
	W	Sen. William F. Reineke, Jr.				R	026		\$650.00
	W	Sen. Mark J. Romanchuk				R	022		\$700.00
		Sen. J. Kirk Schuring			Up in '22	R	029		\$350.00
	W	Sen. Vernon L. Sykes				D	028		\$350.00
		Sen. Cecil Thomas	▲		Up in '22	D	009		\$300.00
		Sen. Sandra R. Williams	▲		Up in '22	D	021		\$300.00
		Sen. Steve Wilson	▲		Up in '22	R	007		\$350.00
		Sen. Kenny Yuko	▲		Up in '22	D	025		\$350.00
STATE HOUSE									
	W	Rep. Cindy Abrams				R	029		\$350.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Adam C. Bird				R	066		\$250.00
	W	Rep. Willis Blackshear, Jr.				D	039		\$250.00
	W	Rep. Kristin Boggs				D	018		\$300.00
	W	Rep. Janine R. Boyd				D	009		\$300.00
	W	Rep. Thomas E. Brinkman, Jr.				R	027		\$350.00
		James Butler				R	041		\$350.00
	W	Rep. Rick Carfagna				R	068		\$350.00
	W	Rep. Sara P. Carruthers				R	051		\$700.00
		Jack Cera				D	096		\$350.00
		Randi Clites				D	075		\$700.00
	W	Rep. Robert R. Cupp				R	004		\$1,000.00
	W	Rep. Alessandro Cutrona				R	059		\$350.00
	W	Rep. Jay Edwards				R	094		\$350.00
	W	Rep. Mark D. Fraizer				R	071		\$350.00
	W	Rep. Tavia Baxter Galonski				D	035		\$300.00
	W	Rep. Haraz N. Ghanbari	▲			R	003		\$350.00
	W	Rep. Timothy Edward Ginter				R	005		\$850.00
	W	Rep. Diane V. Grendell				R	076		\$350.00
	W	Rep. Jennifer L. Gross	▲			R	052		\$250.00
	W	Rep. Adam Holmes				R	097		\$350.00
	W	Rep. James M. Hoops				R	081		\$250.00
	W	Rep. Larry Householder				R	072		\$1,000.00
	W	Rep. Stephanie D. Howse	▲			D	011		\$650.00
	W	Rep. Dontavius L. Jarrells				D	025		\$250.00
	W	Rep. Laura Lanese				R	023		\$350.00
	W	Rep. Jeff LaRe				R	077		\$350.00
	W	Rep. Michele Lepore-Hagan				D	058		\$300.00
	W	Rep. P. Scott Lipps	▲			R	062		\$1,000.00
	W	Rep. Beth W. Liston	▲			D	021		\$700.00
	W	Rep. Susan Manchester				R	084		\$350.00
	W	Rep. Gayle L. Manning				R	055		\$500.00
		Don Manning				R	059		\$350.00
	W	Rep. Derek Merrin				R	047		\$700.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. W. Scott Oelslager				R	048		\$500.00
	W	Rep. Thomas F. Patton				R	007		\$350.00
	W	Rep. Phil Plummer				R	040		\$850.00
	W	Rep. Tracy Richardson				R	086		\$350.00
	W	Rep. Bill Roemer				R	038		\$350.00
	W	Rep. Allison Russo				D	024		\$700.00
		Gary K. Scherer				R	092		\$350.00
	W	Rep. William F. Seitz				R	030		\$350.00
	W	Rep. Jason C. Stephens				R	093		\$350.00
	W	Rep. D.J. Swearingen				R	089		\$350.00
	W	Rep. Bride Rose Sweeney				D	014		\$300.00
	W	Rep. Emilia Strong Sykes				D	034		\$1,050.00
	W	Rep. Terrence Upchurch				D	010		\$700.00
	W	Rep. Thomas E. West				D	049		\$850.00
OKLAHOMA									
US SENATE									
	W	Sen. James M. Inhofe	▲			R			\$2,000.00
		Sen. James Paul Lankford	▲		Up in '22	R			\$10,000.00
US HOUSE									
	W	Rep. Thomas Jeffery Cole				R	004		\$2,000.00
	W	Rep. Markwayne Mullin				R	002		\$5,000.00
STATE SENATE									
	W	Sen. Micheal Bergstrom				R	001		\$500.00
		Sen. Mary B. Boren			Up in '22	D	016		\$200.00
	W	Sen. Tom J. Dugger				R	021		\$300.00
		Sen. Carri Hicks			Up in '22	D	040		\$200.00
	W	Sen. Greg McCortney				R	013		\$550.00
	W	Sen. Lonnie Paxton				R	023		\$300.00
	W	Sen. Adam Pugh				R	041		\$300.00
	W	Sen. J. David Rader				R	039		\$500.00
	W	Sen. Paul Rosino				R	045		\$1,000.00
STATE HOUSE									
	W	Rep. Jeff Boatman				R	067		\$300.00

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Ty D. Burns				R	035		\$300.00
	W	Rep. Trey E. Caldwell, III				R	063		\$300.00
	W	Rep. Rusty Cornwell				R	006		\$300.00
	W	Rep. Jose Cruz				D	089		\$500.00
	W	Rep. Sheila Dills				R	069		\$300.00
	W	Rep. Mike Dobrinski				R	059		\$500.00
	W	Rep. Mickey Dollens				D	093		\$200.00
		Jason Dunnington				D	088		\$200.00
	W	Rep. Jon Echols				R	090		\$500.00
		Derrel Fincher				R	011		\$300.00
	W	Rep. Andy Fugate				D	094		\$200.00
	W	Rep. Jim Grego				R	017		\$800.00
	W	Rep. Toni Hasenbeck				R	065		\$300.00
	W	Rep. Brian Hill				R	047		\$300.00
	W	Rep. Justin Humphrey				R	019		\$300.00
	W	Rep. Ronny Johns				R	025		\$500.00
	W	Rep. Chris Kannady				R	091		\$500.00
		Lundy Kiger				R	003		\$300.00
	W	Rep. Dick Lowe				R	056		\$500.00
	W	Rep. T.J. Marti				R	075		\$300.00
	W	Rep. Nicole Miller				R	082		\$300.00
	W	Rep. Garry Mize				R	031		\$550.00
	W	Rep. Anthony Moore				R	057		\$500.00
	W	Rep. Cyndi Munson				D	085		\$500.00
	W	Rep. Kenton Patzkowsky				R	061		\$300.00
	W	Rep. Logan J. Phillips				R	024		\$500.00
	W	Rep. Ajay Pittman				D	099		\$250.00
	W	Rep. Randy Randleman				R	015		\$300.00
	W	Rep. Cynthia J. Roe				R	042		\$550.00
	W	Rep. Lonnie Sims				R	068		\$300.00
	W	Rep. David Smith				R	018		\$500.00
	W	Rep. Chris Sneed				R	014		\$800.00
	W	Rep. Marilyn M. Stark				R	100		\$800.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Tammy Townley				R	048		\$300.00
	W	Rep. Emily Virgin				D	044		\$200.00
	W	Rep. Collin Walke				D	087		\$500.00
OREGON									
US HOUSE									
	W	Rep. Suzanne Marie Bonamici	▲			D	001		\$3,000.00
	W	Rep. Kurt Schrader	▲			D	005		\$7,500.00
		Gregory Paul Walden				R	002		\$5,000.00
GOVERNOR									
		Gov. Kate Brown	▲		Up in '22	D			\$5,000.00
STATE SENATE									
		Herman Ernst Baertschiger, Jr.				R	002		\$1,000.00
		Denyc Nicole Boles				R	010		\$3,000.00
	W	Sen. Ginny Burdick				D	018		\$1,000.00
		Sen. Peter Courtney			Up in '22	D	011		\$1,000.00
		Melissa Cribbins				D	005		\$1,000.00
	W	Sen. Lynn P. Findley				R	030		\$1,000.00
	W	Sen. Fred F. Girod				R	009		\$2,000.00
	W	Sen. William S. Hansell				R	029		\$2,000.00
		Mark D. Hass				D	014		\$1,000.00
		Sen. Betsy Johnson			Up in '22	D	016		\$3,000.00
	W	Sen. Tim R. Knopp				R	027		\$2,000.00
		Sen. Chuck D. Riley			Up in '22	D	015		\$1,000.00
		Arnold Roblan				D	005		\$1,000.00
		Sen. Chuck William Thomsen			Up in '22	R	026		\$2,000.00
		Sen. Rob Wagner			Up in '22	D	019		\$2,000.00
STATE HOUSE									
		Gregory L. Barreto				R	058		\$1,000.00
	W	Rep. Daniel G. Bonham				R	059		\$1,000.00
	W	Rep. Shelly Boshart Davis				R	015		\$2,000.00
	W	Rep. Vikki Breese-Iverson				R	055		\$1,000.00
	W	Rep. Janelle S. Bynum				D	051		\$1,000.00
	W	Rep. Brian L. Clem				D	021		\$2,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Christine Drazan				R	039	\$3,000.00	
	W	Rep. Paul L. Evans				D	020	\$2,000.00	
	W	Rep. Cedric R. Hayden				R	007	\$2,000.00	
		Cheri Helt				R	054	\$2,000.00	
	W	Rep. Tina Kotek				D	044	\$2,000.00	
	W	Rep. Rick Lewis				R	018	\$1,000.00	
		Caddy H. McKeown				D	009	\$1,000.00	
	W	Rep. Raquel Moore-Green				R	019	\$1,000.00	
	W	Rep. Nancy L. Nathanson				D	013	\$1,000.00	
	W	Rep. Ronald H. Noble				R	024	\$1,000.00	
	W	Rep. Robert A. Nosse				D	042	\$1,000.00	
	W	Rep. Daniel A. Rayfield				D	016	\$2,000.00	
	W	Rep. Jeff Reardon				D	048	\$1,000.00	
	W	Rep. E. Werner Reschke				R	056	\$1,000.00	
	W	Rep. Andrea Salinas				D	038	\$1,000.00	
	W	Rep. Sheri L. Schouten				D	027	\$1,000.00	
	W	Rep. David Brock Smith				R	001	\$1,000.00	
	W	Rep. Gregory Vincent Smith				R	057	\$2,000.00	
	W	Rep. Barbara Smith Warner				D	045	\$3,000.00	
	W	Rep. Marty L. Wilde				D	011	\$1,000.00	
		Carl W. Wilson				R	003	\$1,000.00	
	W	Rep. Brad K. Witt				D	031	\$1,000.00	

PENNSYLVANIA

US SENATE

Sen. Robert P. Casey, Jr.	▲	Up in '24	D	\$5,000.00
---------------------------	---	-----------	---	------------

US HOUSE

W	Rep. Brendan Francis Boyle	▲	D	002	\$3,500.00
W	Rep. Dwight Evans		D	003	\$1,000.00
W	Rep. Christina J. Houlahan	▲	D	006	\$7,000.00
W	Rep. John Joyce		R	013	\$1,000.00
W	Rep. G. Mike J. Kelly		R	016	\$7,000.00

STATE SENATE

Sen. John Patrick Blake		Up in '22	D	022	\$1,000.00
-------------------------	--	-----------	---	-----	------------



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Michele Brooks			Up in '22	R	050		\$1,000.00
		Sen. Patrick M. Browne			Up in '22	R	016		\$2,000.00
		Sen. Jacob D. Corman, III			Up in '22	R	034		\$2,000.00
	W	Sen. Jay Costa, Jr.				D	043		\$2,000.00
		Andrew E. Dinniman	▲			D	019		\$1,000.00
	W	Sen. Vincent J. Hughes				D	007		\$1,000.00
		Thomas H. Killion				R	009		\$1,000.00
		Sen. Robert B. Mensch			Up in '22	R	024		\$2,500.00
		Sen. Katie J. Muth	▲		Up in '22	D	044		\$1,000.00
		Sen. Kristin Lee Phillips-Hill			Up in '22	R	028		\$1,000.00
	W	Sen. Michael R. Regan	▲			R	031		\$1,200.00
		Joseph B. Scarnati, III				R	025		\$2,000.00
		Sen. Mario M. Scavella			Up in '22	R	040		\$1,000.00
	W	Sen. Judith L. Schwank				D	011		\$1,000.00
	W	Sen. Kim L. Ward				R	039		\$1,500.00
		Sen. Judith F. Ward			Up in '22	R	030		\$1,000.00
	W	Sen. Eugene Yaw				R	023		\$1,000.00
STATE HOUSE									
	W	Rep. Kerry A. Benninghoff				R	171		\$2,250.00
	W	Rep. Matthew D. Bradford				D	070		\$750.00
	W	Rep. Tim P. Briggs	▲			D	149		\$1,000.00
	W	Rep. Bryan D. Cutler				R	100		\$2,500.00
	W	Rep. Mary Jo Daley				D	148		\$300.00
	W	Rep. Anthony M. DeLuca				D	032		\$500.00
		Frank J. Dermody				D	033		\$2,000.00
	W	Rep. Valerie S. Gaydos				R	044		\$500.00
	W	Rep. Doyle M. Heffley				R	122		\$500.00
	W	Rep. Malcolm Kenyatta				D	181		\$250.00
	W	Rep. Mark A. Longietti				D	007		\$1,000.00
	W	Rep. Joanna E. McClinton				D	191		\$500.00
	W	Rep. Steven Curtis Mentzer				R	097		\$1,000.00
	W	Rep. Eric R. Nelson				R	057		\$500.00
	W	Rep. Donna R. Oberlander				R	063		\$1,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Tina L. Pickett				R	110		\$1,000.00
	W	Rep. Kathy L. Rapp				R	065		\$1,700.00
	W	Rep. Stanley E. Saylor				R	094		\$1,000.00
	W	Rep. Michael H. Schlossberg				D	132		\$550.00
	W	Rep. Melissa L. Shusterman	▲			D	157		\$1,000.00
		Marcy Toepel				R	147		\$1,000.00
	W	Rep. Jesse W. Topper				R	078		\$500.00
		Michael C. Turzai				R	028		\$2,000.00
	W	Rep. Martina A. White	▲			R	170		\$500.00
	W	Rep. David H. Zimmerman				R	099		\$500.00
PUERTO RICO									
STATE SENATE									
	W	Hon. Carmelo J. Rios Santiago				PNP			\$750.00
	W	Hon. Thomas Rivera Schatz				R			\$1,000.00
STATE HOUSE									
	W	Hon. Joel Isaac Franqui Atilés				PNP			\$500.00
	W	Hon. Rafael Hernandez Montanez				PPD			\$500.00
	W	Hon. Jose E. Melendez Ortiz				PNP			\$750.00
	W	Rep. Johnny Mendez				R			\$1,000.00
	W	Hon. Juan Oscar Morales Rodriguez				PNP			\$500.00
SOUTH CAROLINA									
US SENATE									
	W	Sen. Lindsey Olin Graham	▲			R			\$5,000.00
		Sen. Timothy Eugene Scott	▲		Up in '22	R			\$4,000.00
US HOUSE									
	W	Rep. James Enos Clyburn	▲			D	006		\$10,000.00
	W	Rep. Tom Rice				R	007		\$3,500.00
		Rep. Tom Rice			Up in '22	R	007		\$2,500.00
STATE SENATE									
	W	Sen. Tom Davis				R	046	\$1,000.00	
	W	Sen. C. Bradley Hutto				D	040	\$1,000.00	
	W	Sen. Darrell Jackson	▲			D	021	\$500.00	

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Sen. Mia S. McLeod				D	022	\$500.00	
	W	Sen. Daniel B. Verdin, III				R	009	\$1,000.00	
STATE HOUSE									
	W	Rep. Leon Howard				D	076	\$1,000.00	
	W	Rep. James H. Lucas				R	065	\$1,000.00	
		Robert L. Ridgeway, III				D	064	\$1,000.00	
	W	Rep. J. Todd Rutherford				D	074	\$1,000.00	
	W	Rep. G. Murrell Smith, Jr.				R	067	\$1,000.00	
SOUTH DAKOTA									
US SENATE									
	W	Sen. M. Michael Rounds	▲			R			\$4,000.00
		Sen. John Randolph Thune	▲		Up in '22	R			\$5,000.00
GOVERNOR									
		Gov. Kristi Lynn Noem	▲		Up in '22	R			\$5,000.00
STATE SENATE									
	W	Sen. Gary L. Cammack				R	029		\$500.00
	W	Sen. R. Blake Curd				R	012		\$500.00
	W	Sen. Michael G. Diedrich				R	034		\$250.00
	W	Sen. Brock L. Greenfield				R	006		\$500.00
		Kris K. Langer				R	025		\$500.00
	W	Sen. Lee Schoenbeck				R	005		\$500.00
	W	Sen. Wayne H. Steinhauer				R	009		\$250.00
	W	Sen. Erin Tobin				R	021		\$250.00
STATE HOUSE									
	W	Rep. Arch Beal				R	012		\$250.00
	W	Rep. Spencer Gosch				R	023		\$500.00
	W	Rep. Jon Hansen				R	025		\$250.00
	W	Rep. Kevin D. Jensen				R	016		\$500.00
	W	Rep. Kent S. Peterson				R	019		\$500.00
	W	Rep. Jamie Smith				D	015		\$500.00
	W	Rep. Dean Wink				R	029		\$250.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
TENNESSEE									
US SENATE									
		Sen. Marsha Wedgeworth Blackburn	▲		Up in '24	R			\$2,000.00
	W	Sen. Bill Hagerty	▲			R			\$10,000.00
US HOUSE									
	W	Rep. Mark E. Green				R	007		\$2,000.00
	W	Rep. David F. Kustoff	▲			R	008		\$1,000.00
	W	Rep. John W. Rose				R	006		\$1,000.00
STATE SENATE									
		Sen. Paul Bailey			Up in '22	R	015		\$2,000.00
		Sen. Richard Briggs			Up in '22	R	007		\$1,500.00
		Sen. Rusty Crowe, II			Up in '22	R	003		\$2,000.00
	W	Sen. Ferrell Haile				R	018		\$500.00
	W	Sen. Joey Hensley				R	028		\$1,500.00
		Sen. Jack Johnson			Up in '22	R	023		\$2,000.00
	W	Sen. Jon C. Lundberg	▲			R	004		\$1,500.00
		Sen. Randy McNally, III			Up in '22	R	005		\$1,500.00
	W	Sen. Shane Reeves				R	014		\$2,000.00
	W	Sen. John D. Stevens				R	024		\$500.00
	W	Sen. Art Swann				R	002		\$1,000.00
		Sen. Bo Watson			Up in '22	R	011		\$1,000.00
	W	Sen. Ken Yager				R	012		\$2,000.00
		Sen. Jeff Yarbrow			Up in '22	D	021		\$1,000.00
STATE HOUSE									
	W	Rep. Clark Boyd				R	046		\$1,500.00
	W	Rep. Michael G. Curcio				R	069		\$1,000.00
	W	Rep. Jeremy Faison				R	011		\$2,500.00
	W	Rep. Ron M. Gant				R	094		\$1,500.00
	W	Rep. Mark Hall				R	024		\$1,000.00
	W	Rep. David B. Hawk				R	005		\$1,000.00
	W	Rep. Patsy Hazlewood				R	027		\$1,500.00
	W	Rep. Esther Helton				R	030		\$2,000.00

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Gary W. Hicks, Jr.				R	009		\$1,000.00
		Matthew Hill				R	007		\$500.00
		Timothy Hill				R	003		\$500.00
		Andrew H. Holt				R	076		\$1,000.00
	W	Rep. Chris Hurt				R	082		\$1,000.00
	W	Rep. Curtis G. Johnson				R	068		\$1,000.00
	W	Rep. Kelly T. Keisling				R	038		\$1,000.00
	W	Rep. Sabi Kumar				R	066		\$1,000.00
	W	Rep. William G. Lamberth				R	044		\$1,000.00
	W	Rep. Thomas F. Leatherwood, III				R	099		\$500.00
	W	Rep. Pat Marsh				R	062		\$2,000.00
	W	Rep. Cameron Sexton				R	025		\$2,500.00
	W	Rep. Robin T. Smith				R	026		\$2,000.00
	W	Rep. Mike Stewart				D	052		\$1,000.00
	W	Rep. Bryan Terry				R	048		\$1,000.00
	W	Rep. Kevin Vaughan				R	095		\$2,000.00
	W	Rep. Mark White	▲			R	083		\$1,500.00
	W	Rep. Sam Whitson				R	065		\$1,500.00
TEXAS									
US SENATE									
	W	Sen. John Cornyn, III	▲			R			\$7,000.00
US HOUSE									
	W	Rep. Jodey Cook Arrington				R	019		\$4,500.00
	W	Rep. Kevin Patrick Brady				R	008		\$5,000.00
	W	Rep. Michael Clifton Burgess	▲			R	026		\$5,000.00
	W	Rep. Daniel Crenshaw				R	002		\$3,500.00
	W	Rep. Henry Roberto Cuellar				D	028		\$1,000.00
	W	Rep. Veronica Escobar				D	016		\$3,000.00
	W	Rep. Sylvia R. Garcia				D	029		\$5,000.00
	W	Rep. Vicente Gonzalez				D	015		\$6,000.00
	W	Rep. Sheila Jackson Lee				D	018		\$2,000.00
		Kenny Ewell Marchant	▲			R	024		\$2,000.00
	W	Rep. Marc A. Veasey				D	033		\$6,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Filemon Bartolome Vela, Jr.				D	034		\$5,000.00
GOVERNOR									
		Gov. Greg Abbott	▲		Up in '22	R			\$5,000.00
LIEUTENANT GOVERNOR									
		Hon. Dan Patrick	▲		Up in '22	R			\$5,000.00
STATE ATTORNEY GENERAL									
		AG Ken Paxton	▲		Up in '22	R			\$5,000.00
STATE TREASURER									
		Hon. Glenn Hegar	▲		Up in '22	R			\$1,000.00
LAND COMMISSIONER									
		Hon. George P. Bush			Up in '22	R			\$2,500.00
STATE SENATE									
	W	Sen. Cesar Blanco				D	029		\$1,000.00
	W	Sen. Dawn Buckingham				R	024		\$1,000.00
		Sen. Donna Campbell			Up in '22	R	025		\$1,000.00
	W	Sen. C. Brandon Creighton				R	004		\$1,000.00
		Sen. Sarah Eckhardt	▲		Up in '22	D	014		\$2,000.00
	W	Sen. Roland Gutierrez				D	019		\$2,000.00
		Sen. Kelly Hancock	▲		Up in '22	R	009		\$3,000.00
	W	Sen. Bryan Hughes				R	001		\$1,500.00
		Sen. Nathan Johnson	▲		Up in '22	D	016		\$2,000.00
	W	Sen. Lois W. Kolkhorst				R	018		\$3,000.00
	W	Sen. Eduardo A. Lucio, Jr.				D	027		\$1,000.00
	W	Sen. Borris L. Miles				D	013		\$2,000.00
	W	Sen. Jane Nelson				R	012		\$1,000.00
		Sen. Robert Nichols			Up in '22	R	003		\$1,000.00
		Sen. Angela Paxton			Up in '22	R	008		\$1,000.00
	W	Sen. Charles Perry				R	028		\$1,000.00
		Sen. Beverly Powell			Up in '22	D	010		\$1,000.00
		Rep. Eduardo Rodriguez	▲			D	014		\$3,500.00
		Sen. Kelton G. Seliger			Up in '22	R	031		\$1,000.00
		Kirk Watson	▲		Up in '22	D	014		\$1,000.00
	W	Sen. Judith Zaffirini	▲			D	021		\$2,000.00

W
Winner

NP
Non-Partisan

●
Debt-Retirement

▲
Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
STATE HOUSE									
	W	Rep. Steve Allison				R	121		\$2,000.00
	W	Rep. Rafael Anchia				D	103		\$500.00
	W	Rep. Trenton E. Ashby				R	057		\$500.00
	W	Rep. Greg Bonnen				R	024		\$1,000.00
	W	Rep. Brad Buckley				R	054		\$500.00
	W	Rep. Angie Chen Button				R	112		\$1,000.00
	W	Rep. Giovanni Capriglione	▲			R	098		\$1,000.00
	W	Rep. Travis Clardy				R	011		\$500.00
		Sarah Davis				R	134		\$1,500.00
	W	Rep. James Frank				R	069		\$1,000.00
	W	Rep. John Frullo				R	084		\$1,000.00
	W	Rep. Craig Goldman				R	097		\$1,000.00
	W	Rep. Mary E. Gonzalez				D	075		\$1,000.00
	W	Rep. Bobby Guerra				D	041		\$1,000.00
	W	Rep. Justin Holland				R	033		\$500.00
	W	Rep. Stephanie Klick				R	091		\$1,000.00
	W	Rep. Matt Krause				R	093		\$1,000.00
	W	Rep. Stan Lambert				R	071		\$2,000.00
	W	Rep. Lyle Larson				R	122		\$1,000.00
	W	Rep. Jeff Leach				R	067		\$2,000.00
	W	Rep. Eddie Lucio, III				D	038		\$2,000.00
	W	Rep. Trey Martinez Fischer				D	116		\$1,000.00
	W	Rep. Morgan Meyer				R	108		\$1,000.00
	W	Rep. Joseph E. Moody				D	078		\$1,000.00
	W	Rep. Tom Oliverson				R	130		\$2,500.00
	W	Rep. Chris Paddie				R	009		\$1,000.00
	W	Rep. Dennis Paul				R	129		\$1,000.00
	W	Rep. W. Four Price				R	087		\$3,000.00
	W	Rep. Richard Pena Raymond				D	042		\$2,000.00
	W	Rep. Eduardo Rodriguez	▲			D	051		\$1,000.00
		J.D. Sheffield				R	059		\$2,000.00
	W	Rep. Carl O. Sherman, Sr.				D	109		\$500.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Lynn Stucky				R	064		\$2,000.00
	W	Rep. Senfronia Thompson				D	141		\$1,500.00
	W	Rep. Chris Turner				D	101		\$2,000.00
	W	Rep. Hubert Vo				D	149		\$1,000.00
	W	Rep. Armando L. Walle				D	140		\$1,000.00
	W	Rep. Gene Wu				D	137		\$1,000.00
CITY COUNCILPERSON (Houston)									
	W	Cnclm Abbie Kamin				D	C		\$2,500.00
UTAH									
US SENATE									
		Sen. Michael Shumway Lee	▲		Up in '22	R			\$1,000.00
US HOUSE									
	W	Rep. John R. Curtis				R	003		\$2,000.00
GOVERNOR									
	W	Gov. Spencer J. Cox	▲			R		\$4,500.00	
STATE ATTORNEY GENERAL									
	W	AG Sean D. Reyes	▲			R		\$5,000.00	
STATE SENATE									
		Sen. J. Stuart Adams			Up in '22	R	022	\$2,000.00	
	W	Sen. Curtis S. Bramble				R	016	\$1,250.00	
		Sen. Kirk A. Cullimore, Jr.			Up in '22	R	009	\$1,000.00	
		Daniel Hemmert				R	014	\$1,500.00	
		Sen. Ann Millner			Up in '22	R	018	\$750.00	
		Sen. Scott D. Sandall			Up in '22	R	017	\$500.00	
		Sen. Evan J. Vickers			Up in '22	R	028	\$2,000.00	
	W	Sen. Chris H. Wilson				R	025	\$250.00	
		Sen. Ronald Winterton			Up in '22	R	026	\$500.00	
STATE HOUSE									
	W	Rep. James A. Dunnigan				R	039	\$1,000.00	
	W	Rep. Steven Eliason				R	045	\$250.00	
	W	Rep. Francis D. Gibson				R	065	\$1,500.00	
	W	Rep. Bradley G. Last				R	071	\$250.00	
	W	Rep. Kelly B. Miles				R	011	\$800.00	



Winner



Non-Partisan



Debt-Retirement



Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Calvin R. Musselman				R	009	\$750.00	
		Val K. Potter				R	003	\$500.00	
	W	Rep. Paul Ray				R	013	\$2,000.00	
	W	Rep. Mike Schultz				R	012	\$1,250.00	
	W	Rep. Casey Snider				R	005	\$250.00	
	W	Rep. Robert Spendlove				R	049	\$500.00	
	W	Rep. Andrew Stoddard				D	044	\$250.00	
	W	Rep. Steve Waldrip				R	008	\$450.00	
	W	Rep. Brad R. Wilson				R	015	\$2,000.00	
VERMONT									
GOVERNOR									
	W	Gov. Philip B. Scott	F			R		\$3,500.00	
VIRGIN ISLANDS									
US HOUSE									
	W	Rep. Stacey Elizabeth Plaskett				D	001		\$1,000.00
VIRGINIA									
US SENATE									
		Sen. Timothy Michael Kaine	F		Up in '24	D			\$2,500.00
	W	Sen. Mark Robert Warner	F			D			\$5,000.00
US HOUSE									
	W	Rep. Gerald E. Connolly	F			D	011		\$3,500.00
	W	Rep. H. Morgan Griffith	F			R	009		\$7,500.00
	W	Rep. A. Donald McEachin	F			D	004		\$2,000.00
STATE SENATE									
	W	Sen. George L. Barker				D	039	\$1,000.00	
		Sen. George L. Barker			Up in '23	D	039	\$1,000.00	
	W	Sen. John J. Bell				D	013	\$750.00	
		Sen. John J. Bell			Up in '23	D	013	\$500.00	
	W	Sen. Jennifer B. Boysko				D	033	\$1,000.00	
		Rosalyn R. Dance				D	016	\$1,000.00	
		Sen. R. Creigh Deeds			Up in '23	D	025	\$500.00	
	W	Sen. William R. DeSteph				R	008	\$750.00	
	W	Sen. Siobhan S. Dunnivant	F			R	012	\$1,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Siobhan S. Dunnivant	▲		Up in '23	R	012	\$500.00	
		Sen. Adam P. Ebbin			Up in '23	D	030	\$500.00	
		Sen. John S. Edwards	▲		Up in '23	D	021	\$500.00	
	W	Sen. Barbara A. Favola				D	031	\$1,000.00	
	W	Sen. Emmett W. Hanger, Jr.				R	024	\$1,500.00	
		Sen. Emmett W. Hanger, Jr.			Up in '23	R	024	\$500.00	
		Sen. Ghazala F. Hashmi			Up in '23	D	010	\$500.00	
	W	Sen. Janet Denison Howell	▲			D	032	\$1,000.00	
		Sen. Janet Denison Howell	▲		Up in '23	D	032	\$1,500.00	
		Sen. Jen A. Kiggans				R	007	\$750.00	
	W	Sen. Lynwood W. Lewis, Jr.				D	006	\$1,000.00	
		Sen. Lynwood W. Lewis, Jr.			Up in '23	D	006	\$500.00	
	W	Sen. Mamie E. Locke				D	002	\$1,000.00	
		Sen. Mamie E. Locke			Up in '23	D	002	\$1,500.00	
	W	Sen. L. Louise Lucas				D	018	\$1,000.00	
		Sen. L. Louise Lucas			Up in '23	D	018	\$1,500.00	
		Sen. David W. Marsden			Up in '23	D	037	\$500.00	
		Sen. T. Montgomery Mason			Up in '23	D	001	\$500.00	
	W	Sen. Ryan T. McDougale				R	004	\$1,000.00	
		Sen. Ryan T. McDougale			Up in '23	R	004	\$500.00	
	W	Sen. Jeremy S. McPike				D	029	\$1,000.00	
	W	Sen. Joseph D. Morrissey				D	016	\$750.00	
	W	Sen. Stephen D. Newman				R	023	\$1,000.00	
		Sen. Stephen D. Newman			Up in '23	R	023	\$500.00	
	W	Sen. Thomas K. Norment, Jr.				R	003	\$1,250.00	
		Sen. Thomas K. Norment, Jr.			Up in '23	R	003	\$1,000.00	
		Sen. Mark J. Peake			Up in '23	R	022	\$500.00	
		Sen. J. Chapman Petersen			Up in '23	D	034	\$500.00	
	W	Sen. Todd E. Pillion				R	040	\$1,000.00	
	W	Sen. Bryce E. Reeves				R	017	\$1,000.00	
		Sen. Bryce E. Reeves			Up in '23	R	017	\$500.00	
	W	Sen. Frank M. Ruff, Jr.				R	015	\$1,000.00	
	W	Sen. Richard L. Saslaw				D	035	\$2,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Sen. Richard L. Saslaw			Up in '23	D	035	\$1,500.00	
	W	Sen. Lionell Spruill, Sr.				D	005	\$750.00	
		Sen. Lionell Spruill, Sr.			Up in '23	D	005	\$750.00	
	W	Sen. William M. Stanley, Jr.	▲			R	020	\$750.00	
		Sen. William M. Stanley, Jr.	▲		Up in '23	R	020	\$500.00	
		Glen H. Sturtevant, Jr.				R	010	\$1,000.00	
		Sen. David R. Suetterlein			Up in '23	R	019	\$500.00	
	W	Sen. Scott A. Surovell				D	036	\$1,000.00	
		Sen. Scott A. Surovell			Up in '23	D	036	\$750.00	
STATE HOUSE									
		Del. Dawn M. Adams			Up in '21	D	068	\$500.00	
	W	Del. Lashrecse D. Aird				D	063	\$1,000.00	
		Del. Lashrecse D. Aird			Up in '21	D	063	\$500.00	
		Del. G. John Avoli			Up in '21	R	020	\$500.00	
						R	020	\$500.00	
		Del. Lamont Bagby			Up in '21	D	074	\$1,000.00	
		Del. Amanda E. Batten				R	096	\$500.00	
	W	Del. Jeff M. Bourne	▲			D	071	\$500.00	
		Del. Jeff M. Bourne	▲		Up in '21	D	071	\$500.00	
	W	Del. Kathy J. Byron				R	022	\$500.00	
		Del. Kathy J. Byron			Up in '21	R	022	\$500.00	
	W	Del. M. Kirkland Cox				R	066	\$2,250.00	
		Del. Carrie Emerson Coyner				R	062	\$500.00	
	W	Del. Glenn R. Davis				R	084	\$500.00	
		Del. Karrie K. Delaney			Up in '21	D	067	\$500.00	
	W	Del. Eileen Filler-Corn				D	041	\$1,000.00	
		Del. Eileen Filler-Corn			Up in '21	D	041	\$2,000.00	
	W	Del. C. Todd Gilbert				R	015	\$750.00	
		Del. C. Todd Gilbert			Up in '21	R	015	\$1,000.00	
		Del. Gwendolyn W. Gooditis			Up in '21	D	010	\$500.00	
		Del. Elizabeth R. Guzman			Up in '21	D	031	\$500.00	
		Del. C.E. Cliff Hayes, Jr.			Up in '21	D	077	\$500.00	
	W	Del. Christopher T. Head				R	017	\$500.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Del. Christopher T. Head			Up in '21	R	017	\$500.00	
		Del. Stephen E. Heretick			Up in '21	D	079	\$500.00	
		Del. Charniele L. Herring			Up in '21	D	046	\$1,000.00	
	W	Del. M. Keith Hodges				R	098	\$1,000.00	
		Del. M. Keith Hodges			Up in '21	R	098	\$500.00	
	W	Del. Patrick A. Hope				D	047	\$750.00	
		Del. Patrick A. Hope			Up in '21	D	047	\$500.00	
		Timothy D. Hugo				R	040	\$1,000.00	
	W	Del. Chris L. Hurst	▲			D	012	\$500.00	
		Steven Christopher Jones				R	076	\$1,000.00	
		Del. Terry G. Kilgore			Up in '21	R	001	\$500.00	
	W	Del. Mark Herbert Levine				D	045	\$750.00	
		Joseph C. Lindsey			Up in '21	D	090	\$500.00	
	W	Del. Alfonso H. Lopez				D	049	\$1,000.00	
		Del. Martha M. Mugler				D	091	\$500.00	
	W	Del. Michael P. Mullin				D	093	\$500.00	
		Del. Michael P. Mullin			Up in '21	D	093	\$500.00	
	W	Del. Robert D. Orrock, Sr.				R	054	\$750.00	
		Del. Robert D. Orrock, Sr.			Up in '21	R	054	\$500.00	
		Del. Margaret Bevans Ransone			Up in '21	R	099	\$500.00	
		Del. Roxann L. Robinson			Up in '21	R	027	\$500.00	
		Del. Christopher S. Runion				R	025	\$500.00	
	W	Del. Larry Nick Rush				R	007	\$750.00	
		Del. Don L. Scott, Jr.				D	080	\$500.00	
	W	Del. Mark D. Sickles				D	043	\$1,000.00	
		Del. Mark D. Sickles			Up in '21	D	043	\$1,500.00	
		Del. Marcus B. Simon			Up in '21	D	053	\$500.00	
		Christopher P. Stolle				R	083	\$750.00	
	W	Del. Richard C. Sullivan, Jr.				D	048	\$750.00	
		Del. Richard C. Sullivan, Jr.			Up in '21	D	048	\$1,000.00	
	W	Del. Luke E. Torian				D	052	\$1,000.00	
		Del. Luke E. Torian			Up in '21	D	052	\$1,500.00	
		Del. Kathy K. L. Tran			Up in '21	D	042	\$500.00	



Winner



Non-Partisan



Debt-Retirement



Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
		Del. Wendell S. Walker			Up in '21	R	023	\$500.00	
	W	Del. Jeion A. Ward				D	092	\$750.00	
		Del. Jeion A. Ward			Up in '21	D	092	\$1,500.00	
		Del. R. Lee Ware, Jr.			Up in '21	R	065	\$500.00	
	W	Del. Bill D. Wiley				R	029	\$500.00	
		Del. Rodney T. Willett	▲		Up in '21	D	073	\$500.00	
		Del. Scott A. Wyatt				R	097	\$500.00	
WASHINGTON									
US SENATE									
		Sen. Patricia Lynn Murray	▲		Up in '22	D			\$1,500.00
US HOUSE									
	W	Rep. Suzan Kay DelBene				D	001		\$3,000.00
	W	Rep. Derek Kilmer				D	006		\$4,000.00
	W	Rep. Cathy McMorris Rodgers				R	005		\$2,500.00
	W	Rep. Marilyn Strickland	▲			D	010		\$1,000.00
GOVERNOR									
	W	Gov. Jay Inslee	▲			D		\$4,000.00	
STATE SENATE									
	W	Sen. John E. Braun				R	020	\$2,000.00	
	W	Sen. Annette Cleveland				D	048	\$1,000.00	
	W	Sen. Curtis P. King				R	014	\$2,000.00	
	W	Sen. Mark Mullet				D	005	\$2,000.00	
		Steve O'Ban				R	028	\$2,000.00	
	W	Sen. Ann Rivers				R	018	\$2,000.00	
	W	Sen. June Robinson				D	038	\$1,500.00	
	W	Sen. Christine Rolfes				D	023	\$2,000.00	
		Dean A. Takko				D	019	\$2,000.00	
	W	Sen. Kevin Van De Wege				D	024	\$2,000.00	
STATE HOUSE									
	W	Rep. Peter Abbarno				R	020	\$1,000.00	
	W	Rep. Andrew K. Barkis				R	002	\$500.00	
	W	Rep. Michelle Caldier				R	026	\$500.00	
	W	Rep. Kelly Chambers				R	025	\$2,000.00	



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
	W	Rep. Eileen L. Cody				D	034	\$1,000.00	
	W	Rep. Jeremie Dufault				R	015	\$1,000.00	
	W	Rep. Roger E. Goodman				D	045	\$500.00	
	W	Rep. Paul Harris				R	017	\$2,000.00	
	W	Rep. Laurie Jenkins				D	027	\$2,000.00	
		Christine Kilduff				D	028	\$1,000.00	
	W	Rep. Mari Leavitt				D	028	\$500.00	
	W	Rep. John Lovick				D	044	\$1,500.00	
	W	Rep. Nicole Macri				D	043	\$1,000.00	
	W	Rep. Jacquelin Maycumber				R	007	\$1,000.00	
	W	Rep. Joe Schmick				R	009	\$2,000.00	
	W	Rep. Vandana Slatter				D	048	\$1,500.00	
	W	Rep. Larry S. Springer				D	045	\$500.00	
	W	Rep. Drew Stokesbary				R	031	\$1,000.00	
	W	Rep. Monica Jurado Stonier				D	049	\$2,000.00	
	W	Rep. Pat Sullivan				D	047	\$2,000.00	
	W	Rep. My-Linh Thai				D	041	\$1,500.00	
		Luanne Van Werven				R	042	\$1,000.00	
	W	Rep. Brandon Vick				R	018	\$1,000.00	
	W	Rep. Amy Walen				D	048	\$1,500.00	
	W	Rep. Emily Wicks				D	038	\$1,000.00	
	W	Rep. J.T. Wilcox				R	002	\$1,000.00	
WEST VIRGINIA									
US SENATE									
	W	Sen. Shelley Moore Capito	▲			R			\$6,500.00
STATE SENATE									
	W	Sen. Craig P. Blair				R	015		\$1,000.00
		Denise Lynne Campbell				D	011		\$1,000.00
	W	Sen. Glenn D. Jeffries	▲			D	008		\$2,000.00
	W	Sen. Michael J. Maroney				R	002		\$1,000.00
	W	Sen. Fredrik Eric Nelson				R	017		\$2,000.00
	W	Sen. Robert H. Plymale				D	005		\$2,000.00
		Roman W. Prezioso, Jr.				D	013		\$1,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
STATE HOUSE									
	W	Del. Moore Capito				R	035		\$2,000.00
	W	Del. Vernon Criss				R	010		\$1,000.00
	W	Del. Joe C. Ellington, Jr.				R	027		\$2,000.00
	W	Del. Paul A. Espinosa				R	066		\$2,000.00
	W	Del. Roger Glen Hanshaw				R	033		\$1,000.00
	W	Del. Matthew Alan Rohrbach				R	017		\$2,000.00
		Margaret Anne Staggers				D	032		\$2,000.00
	W	Del. Erikka Lynn Storch				R	003		\$1,000.00
WISCONSIN									
US HOUSE									
	W	Rep. Michael John Gallagher				R	008		\$1,000.00
	W	Rep. Ronald James Kind				D	003		\$6,500.00
	W	Rep. Gwendolynne Moore				D	004		\$1,000.00
STATE SENATE									
		Sen. Janet Bewley			Up in '22	D	025		\$250.00
		Rep. Scott L. Fitzgerald			Up in '22	R	013		\$1,000.00
		Sen. Roger J. Roth, Jr.			Up in '22	R	019		\$1,000.00
		Jennifer Shilling				D	032		\$1,000.00
	W	Sen. Patrick Testin				R	024		\$1,500.00
		Sen. Van H. Wanggaard	▲		Up in '22	R	021		\$250.00
STATE HOUSE									
	W	Rep. Samantha Kerkman	▲			R	061		\$250.00
	W	Rep. Thaddeus P. McGuire				D	064		\$250.00
	W	Rep. Joe Sanfelippo				R	015		\$500.00
WYOMING									
US SENATE									
		Sen. John Anthony Barrasso	▲		Up in '24	R			\$2,500.00
	W	Sen. Cynthia Marie Lummis	▲			R			\$5,000.00
US HOUSE									
	W	Rep. Elizabeth Cheney	▲			R	001		\$1,000.00
GOVERNOR									
		Gov. Mark Gordon	▲		Up in '22	R			\$1,000.00



Winner



Non-Partisan



Debt-Retirement



Facility

Pfizer Political Contributions Recipients January 2019 – December 2020

State/Office	Win	Full Name	Facility	Debt Retirement	Future Election	Party	District	Corp	PAC
STATE SENATE									
	W	Sen. Fred A. Baldwin				R	014		\$200.00
	W	Sen. Brian S. Boner				R	002		\$400.00
	W	Sen. Affie Ellis				R	008		\$500.00
	W	Sen. Tara Nethercott				R	004		\$400.00
	W	Sen. Charles K. Scott				R	030		\$200.00
STATE HOUSE									
	W	Rep. Landon J. Brown				R	009		\$400.00
	W	Rep. Shelly Duncan				R	005		\$200.00
	W	Rep. John Eklund, Jr.				R	010		\$300.00
	W	Rep. Mike Greear				R	027		\$300.00
	W	Rep. Bill Henderson				R	041		\$300.00
		Dan R. Kirkbride				R	004		\$400.00
	W	Rep. Lloyd Charles Larsen				R	054		\$400.00
	W	Rep. Dan Laursen				R	025		\$300.00
		Tyler Lindholm				R	001		\$500.00
	W	Rep. Sandy Newsome				R	024		\$200.00
	W	Rep. Jared Olsen				R	011		\$400.00
	W	Rep. Tom Walters				R	038		\$400.00
	W	Rep. Cyrus Western				R	051		\$400.00
	W	Rep. Sue Wilson				R	007		\$200.00
	W	Rep. Dan Zwonitzer				R	043		\$400.00
Total – Candidate Committees								\$1,002,075.00	\$1,535,875.11



Winner



Non-Partisan



Debt-Retirement



Facility



Pfizer PAC

Political Action Committee

Leading the Conversation

**Leadership PACs,
Trade Associations, and
Party Committees**

January 2019 – December 2020



State	Committee Name	Party	Corp	PAC
ALABAMA	Alabama Democratic Senators, Inc.	D	\$1,000.00	
	Alabama House Democratic Caucus, Inc.	D	\$1,000.00	
	Alabama Republican Party (Non-Federal)	R	\$5,000.00	
	Alabama Senate Republican Conference	R	\$2,500.00	
	Reaching For A Brighter America PAC (Rep. Robert Brown Aderholt)	R		\$2,500.00
	Seeking Justice PAC (Doug Jones)	D		\$10,000.00
ARIZONA	Arizona Democratic Party (Non-Federal)	D	\$1,000.00	
	Arizona Republican Party (Non-Federal)	R	\$3,000.00	\$500.00
	Getting Stuff Done PAC (GSD-PAC) (Sen. Kyrsten Sinema)	D		\$5,000.00
CALIFORNIA	AdvaMed California PAC	NP	\$4,000.00	
	Asian Pacific Islander Leadership PAC	NP	\$1,500.00	
	BioCom PAC	NP	\$7,000.00	
	California Armenian Legislative Caucus	NP	\$1,000.00	
	California Democratic Party (Non-Federal)	D	\$60,000.00	
	California Jewish PAC	NP	\$1,000.00	
	California Latino Caucus Leadership PAC	D	\$1,500.00	
	California Life Sciences Association PAC (CLSA PAC)	NP	\$12,000.00	
	California Republican Party (Non-Federal)	R	\$15,000.00	
	Conference of Western Attorneys General (CWAG)	NP	\$1,050,000.00	
	Democrats Reshaping America (DREAMPAC) (Rep. Linda T. Sanchez)	D		\$4,000.00
	Dr. Richard Pan Senate 2018 Officeholder Account (Sen. Richard Pan)	D	\$7,800.00	
	FairPAC (Civil Justice Association of California)	NP	\$3,000.00	
	Majority Committee PAC--Mc PAC (Rep. Kevin Owen McCarthy)	R		\$7,500.00
	Nathan Fletcher for Democratic Central Committee 2020 (Nathan Fletcher)	D	\$1,000.00	
	PAC To the Future (Rep. Nancy Pelosi)	D		\$1,000.00
Pharmaceutical Research & Manufacturers Association of America PAC (PhRMA PAC)	NP	\$15,600.00		
Supporting House Problem Solvers - Shp PAC (Rep. Scott H. Peters)	D		\$2,000.00	
COLORADO	Better Colorado Alliance	D	\$9,500.00	
	Colorado Democratic Latino Caucus	D	\$2,500.00	

NP

Non-Partisan

State	Committee Name	Party	Corp	PAC
	Colorado Republican Committee	R		\$1,500.00
	Fenberg Leadership Fund (Sen. Steven Fenberg)	D		\$600.00
	Friends for the Future	R	\$2,500.00	
	Garnett Leadership Fund (Rep. Alec Garnett)	D		\$500.00
	Gotta Have Faith (Sen. Faith Winter)	D		\$200.00
	Leading Colorado Forward	D	\$9,500.00	
	Lundeen Leadership Fund (Sen. Paul Lundeen)	R		\$300.00
	Patrick PAC (Rep. Patrick Neville)	R		\$575.00
	Project West Political Action Committee (Cory Gardner)	R		\$6,000.00
	Senate Majority Fund	R	\$7,500.00	
	The Right Leadership PAC	R		\$200.00
	Values First Colorado	R	\$3,500.00	
CONNECTICUT	Connecticut Democratic State Central Committee	D		\$10,000.00
	Connecticut Republican Party	R		\$10,000.00
	Husky PAC (Rep. Joseph D. Courtney)	D		\$1,000.00
	Leadership Connecticut PAC	NP		\$5,000.00
	Nutmeg PAC (Sen. Richard Blumenthal)	D		\$7,500.00
	Synergy PAC (Rep. John Barry Larson)	D		\$2,000.00
DELAWARE	Blue Hen Federal PAC (Sen. Christopher Andrew Coons)	D		\$10,000.00
	Delaware House Democrats	D	\$450.00	
	First State PAC (Sen. Thomas Richard Carper)	D		\$5,000.00
DISTRICT OF COLUMBIA	Across The Aisle PAC	NP		\$5,000.00
	Aspire PAC	D		\$5,000.00
	Biotechnology Innovation Organization PAC (BIO PAC)	NP		\$10,000.00
	Chamber Of Commerce Of The United States Of America PAC (US CHAMBER PAC)	NP		\$10,000.00
	CHC BOLD PAC	D		\$10,000.00
	Congressional Black Caucus PAC	D		\$10,000.00
	DCCC	D		\$30,000.00
	DCCC (Building Fund)	D		\$55,000.00
	Democratic Attorneys General Association (DAGA)	D	\$250,000.00	
	Democratic Governors Association (DGA)	D	\$1,083,000.00	
	Democratic Legislative Campaign Committee (DLCC)	D	\$150,000.00	



Non-Partisan

State	Committee Name	Party	Corp	PAC
	DNC Services Corporation/Democratic National Committee	D		\$30,000.00
	DSCC	D		\$30,000.00
	DSCC (Building Fund)	D		\$83,900.00
	DSCC (Recount and Legal Fund)	D		\$16,100.00
	Elect Democratic Women	NP		\$10,000.00
	Equality PAC	NP		\$10,000.00
	LGBTQ Victory Fund Federal PAC	D		\$2,500.00
	Moderate Democrats PAC	D		\$5,000.00
	National Association Of Manufacturers PAC (NAM-PAC)	NP		\$10,000.00
	New Democrat Coalition Action Fund	D		\$10,000.00
	NRCC	R		\$30,000.00
	NRCC (Building Fund)	R		\$45,000.00
	NRCC (Recount and Legal Fund)	R		\$5,500.00
	NRSC	R		\$30,000.00
	NRSC (Building Fund)	R		\$75,000.00
	Pharmaceutical Research & Manufacturers of America (PhRMA)	NP	\$689,599.00	
	Pharmaceutical Research & Manufacturers Of America Better Government Committee	NP		\$10,000.00
	Republican Attorneys General Association (RAGA)	R	\$160,000.00	
	Republican Governors Association (RGA)	R	\$765,000.00	
	Republican National Committee	R		\$30,000.00
	Republican State Leadership Committee (RSLC)	R	\$370,000.00	
FLORIDA	Building on Your Dreams Political Committee (Sen. Jim Boyd)	R	\$2,000.00	
	Conservatives for a Better Florida (Rep. Daniel Anthony Perez)	R	\$8,000.00	
	Conservatives for Principled Leadership (Rep. Paul M. Renner)	R	\$11,500.00	
	Democrats Win Seats (DWS PAC) (Rep. Debbie Wasserman Schultz)	D		\$5,500.00
	Florida Conservative Committee (Rep. Bob Rommel)	R	\$2,500.00	
	Florida Democratic Party (Non-Federal)	D	\$10,500.00	
	Florida Republican Senatorial Campaign Committee	R	\$35,000.00	
	Floridians for Early Education	D	\$2,000.00	
	Floridians for Economic Freedom (Rep. Chris Sprowls)	R	\$7,500.00	
	Floridians for Limited Government (Sen. Douglas Vaughn Broxson)	R	\$3,000.00	



Non-Partisan

State	Committee Name	Party	Corp	PAC
	Free Markets for Florida (Sen. Ray Wesley Rodrigues)	R	\$2,000.00	
	Friends of Gayle Harrell (Sen. Gayle B. Harrell)	R	\$3,000.00	
	Friends of Jason Brodeur (Sen. Jason T. Brodeur)	R	\$5,000.00	
	Friends of Lori Berman (Sen. Lori Berman)	D	\$3,000.00	
	Reclaim America PAC (Sen. Marco Antonio Rubio)	R		\$1,500.00
	Republican Party of Florida (Non-Federal)	R	\$35,000.00	
	Women Building the Future (Jennifer Bradley)	R	\$5,000.00	
	Working Together for Florida PAC (Sen. Kathleen C. Passidomo)	R	\$17,000.00	
GEORGIA	21st Century Majority Fund (Johnny H. Isakson)	R		\$5,000.00
	Advance Georgia	R		\$5,000.00
	Buddy PAC (Rep. Earl L. B. Carter)	R		\$3,000.00
	Democratic Party of Georgia (Non-Federal)	D	\$7,500.00	
	DPG - Senate Majority Fund	D	\$5,500.00	
	Georgia House Republican Trust, Inc.	R	\$2,500.00	
	Georgia Republican Senatorial Committee	R	\$6,500.00	
	One Georgia PAC (David Alfred Perdue, Jr.)	R		\$8,500.00
	Point Action Pac, Inc. (Rep. A. Drew Ferguson, IV)	R		\$5,000.00
HAWAII	Hawaii House Democratic PAC	D	\$1,000.00	
	Pineapple PAC (Sen. Mazie Keiko Hirono)	D		\$5,000.00
IDAHO	Freedom Fund (Sen. Michael Dean Crapo)	R		\$7,500.00
ILLINOIS	CHERPAC (Rep. Cheryl L. Bustos)	D		\$5,000.00
	Citizens for Thaddeus Jones (Rep. Thaddeus M. Jones)	D	\$2,500.00	
	JET PAC (Rep. Adam Daniel Kinzinger)	R		\$5,000.00
	Perimeter PAC (Sen. L. Tammy Duckworth)	D		\$10,000.00
INDIANA	Hoosier PAC (Sen. Michael K. Braun)	R		\$2,500.00
	Oorah! Political Action Committee (Sen. Todd Christopher Young)	R		\$9,000.00
	Team Holcomb (Gov. Eric Joseph Holcomb)	R	\$5,000.00	\$5,000.00
IOWA	Jobs Opportunity And New Ideas PAC (Sen. Joni Kay Ernst)	R		\$500.00
	The Hawkeye PAC (Sen. Charles E. Grassley)	R		\$1,000.00
KANSAS	Defend Our Conservative Senate PAC (DOC'S PAC) (Sen. Roger W. Marshall)	R		\$1,500.00
	Future Vision	R	\$2,500.00	
	Kansas Senate Democrats	D	\$2,000.00	



Non-Partisan

State	Committee Name	Party	Corp	PAC
	Lift up Kansas PAC	R	\$1,000.00	
	Preserving America's Traditions (PATPAC) (Pat Roberts)	R		\$5,000.00
	Republican House Campaign Committee	R	\$2,500.00	
	Right Way Kansas Action Fund Inc.	R	\$5,000.00	
	The Kansas Truth Caucus	R	\$1,000.00	
KENTUCKY	Bluegrass Committee (Sen. Mitch McConnell)	R		\$7,500.00
	Building America's Republican Representation PAC (Rep. Andy H. Barr, IV)	R		\$1,000.00
	House Republican Caucus Campaign Committee	R		\$10,000.00
	Reinventing A New Direction Political Action Committee (Sen. Rand Howard Paul)	R		\$1,000.00
	Republican Party Of Kentucky	R		\$10,000.00
	Republican Party of Kentucky (Non-Federal)	R		\$10,000.00
	Senate Republican Caucus Campaign Committee	R		\$10,000.00
LOUISIANA	Bishop PAC (Rep. Stuart J. Bishop)	R	\$250.00	
	Continuing America's Strength And Security PAC (Sen. William Cassidy)	R		\$6,000.00
	Louisiana House Democratic Campaign Committee	D	\$5,000.00	
	Louisiana Republican Legislative Delegation Campaign Committee	R	\$6,000.00	
	Louisiana Senate Democratic Campaign Committee	D	\$5,000.00	
	The Eye Of The Tiger Political Action Committee (Rep. Stephen Joseph Scalise)	R		\$2,500.00
	Who Dat PAC (Cedric Levon Richmond)	D		\$2,500.00
MAINE	Charlotte PAC (Rep. Charlotte May Warren)	D	\$250.00	
	Fecteau for Leadership PAC (Rep. Ryan M. Fecteau)	D	\$1,000.00	
	House Democratic Campaign Committee	D	\$2,000.00	
	House Republican Majority Fund	R	\$5,500.00	
	Libby Leadership PAC (Sen. Nathan L. Libby)	D	\$500.00	
	Maine Senate Republican Majority	R	\$16,500.00	
	One Maine (Rep. Kathleen Rose J. Dillingham)	R	\$500.00	
	Prosperity for Maine's Future PAC (Sen. Matthew G. Pouliot)	R	\$2,000.00	
	The Star City PAC (Sen. Harold L. Stewart, III)	R	\$2,500.00	
	Western Maine Strong PAC (Rep. Nathan J. Wadsworth)	R	\$600.00	
MARYLAND	AMERIPAC The Fund for a Greater America (Rep. Steny Hamilton Hoyer)	D		\$10,000.00

NP

Non-Partisan

State	Committee Name	Party	Corp	PAC
	Blue Dog Political Action Committee	D		\$7,500.00
	Future Forum PAC	D		\$7,500.00
	LEGPAC (Sen. Benjamin L. Cardin)	D		\$5,000.00
	Maryland House Democratic Caucus Committee	D	\$3,000.00	
	Republican House Caucus Committee	R	\$3,000.00	
MASSACHUSETTS	Fair Shot PAC (Rep. Katherine M. Clark)	D		\$1,000.00
	Massachusetts Biotechnology Council Inc. Federal Political Action Committee	NP		\$10,000.00
	Massachusetts Democratic State Committee	D		\$10,000.00
	The Madison PAC (Rep. Richard Edmund Neal)	D		\$10,000.00
MICHIGAN	Bizon Majority Fund (Sen. John Bizon)	R		\$500.00
	Blue Water Liberty Fund (Shane Hernandez)	R		\$1,000.00
	Building Experience Now PAC (Rep. Ben Frederick)	R		\$1,000.00
	Chatfield Majority Fund (Lee Chatfield)	R		\$1,000.00
	Compete Michigan PAC (Sen. Mike Shirkey)	R		\$1,000.00
	Compete Michigan PAC 2 (Sen. Mike Shirkey)	R		\$1,000.00
	Curtis Hertel Jr. for Michigan (Sen. Curtis Hertel, Jr.)	D		\$500.00
	Filler Majority PAC (Rep. Graham Filler)	R		\$500.00
	Hornberger Majority Fund PAC (Rep. Pamela Hornberger)	R		\$500.00
	Joe Tate Leadership PAC (Rep. Joseph Tate)	D		\$250.00
	Lasinski for Michigan PAC (Rep. Donna Lasinski)	D		\$500.00
	MAC PAC (Peter MacGregor)	R		\$1,000.00
	Maintaining Majority Fund (Brandt Iden)	R		\$1,000.00
	McCann for Michigan (Sen. Sean A. McCann)	D		\$500.00
	Michigan Democratic State Central Committee	D		\$5,000.00
	Motor City PAC (Sen. Gary Charles Peters)	D		\$10,000.00
	Nesbitt Majority Fund (Sen. Aric Nesbitt)	R		\$1,000.00
	Trust PAC Team Republicans For Utilizing Sensible Tactics (Rep. Frederick Stephen Upton)	R		\$2,500.00
	VanderWall Majority Fund (Sen. Curt VanderWall)	R		\$2,000.00
	VanWoerkom Solutions PAC (Rep. Greg VanWoerkom)	R		\$500.00
	Wentworth Majority Fund 2 (Rep. Jason Wentworth)	R		\$1,000.00
	Whiteford Leadership Fund (Rep. Mary Whiteford)	R		\$500.00
	Witwer for Michigan (Rep. Angela Witwer)	D		\$250.00

NP

Non-Partisan

State	Committee Name	Party	Corp	PAC
MINNESOTA	House Republican Campaign Committee	R		\$2,000.00
	Minnesota Dfl Senate Caucus	D		\$3,000.00
	Minnesota House DFL Caucus	D		\$2,000.00
	Senate Victory PAC	R		\$7,500.00
MISSOURI	Building Leadership And Inspiring New Enterprise PAC (Rep. W. Blaine Luetkemeyer)	R		\$1,400.00
	DougPAC (Sen. Doug Beck)	D	\$1,000.00	
	Missouri House Republican Campaign Committee	R	\$5,000.00	
	Missouri Senate Campaign Committee	R	\$5,000.00	
	Rely On Your Beliefs Fund (Sen. Roy Dean Blunt)	R		\$10,000.00
	Uniting Missouri PAC	R	\$10,000.00	
MONTANA	Big Sky Opportunity PAC (Sen. Steve David Daines)	R		\$5,000.00
	Montana Democratic Legislative Campaign Committee (MDLCC)	D		\$2,500.00
	Montana Democratic Party	D		\$2,000.00
	Montana Republican Legislative Campaign Committee (MRLCC)	R		\$2,500.00
	Treasure State PAC (Sen. Jon Tester)	D		\$5,000.00
NEBRASKA	Sensible American Solutions Supporting Everyone PAC (Sen. Benjamin Eric Sasse)	R		\$3,000.00
NEVADA	A Bolder Nevada (Sen. Joseph Paul Hardy, M.D.)	R	\$2,000.00	
	All For Our Country Leadership PAC (Sen. Catherine Cortez Masto)	D		\$10,000.00
	Battle Born Nevadan PAC (Sen. James Arnold Settlemeyer)	R	\$2,000.00	
	Leadership in Nevada (Assm. Jason M. Frierson)	D	\$6,000.00	
	Nevada State Democratic Party	D		\$5,000.00
	Nevada Victory PAC (Assm. Thomas A. Roberts)	R	\$1,500.00	
	Smart Solutions PAC (Sen. Jacky Rosen)	D		\$10,000.00
NEW HAMPSHIRE	Committee to Elect House Democrats	D	\$500.00	
	Committee to Elect House Republicans	R	\$2,000.00	
	Granite Values PAC (Sen. Margaret Wood Hassan)	D		\$5,000.00
	Madame President PAC (Sen. Donna M. Soucy)	D	\$6,500.00	
	New Hampshire Senate Democratic Caucus	D	\$10,500.00	
	New Hampshire Senate Republicans Political Action Committee	R	\$4,000.00	



Non-Partisan

State	Committee Name	Party	Corp	PAC
	Senate Republican Majority PAC	R	\$5,000.00	
NEW JERSEY	Andrzejczak, Land and Milam	D	\$500.00	
	New Jobs	NP	\$500.00	
	New Millennium PAC (Sen. Robert Menendez)	D		\$7,500.00
	Shore PAC (Rep. Frank Pallone, Jr.)	D		\$5,000.00
	Swain and Tully for Assembly	D	\$500.00	
NEW MEXICO	Democratic Party of New Mexico (Non-Federal)	D	\$3,700.00	
	LOBO PAC (Sen. Martin Heinrich)	D		\$5,000.00
NEW YORK	Democratic Assembly Campaign Committee	D	\$5,000.00	\$5,500.00
	Democratic Assembly Campaign Committee Housekeeping Account	D	\$12,500.00	
	IMPACT (Sen. Charles E. Schumer)	D		\$10,000.00
	New York State Democratic Committee - Housekeeping Account	D	\$30,000.00	
	New York State Democratic Committee (Non-Federal)	D		\$9,500.00
	NYS Democratic Senate Campaign Committee	D	\$5,000.00	\$3,500.00
	NYS Democratic Senate Campaign Committee - Housekeeping	D	\$13,500.00	
	NYS Senate Republican Campaign Committee	R		\$2,000.00
	NYS Senate Republican Campaign Committee - Housekeeping Account	R	\$3,000.00	
	Partnership for New York City PAC	D		\$2,500.00
	Republican Assembly Campaign Committee	R		\$2,000.00
	Speaker Heastie PAC (Assm. Carl E. Heastie)	D		\$2,000.00
NORTH CAROLINA	Conservative Roundtable (George E. Holding)	R		\$2,500.00
	First In Freedom PAC (Rep. Richard Lane Hudson, Jr.)	R		\$5,000.00
	New South Leadership PAC (Rep. George Kenneth Butterfield, Jr.)	D		\$2,000.00
	Together Holding Our Majority PAC (Sen. Thomas Roland Tillis)	R		\$10,000.00
NORTH DAKOTA	Badlands PAC (Sen. Kevin John Cramer)	R		\$1,000.00
	North Dakota House Democratic-NPL Caucus	D		\$1,000.00
	North Dakota Senate Democratic - NPL Caucus	D		\$1,000.00
	North Dakota Senate Republican Caucus	R		\$2,000.00
	Republican House Caucus	R		\$2,000.00



Non-Partisan

State	Committee Name	Party	Corp	PAC
OHIO	Leadership For America Today Tomorrow And Always PAC (Rep. Robert E. Latta)	R		\$2,500.00
	Promoting Our Republican Team PAC (Sen. Rob J. Portman)	R		\$5,000.00
	Securing Ohio's Future	R	\$13,000.00	
OKLAHOMA	Marathon PAC	NP		\$5,000.00
OREGON	OregonBioPAC	NP	\$6,000.00	
	Three Rivers Political Action Committee (Rep. Kurt Schrader)	D		\$5,000.00
	Votevets	D		\$2,500.00
PENNSYLVANIA	Citizens For Prosperity In America Today PAC (Sen. Patrick Joseph Toomey)	R		\$5,000.00
	House Democratic Campaign Committee (HDCC)	D		\$2,000.00
	House Republican Campaign Committee (HRCC)	R		\$4,000.00
	Keep America Rolling (Rep. G. Mike J. Kelly)	R		\$2,500.00
	Keystone America PAC (Sen. Robert P. Casey, Jr.)	D		\$10,000.00
	Life Sciences Pennsylvania PAC	NP		\$500.00
	Senate Democratic Campaign Committee	D		\$2,000.00
Senate Republican Campaign Committee (SRCC)	R		\$4,000.00	
SOUTH CAROLINA	Building Relationships In Diverse Geographic Environments PAC (BRIDGE PAC) (Rep. James Enos Clyburn)	D		\$10,000.00
	House Republican Caucus	R	\$3,500.00	
	Jobs, Energy And Our Founding Fathers PAC-Jeff PAC (Rep. Jeffrey D. Duncan)	R		\$2,500.00
	South Carolina Democratic Party (Non-Federal)	D	\$3,500.00	
	South Carolina House Democratic Caucus	D	\$5,750.00	
	South Carolina Republican Party (Non-Federal)	R	\$3,500.00	
	South Carolina Senate Democratic Caucus	D	\$7,000.00	
	South Carolina Senate Republican Caucus	R	\$7,000.00	
	Tomorrow Is Meaningful PAC (Sen. Timothy Eugene Scott)	R		\$9,000.00
	Upstate Sc PAC (Rep. William R. Timmons, IV)	R		\$2,500.00
SOUTH DAKOTA	Bluestem Initiative PAC (Rep. Jamie Smith)	D		\$250.00
	Heartland Values PAC (Sen. John Randolph Thune)	R		\$10,000.00
	House GOP PAC	R		\$3,250.00
	Senate Republican Campaign Committee	R		\$3,250.00
	The Majority Project (Sen. Troy Heinert)	D		\$250.00



Non-Partisan

State	Committee Name	Party	Corp	PAC
TENNESSEE	CAM PAC (Rep. Cameron Sexton)	R		\$5,000.00
	Haile PAC (Sen. Ferrell Haile)	R		\$500.00
	Healthcare Freedom Fund (David Philip Roe)	R		\$2,500.00
	Lamberth PAC (Rep. William G. Lamberth)	R		\$1,000.00
	Making A Responsible Stand For Households In America PAC (Sen. Marsha Wedgeworth Blackburn)	R		\$5,500.00
	McPAC (Sen. Randy McNally, III)	R		\$1,000.00
	Sargent Legacy Fund	R		\$1,000.00
	Tenn Political Action Committee Inc (TENN PAC) (Lamar Alexander)	R		\$2,500.00
	Tennessee Chamber of Commerce and Industry PAC	NP		\$2,000.00
	Tennessee Republican Party (Non-Federal)	R		\$5,000.00
TEXAS	Alamo PAC (Sen. John Cornyn, III)	R		\$1,500.00
	Lone Star Leadership PAC (Rep. Michael Clifton Burgess)	R		\$5,000.00
	Manufacturers PAC of Texas (MPACT)	NP		\$1,000.00
	Republican Party Of Texas	R		\$5,000.00
UTAH	Believe In America PAC (Sen. Mitt Romney)	R		\$7,500.00
	Utah House Republican Election Committee	R	\$2,000.00	
	Utah Republican Senate Campaign Committee	R	\$2,000.00	
	Utah Republican Senate Campaign Committee (URSCC)	R	\$2,000.00	
VERMONT	Green Mountain PAC (Sen. Patrick Joseph Leahy)	D		\$6,000.00
VIRGINIA	Common Ground PAC (Sen. Timothy Michael Kaine)	D		\$10,000.00
	Democratic Party Of Virginia	D		\$5,000.00
	Fightin' Ninth Political Action Committee (Rep. H. Morgan Griffith)	R		\$2,500.00
	Forward Together PAC (Sen. Mark Robert Warner)	D		\$10,000.00
WASHINGTON	Citizens Alliance for a Legislative Majority	NP	\$5,000.00	
	CMR Political Action Committee (Rep. Cathy McMorris Rodgers)	R		\$5,000.00
	Harry Truman Fund	D	\$3,500.00	
	Kennedy Fund	D	\$3,000.00	
	M-PAC (Sen. Patricia Lynn Murray)	D		\$10,000.00
	The Reagan Fund	R	\$3,000.00	
WEST VIRGINIA	West Virginia Republican Senate Committee	R		\$1,500.00



Non-Partisan

State	Committee Name	Party	Corp	PAC
WISCONSIN	Wild And Wonderful PAC (Sen. Shelley Moore Capito)	R		\$1,000.00
	Assembly Democratic Campaign Committee	D		\$1,000.00
	Committee to Elect a Republican Senate	R		\$10,500.00
	Republican Assembly Campaign Committee (RACC)	R		\$15,500.00
	State Senate Democratic Committee	D		\$1,000.00
WYOMING	Common Values PAC (Sen. John Anthony Barrasso)	R		\$7,500.00
	Making Business Excel Political Action Committee (Michael Bradley Enzi)	R		\$2,000.00
Total - Leadership PAC's, Trade Associations and Party Committees			\$5,151,999.00	\$1,288,275.00

Summary of 2019-2020 Political Contributions:				
Total - Candidate Committees			\$1,002,075.00	\$1,535,875.11
Total - Leadership PAC's, Trade Associations and Party Committees			\$5,151,999.00	\$1,288,275.00
Total 2019 – 2020 Political Contributions			\$6,154,074.00	\$2,848,150.11
Total PAC and Corporate Political Contributions in 2019 – 2020				\$8,978,224.11



Non-Partisan



Pfizer PAC

Political Action Committee

Leading the Conversation

**Financial
Statements**

January 2019 – December 2020



PFIZER INC. POLITICAL ACTION COMMITTEE
Combined Financial Statements – Cash Basis
December 31, 2020 and 2019
With Independent Auditor’s Report

Pfizer Inc. Political Action Committee
Table of Contents
December 31, 2020 and 2019

Independent Auditor's Report	1-2
Financial Statements	
Combined Statements of Assets, Liabilities and Net Assets Arising from Cash Transactions	3
Combined Statements of Revenue, Expenses and Changes in Net Assets Arising from Cash Transactions	4
Notes to Combined Financial Statements – Cash Basis	5-6

INDEPENDENT AUDITOR'S REPORT

To the Steering Committee,
Pfizer Inc. Political Action Committee:

Report on the Financial Statements

We have audited the accompanying combined financial statements of Pfizer Inc. Political Action Committee, which comprise the combined statements of assets, liabilities and net assets arising from cash transactions as of December 31, 2020 and 2019 and the related combined statements of revenue, expenses, and changes in net assets arising from cash transactions for the years then ended, and the related notes to combined financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these combined financial statements in accordance with the cash basis of accounting described in Note 2; this includes determining that the cash basis of accounting is an acceptable basis for the preparation of the combined financial statements in the circumstances. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of combined financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these combined financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the combined financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the combined financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the combined financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the combined financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the combined financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the combined financial statements referred to above present fairly, in all material respects, the assets, liabilities, and net assets of Pfizer Inc. Political Action Committee as of December 31, 2020 and 2019, and its revenue, expenses and changes in net assets for the years then ended in accordance with the basis of accounting as described in Note 2.

Basis of Accounting

We draw attention to Note 2 of the combined financial statements, which describes the basis of accounting. The combined financial statements are prepared on the cash basis of accounting, which is a basis of accounting other than accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to that matter.

Withum Smith + Brown, PC

March 22, 2021

Pfizer Inc. Political Action Committee
Combined Statements of Assets, Liabilities and Net Assets Arising From Cash
Transactions
December 31, 2020 and 2019

	<u>2020</u>	<u>2019</u>
Assets		
Cash	\$ 765,689	\$ 764,056
Liabilities and Net Assets		
Liabilities	\$ -	\$ -
Net assets without donor restrictions	<u>765,689</u>	<u>764,056</u>
Total liabilities and net assets	<u>\$ 765,689</u>	<u>\$ 764,056</u>

The Notes to Combined Financial Statements – Cash Basis are an integral part of these statements.

Pfizer Inc. Political Action Committee
Combined Statements of Revenue, Expenses and Changes in Net Assets Arising from
Cash Transactions
Years Ended December 31, 2020 and 2019

	<u>2020</u>	<u>2019</u>
Revenue collected		
Contributions	\$ 1,512,572	\$ 1,594,894
Other	<u>2,500</u>	<u>14,150</u>
Total revenue collected	<u>1,515,072</u>	<u>1,609,044</u>
Expenses paid		
Program		
Political contributions		
U.S. Senate candidates	146,800	117,886
U.S. House candidates	331,000	327,000
State and Local candidates	311,239	301,950
Political parties and other PAC funds	<u>724,400</u>	<u>563,875</u>
Total program	<u>1,513,439</u>	<u>1,310,711</u>
Excess of revenue collected over expenses paid	1,633	298,333
Net assets without donor restrictions		
Beginning of year	<u>764,056</u>	<u>465,723</u>
End of year	<u>\$ 765,689</u>	<u>\$ 764,056</u>

The Notes to Combined Financial Statements – Cash Basis are an integral part of these statements.

Pfizer Inc. Political Action Committee
Notes to Combined Financial Statements – Cash Basis
December 31, 2020 and 2019

1. COMMITTEE DESCRIPTION

The Pfizer Inc. Political Action Committee (the “Committee”) was formed by Pfizer Inc. (the “Company”) to solicit and receive voluntary political contributions from employees and stockholders of the Company and certain subsidiaries to assist candidates for elective office. The Committee was registered with the Federal Election Commission in April 1976. During 2020 and 2019, contributions could be designated by the contributor to a specific candidate or political party for political office. Designated contributions are remitted directly to the candidate or political party by the Committee on behalf of the contributor. There were no such designated contributions in 2020 and 2019. Contributions to the Committee which are undesignated are subsequently designated by the Committee's Steering Committee.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The combined financial statements of the Committee have been prepared using the cash basis of accounting, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America. Under this basis, revenue and the related assets are recognized when received rather than when earned. Expenses are recognized when paid rather than when the obligation is incurred. The combined financial statements of the Committee include several political action committees which were formed to comply with certain state laws.

Accounting Estimates

The preparation of combined financial statements requires management to make estimates and assumptions that affect the reporting of assets, liabilities and contingencies, if any, at the date of the combined financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Revenue and Expense Recognition

Contributions are recognized as revenue in the period cash is received or withheld from the Company's payroll. Contributions to candidates at the discretion of the Committee are recognized when distributed. Interest income and bank charges are recognized when reported on the bank statement.

The Company pays all administrative salaries and benefits, legal fees, and other administrative fees on behalf of the Committee. These costs are not reflected in the accompanying combined statements of revenue, expenses, and changes in net assets arising from cash transactions.

Net Assets

Net assets are reported as with donor restriction if they arise from contributions received with donor stipulations on their use. When a donor restriction expires, that is, the purpose of the restriction is accomplished, net assets with restrictions are reclassified to net assets without restrictions and reported in the combined statements of revenue, expenses and changes in net assets arising from cash transactions as net assets released from restrictions. There were no net assets with donor restrictions held by the Committee at December 31, 2020 and 2019 or during the years then ended.

Functional Expenses

For the years ended December 31, 2020 and 2019, political expenses are shown as program expenses, and state filing fees are shown as administrative expenses on the combined statements of revenue, expenses and changes in net assets arising from cash transactions. No state filing fees were incurred during the years ended December 31, 2020 and 2019. No costs have been allocated among program and administrative expenses.

Pfizer Inc. Political Action Committee
Notes to Combined Financial Statements – Cash Basis
December 31, 2020 and 2019

Subsequent Events

In preparing these combined financial statements, management of the Committee has evaluated events and transactions that occurred after December 31, 2020 for potential disclosure in the combined financial statements. These events and transactions were evaluated through March 22, 2021 the date that the combined financial statements were available to be issued and no items have come to the attention of management that require disclosure.

3. INFORMATION REGARDING LIQUIDITY

As of December 31, 2020 and 2019, the Committee has \$765,689 and \$764,056, respectively, of cash available to meet the cash needs for general expenditures within one year. None of the cash is subject to donor or other contractual restrictions that make it unavailable for general expenditures. As the Committee pays the operating expenses of the Committee, the Committee generally uses the cash to make political contributions.

4. INCOME TAXES

The Committee is exempt from federal and state income taxes under Section 527 of the Internal Revenue Code and related state statutes, except for taxes on its investment income, which is taxed at the highest corporate tax rate.

Management of an organization is required to evaluate income tax positions taken and disclose an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has analyzed the income tax positions taken by the Committee and concluded that as of December 31, 2020 and 2019, there are no uncertain positions taken or expected to be taken that would require disclosure of a liability in the combined financial statements. The Committee is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods. In addition, there have been no tax related interest or penalties for the periods presented in these combined financial statements. Should such penalties and interest be incurred, the Committee's policy is to recognize them as operating expenses. Management believes the Committee is no longer subject to income tax examinations for years prior to 2018.

5. CONCENTRATIONS

The Committee maintains its cash in bank accounts which exceed federally insured limits, subjecting the Committee to concentrations of credit risk. The Committee has not experienced, and management does not anticipate, any credit losses on such accounts.

6. RISKS AND UNCERTAINTIES

Management is continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Committee's financial position, and results of its operations, the specific impact is not readily determinable as of the date of these combined financial statements. The combined financial statements do not include any adjustments that might result from the outcome of this uncertainty.



Pfizer PAC
Political Action Committee

Leading the Conversation

235 East 42nd Street,
New York, NY 10017

www.pfizer.com/about/corporate_governance/political_action_committee_report

EXHIBIT D

(see attached)



~~Via Fed-Ex~~

August 31, 2021

Margaret M. Madden
Corporate Secretary
Pfizer, Inc.
235 East 42nd Street
New York, NY 10017

Dear Ms. Madden,

I hereby submit the enclosed shareholder proposal ("Proposal") for inclusion in the Pfizer, Inc. (the "Company") proxy statement to be circulated to Company shareholders in conjunction with the next annual meeting of shareholders. The Proposal is submitted under Rule 14(a)-8 (Proposals of Security Holders) of the United States Securities and Exchange Commission's proxy regulations.

I submit the Proposal as the Director of the Free Enterprise Project of the National Center for Public Policy Research, which has continuously owned Company stock with a value exceeding \$2,000 for at least 3 years prior to and including the date of this Proposal and which intends to hold these shares through the date of the Company's 2022 annual meeting of shareholders. A Proof of Ownership letter is forthcoming and will be delivered to the Company.

Copies of correspondence or a request for a "no-action" letter should be sent to me at the National Center for Public Policy Research, [REDACTED] and emailed to [REDACTED]

Sincerely,

Scott Shepard

Enclosure: Shareholder Proposal

Political Expenditures Congruency Report

Resolved: Pfizer publish an annual report, at reasonable expense, analyzing the congruency of political and electioneering expenditures during the preceding year against the company's fundamental purpose and publicly stated company values and policies.

Supporting Statement

The Pfizer Inc. Board's Governance and Sustainability Committee is responsible for "maintain[ing] an informed status on the Company's issues related to public policy, including political spending policies and practices, through...periodic reports from management; and [for] monitor[ing] emerging issues potentially affecting the reputation of the pharmaceutical industry and the Company." Company policy states that "political contributions are made to support the election of candidates, political parties and committees that support public policies important to the industry, such as innovation and access to medicines."

However, Pfizer's politically focused expenditures appear to be misaligned with the company's purpose, values and interests.

- Pfizer's fundamental purpose and legal duty, as a Delaware business corporation, are to maximize long-term shareholder value by deft development, production and sale of pharmaceuticals. Yet it has supported many candidates who support government-run single-payer or universal health-care programs that will stifle innovation and resources that support research and development, all while increasing taxes exponentially.¹ This will undermine Pfizer's long-term prospects.
- Pfizer's non-discrimination policy states that "[a]ll workplace decisions are made without regard to personal characteristics protected under applicable laws and Pfizer policy, including race, age, gender, religion, etc. We do not tolerate discrimination, harassment, or retaliation of any kind."² Yet it has supported many candidates and advocacy organizations that support legislation and regulation that would force Pfizer and other companies into facial discrimination against white and male employees, while demeaning the talents and responsibility of other employees.
- Pfizer opposes the "use of all forms of forced, bonded, indentured, or compulsory labor," and recognizes that "the risks of modern slavery are particularly likely where our business partners rely upon migrant workers," but it supports many candidates who

¹ https://cdn.pfizer.com/pfizercom/investors/corporate/2019-2020_Pfizer_PAC_and_Corporate_Political_Contributions_Report.pdf; <https://www.opensecrets.org/political-action-committees/pacs/pfizer-inc/C00016683/candidate-recipients/2020>; <https://www.congress.gov/bill/116th-congress/house-bill/1384/cosponsors>; <https://www.hhs.gov/sites/default/files/Reforming-Americas-Healthcare-System-Through-Choice-and-Competition.pdf>; <https://www.heritage.org/health-care-reform/report/the-real-price-public-health-plan-less-innovation-and-lower-quality>; <https://bigthink.com/videos/government-regulation-stifles-innovation>; <https://americansforprosperity.org/government-option-is-the-wrong-approach-to-health-care-at-the-2020-presidential-election/>; https://www.rand.org/pubs/research_reports/RR2424.html.

² <https://cdn.pfizer.com/pfizercom/about/Human-Rights-Policy-Aug-2020.pdf>.

have failed to support legislation that would end Uyghur forced labor and who fuel the vulnerable migrant worker problem here by opposing sensible border security.³

- Pfizer recognizes “the rights to a healthy environment, *life*, health, water and sanitation, and standard of living,” but it supports many candidates who oppose even minimal, common-sense pro-life policies to protect society’s most vulnerable members.

Proponents believe Pfizer should establish policies and reporting systems that minimize risk to the firm's reputation and brand by addressing possible missteps in corporate electioneering and political spending that contrast with its fundamental fiduciary purpose and stated policy objectives.

Proponents recommend that the report also contain management's analysis of risks to our company's brand, reputation, or shareholder value of expenditures in conflict with publicly stated company values. “Expenditures for electioneering communications” means spending, from the corporate treasury and from PACs, directly or through a third party, at any time during the year, which are reasonably interpretable as in support of or opposition to a specific candidate.

³ <https://www.rubio.senate.gov/public/index.cfm/2021/1/rubio-merkley-colleagues-re-introduce-uyghur-forced-labor-prevention-act>; <https://www.washingtonexaminer.com/opinion/the-new-guard-of-the-democratic-party-absolutely-supports-open-borders>; https://www.huffpost.com/entry/decriminalizing-border-crossing-democrats-2020_n_5d15884ee4b03d6116392906.

SANFORD J. LEWIS, ATTORNEY

PO Box 231
Amherst, MA 01004-0231
413 549-7333
sanfordlewis@strategiccounsel.net

January 24, 2022
Via electronic mail

Office of Chief Counsel
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Re: Shareholder Proposal to Pfizer Inc. Regarding Annual Report on Congruency of Political, Lobbying, and Electioneering Contributions on Behalf of Tara Health Foundation

Ladies and Gentlemen:

Tara Health Foundation (the “Proponent”) is beneficial owner of common stock of Pfizer Inc. (the “Company”) and has submitted a shareholder proposal (the “Proposal”) to the Company. I have been asked by the Proponent to respond to the letter dated December 21, 2022 ("Company Letter") sent to the Securities and Exchange Commission by Margaret M. Madden. In that letter, the Company contends that the Proposal may be excluded from the Company’s 2022 proxy statement.

I have reviewed the Proposal, as well as the Company Letter, and based upon the foregoing, as well as the relevant rules, the Proposal must be included in the Company’s 2022 proxy materials and that it is not excludable under Rule 14a-8. A copy of this letter is being emailed concurrently to Margaret M. Madden.

SUMMARY

Rule 14a-8(i)(10)

The proposal requests that Pfizer publish an annual report, at reasonable expense, analyzing the congruency of political, lobbying and electioneering expenditures during the preceding year against publicly stated company values and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have led to a change in future expenditures or contributions. (Full proposal attached as Appendix.)

The Company Letter asserts that the Company’s existing actions, consisting of the Company’s disclosures of its trade association support through an industry association webpage on the Company website, the Company’s alignment with its “most significant trade association memberships” on certain public policy positions, internal review of Company or Company PAC (“Pfizer PAC”) contributions, disclosures of the amount of PAC contributions, and acknowledgment of the *potential* for incongruities, constitutes substantial implementation of the Proposal. However, the company has fulfilled neither the guidelines nor the essential purpose of the proposal, and therefore the proposal is not excludable pursuant to Rule 14a-8(i)(10).

While Company publishes certain information regarding political contributions, it offers no annual analysis as requested by the proposal, of the board or management’s analysis of instances of incongruency of political and electioneering expenditures during the preceding year against publicly stated Company values and policies.

As demonstrated by the current controversies relevant to the Company's political contributions, such a congruency analysis by the management is quite distinct from the company's generic statement that the driving force behind the Company's political and electioneering expenditures is to "support candidates of both political parties who support policies that impact [the Company's] purpose: Breakthroughs that change patients' lives," or even in its acknowledgments that incongruities *may* happen.

The Company has neither implemented the guidelines nor essential purpose of the Proposal, and therefore the proposal is not substantially implemented.

Rule 14a-8(i)(11)

The proponent concedes that the previously submitted proposal can be viewed as duplicative with the current proposal. To the extent that the prior proposal will appear on the proxy, the proponent agrees that the current proposal need not also appear on the proxy.

ANALYSIS

I. **The Proposal is not excludable pursuant to Rule 14a-8(i)(10).**

The Company argues that the Proposal may be excluded from the 2022 Proxy Materials under Rule 14a-8(i)(10). The Company argues that its internal policies for review of congruency prior to granting of contributions, and its publication of the amount of contributions made, together with an acknowledgment of the potential for incongruities, and the general statements that the Company will "advocate for the trade association to come into alignment" and where "misalignment is egregious" and "membership benefits... are outweighed by the misalignments, [the Company] will *reduce* [emphasis added] or end involvement with the organization" constitutes substantial implementation of the Proposal.

For the Company to meet its burden of proving substantial implementation pursuant to Rule 14a-8(i)(10), it must show that its activities meet the guidelines and essential purpose of the Proposal. The Staff has noted that a determination that a company has substantially implemented a proposal depends upon whether a company's particular policies, practices, and procedures compare favorably with the guidelines of the proposal. *Texaco, Inc.* (Mar. 28, 1991). Substantial implementation under Rule 14a-8(i)(10) requires a company's actions to have satisfactorily addressed *both* the proposal's guidelines and its essential objective. See, e.g., *Exelon Corp.* (Feb. 26, 2010).

Thus, when a company can demonstrate that it has already taken actions that meet most of the guidelines of a proposal and meet the proposal's essential purpose, the Staff has concurred that the proposal has been "substantially implemented." In the current instance, the Company has substantially fulfilled *neither* the guidelines nor the essential purpose of the Proposal.

The Company's Letter notably focuses on whether it has implemented the Proposal's essential objectives, no doubt because its "particular policies, practices and procedures" do not compare favorably with the guidelines of the proposal.

A. **The Proposal requires analysis of the last year's incongruities and trade association donations**

At its core, the Proposal requests that the company publish an annual report analyzing the congruency of

political, lobbying, and electioneering expenditures during the preceding year against publicly stated company values and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have led to a change in future expenditures or contributions. The Proposal also includes further recommendation that such report contain management's analysis of risks to our company's brand, reputation, or shareholder value of expenditures in conflict with publicly stated company values. The Company has done nothing to publish such an analysis. Further, it does not substantially implement the Proposal for the company to only disclose trade associations supported by the company that are required to report certain nondeductible expenditures.

The Company Letter asserts that the Proposal is fulfilled by the publications on its website:

In addition, Pfizer publishes on its website an annual report titled the Pfizer PAC and Corporate Contributions Report (the "Political Contributions Report"), which lists the candidates and political committees supported by either Pfizer Inc. or the Pfizer political action committee (the "Pfizer PAC") and clearly explains Pfizer's rationale and motivation for making such political expenditures.

The Company Letter states that the Report indicates that the driving force behind Pfizer's political and electioneering expenditures is the "support [of] candidates from both political parties who value Pfizer's purpose to discover, develop and deliver breakthroughs that change patients' lives." This statement of the company's internal policy for deciding how to direct political contributions is not equivalent to a statement by management explaining glaring incongruities in donations, some of which might threaten to overwhelm the benefits to the company associated with company donations.

The Company Letter notes "Moreover, the Political Contributions Report acknowledges that politicians will have a range of views about policy that are both related and unrelated to Pfizer's business. While the Political Contributions Report identifies recipients of contributions who hold a diversity of political positions, it clearly states that contributions made to such recipients "[do] not imply an endorsement of a candidate's position on any social, or religious."

While this language might provide the equivalent of a fine print legal disclaimer, it does not negate or respond to investor concern about the existence and impact of incongruent contributions, nor the need for an annual assessment.

The Company mischaracterizes the essential purpose of the Proposal as ensuring that management is analyzing the congruencies between expenditures and corporate values. However, the essential purpose of the Proposal is to ensure *transparency* regarding such analyses. The Proposal is not satisfied by the current practice by which the Company makes seemingly incongruent contribution decisions behind closed doors, and then does not publicly acknowledge and assess the incongruencies.

A. Examples of Unexplained Incongruencies

While the Company may support politicians who advance company-supportive policies on some matters, if those same politicians are well known as leaders of policy initiatives that directly undercut company interests or values, investors may appropriately ask for an explanation of whether support for those individuals is appropriate and congruent and could reasonably seek explanation from management.

The Company implies that disclosing its internal review process and acknowledging the potential for incongruencies qualifies as implementation of the proposal's essential objective. But review of numerous unexplained political contributions which are in direct contrast to company policies and values demonstrates

the continued need of investors for the report sought by the proposal, signifying the need and value for an annual review to assess the extent of incongruencies, and to make midcourse corrections.

The attack on the Capitol and on democratic norms

Currently, a top issue for many US companies is whether their contributions to politicians have inadvertently supported the January 6 attack on the US Capitol, as well as the underlying attempt of some legislators to advance the Big Lie told by former President Donald Trump that the presidential election was stolen, despite extensive testing and rejection of that theory in the courts.

One report calculates that Pfizer gave \$405,500 to members of Congress who voted to challenge the electoral college vote.¹ The company's chief executive calling the events "deeply disturbing."² Numerous companies have stated that they are suspending political contributions in light of the recent developments³ and in an internal memo, the Company communicated that it would not donate, for at least six months, to the 147 members of Congress who voted against certifying the election results. However, following that period, the Company PAC has donated to at least six members of Congress who have yet to repudiate these unfounded claims of election fraud.

The National Association of Manufacturers, of which Pfizer is a member, also posted a statement encouraging removal of Trump from office and noting:

Armed violent protestors who support the baseless claim by outgoing president Trump that he somehow won an election that he overwhelmingly lost have stormed the U.S. Capitol today, attacking police officers and first responders, because Trump refused to accept defeat in a free and fair election. Throughout this whole disgusting episode, Trump has been cheered on by members of his own party, adding fuel to the distrust that has enflamed violent anger. This is not law and order. This is chaos. It is mob rule. It is dangerous. This is sedition and should be treated as such. The outgoing president incited violence in an attempt to retain power, and any elected leader defending him is violating their oath to the Constitution and rejecting democracy in favor of anarchy. **Anyone indulging conspiracy theories to raise campaign dollars is complicit.**⁴ [emphasis added]

In light of this statement by the Company's own trade association, the congruency analysis requested by the report seems an essential first step to making corrections in where its donations are directed.

Moreover, the same disinformation environment that is propagating false information about a stolen presidential election is also promoting misinformation about vaccines and may even be discouraging the public from getting vaccinated, even with the Company's vaccines. The proponent believes that the Company owes its investors a careful accounting as to whether it has inadvertently supported leaders of conspiracy theories that run against Company values and interests.

Health Insurance Coverage

Pfizer has stated that "Expanded access to health insurance coverage will help ensure that patients with under-diagnosed and undertreated conditions are able to address them; and that those who will benefit from Pfizer

¹ <https://mkus3lurbh3lbztg254fzode-wpengine.netdna-ssl.com/wp-content/uploads/Bankrolling-the-Disenfranchisers.pdf>

² <https://www.nytimes.com/2021/01/09/business/national-association-manufacturers-trump.html>

³ <https://www.nytimes.com/2021/01/11/business/dealbook/corporate-political-donations.html>

⁴ <https://www.nam.org/manufacturers-call-on-armed-thugs-to-cess-violence-at-capitol-11628/?stream=series-press-releases>

medicines are better able to have access to them." Yet the report *Conflicted Consequences* revealed that in 2018, Pfizer was a top contributor to a 527 organization that has been leading efforts to strike down the Affordable Care Act, which has made prescription drugs more accessible for millions of Americans.⁵

Access To Contraceptives and Abortion

Pfizer manufactures contraceptives and a drug commonly prescribed for use as an abortifacient. The contradictory and potentially self-defeating impact of Pfizer's support for anti-choice politicians has been noted in media coverage.⁶

Yet *Conflicted Consequences* notes that Pfizer was a top contributor to a 527 organization that funds state legislators' efforts to implement extreme anti-abortion measures. The 2019 report *Funding the Bans* estimated that Pfizer contributed at least \$206,725 to politicians and committees supporting extreme state-level abortion bans, including \$195,825 to the Republican State Leadership committee (2018), \$2500 to Georgia politicians (2017) and \$7,500 to Alabama politicians (2017, 2018).⁷

Medication-based abortion currently comprises roughly 41% of all abortions at 8 weeks' gestation or less.⁸ Cytotec, a Pfizer product is registered in more than 80 countries, was the first misoprostol product on the market and is the most widely available. Misoprostol stimulates strong contractions of the uterus, expelling the products of conception.⁹

The proponent estimates that in the 2016-2020 cycles, Pfizer and its employee PACs have made political donations totaling at least \$8.4 million to politicians and political organizations working to weaken women's access to reproductive health care.

Climate Change

Pfizer has committed to achieving science-based greenhouse gas reduction targets yet is a member of the U.S. Chamber of Commerce, which has consistently lobbied to roll back specific US climate regulations and promote regulatory frameworks that would slow the transition towards a lower-carbon economy. This raises questions about whether Pfizer is also supporting electioneering efforts that conflict with its environmental commitments.

Trade Associations

The trade associations that the company participates in and through which the company channels substantial funds for lobbying include the US Chamber of Commerce (\$383,000 in 2019) and PhRMA (\$2.7 million in 2019). Although these sums are disclosed on the company's website, the substantial likelihood that the US Chamber in particular engages in lobbying that contradicts the company's ostensible policy positions are quite substantial.

As the *Economist* notes:

⁵ <https://politicalaccountability.net/hifi/files/Conflicted-Consequences.pdf>

⁶ "These six corporations are financing the war on women in six states," *Popular Info*, May 20, 2019 at <https://popular.info/p/these-six-corporations-are-financing>.

⁷ https://equityfwd.org/sites/default/files/equity_forward_funding_the_bans_report_august_2019.pdf

⁸ Kaiser Family Foundation, Availability and Use of Medication Abortion, June 8, 2020.

⁹ Reproductive Health Supplies Coalition product brief.

In a letter to a Philip Morris executive just after he took over, Mr. Donohue [of the US Chamber of Commerce] said that small firms “provide the foot soldiers, and often the political cover, for issues big companies want pursued,” because Congress listens more to them than to big business.

That is not the only cover the Chamber provides. Oil and drug companies, among others, use it as a proxy through which to pursue their less popular causes anonymously, avoiding the pillorying they might incur if they spoke up directly.

Mr. Donohue...once told the Washington Monthly: ... “I want to give [members] all the deniability they need.”

The black-box nature of the Chamber makes deniability easier. As a 501(c)(6) nonprofit, it has to list all donations over \$5,000 but not the names of the givers. Its latest tax filing, for 2010, includes dozens of pages of individual contributions, each with a blank in the “name” field. (Only a handful of companies have voluntarily published their contributions.) Donations of \$1m or more accounted for over half of total contributions, suggesting that large firms dominate its funding.¹⁰

Concerns have been raised regarding positions taken by trade organizations that contradict an individual company’s policy positions, espoused values and public profiles. For instance, companies may assert they are giving priority to solving climate change, while simultaneously supporting trade groups that oppose legislative or regulatory climate change solutions. A pharmaceutical company like Pfizer may find that by supporting the US Chamber of Commerce, they are indirectly lobbying in defense of tobacco even though such positions undermine public health.

Last year a similar proposal voted on at the Company’s AGM received 47% support of the Company’s shareholders – so a vast number of shareholders agree with this concern.

A. The Company’s existing reports do not fulfill the Proposal

The existing reports from the Company do not analyze the incongruity of these exemplary donations. Proponents believe that Pfizer should establish policies and reporting systems that minimize risk to the firm's reputation and brand by providing an accounting of any possible missteps in corporate electioneering and political spending in the prior year that are in contrast to its stated healthcare and environmental objectives and ensuring midcourse corrections when needed.

Under the framework of the Proposal, it does not rest with the Proponent to determine which donations were incongruent; rather it rests with the company to explain the incongruity of specific donations, and what overriding considerations cause it to provide donations despite incongruent voting records of some donation recipients.

The Proponent believes that these examples illustrate that while the Company may have put in place evaluation procedures in advance of making political contributions, the Company has not implemented the needed publication of an analysis explaining its assessments of congruency and whether and where it is making exceptions in contributions between its stated values priorities and the contributions to political candidates and campaigns.

Review of Staff precedents confirms that failure to publish a core analysis requested by a

¹⁰ <http://www.economist.com/node/21553020>

Proposal, especially on political contributions precludes substantial implementation

The Staff has confirmed repeatedly that proposals will not be excluded despite a claim of substantial implementation if a core analysis requested by the proposal has not been performed and published.

The courts have long acknowledged the challenges posed by the corporate form that board and management might use the corporate treasury to advance their own political predilections, and therefore the right of shareholders to weigh in and demand transparency. For instance, in *Medical Committee for Human Rights v. SEC*, 432 F.2d 659 (D.C. Cir. 1985) in which the D.C. Circuit Court found that shareholder proposals are proper (not ordinary business) when they raise issues of corporate social responsibility or question the unaccountable exercise of "political and moral predilections" of board or management in the management of the company.

In more recent years, this responsibility and right of shareholders was amplified and echoed by Justice Anthony Kennedy in *Citizens United*, who described the need and potential for shareholders to hold their companies accountable for misdirected corporate political spending. The *Citizens United* majority wrote that the rights of shareholders dissenting to political spending by board and management would be protected "through the procedures of corporate democracy." *Citizens United*, 558 U.S. 310 (2010).

Since *Citizens United*, institutional and individual investors and coalitions have recognized their responsibility to monitor political spending transparency and to demand disclosure across all publicly traded companies. A rulemaking petition to the SEC for standardized mandatory disclosure of corporate political spending, including disclosure of trade association funding and other lobbying initiatives, received a record level of support: more than 1.2 million comment letters have been submitted on the petition, the vast majority in support of the proposed rule.¹¹

Key precedent: CVS Health Corporation

A key staff precedent is *CVS Health Corporation* (February 9, 2015, recon denied, March 23, 2015) where the company made similar assertions on a very similar proposal requesting a report on congruency between the corporate values and electioneering contributions. CVS had asserted that the Company's existing disclosures would allow shareholders to assess for themselves the issues of congruency should they choose to. ***Proponents successfully argued that since the essential purpose of the Proposal is for the management to publish its own analysis of the congruency of its donations and to explain the exceptions made, the Company's actions fail to constitute substantial implementation for purposes of Rule 14a-8(i)(10). The same is true in the present instance.***

Strict scrutiny of substantial implementation in proposals on political contributions

The staff has used rigorous standards in assessing substantial implementation on proposals relating to political contributions and lobbying, because these are issues that are of major concern to many investors and are implicated by *Citizens United* as issues meriting engagement through the "instruments of shareholder democracy."

Investors have frequently asserted in recent years that considering the Supreme Court ruling in *Citizens United v. Federal Election Commission*, and ongoing public backlash against corporate political

¹¹ <https://corpgov.law.harvard.edu/2014/09/04/the-million-comment-letter-petition-the-rulemaking-petition-on-disclosure-of-political-spending-attracts-more-than-1000000-sec-comment-letters/>

spending, disclosure of how companies are managing these issues and risks of merits rigorous and comparable disclosure for shareholders to assess potential exposure to risks caused by our future electioneering contributions.

The Staff has previously rejected numerous efforts by companies to claim substantial implementation of political spending disclosure proposals when the companies had only prepared disclosures that partially fulfilled the requests. For example, see *NextEra Energy, Inc.* (February 24, 2020); *Exxon Mobil Corp.* (April 2, 2019); *Goldman Sachs Group, Inc.* (March 14, 2013); *EQT Corp.* (January 23, 2013); *NIKE Inc.* (July 5, 2012); *Southwestern Energy Co.* (March 15, 2011); *The Boeing Co.* (February 14, 2011); *Citigroup Inc.* (March 9, 2007); *Bristol-Myers Squibb Co.* (February 18, 2005); *Exxon Mobil Corp.* (March 5, 2004); *Wells Fargo Co.* (February 11, 2004).

The decision in *Southwestern Energy* (March 15, 2011) illustrates why the Company cannot successfully assert substantial implementation without meeting the Proposal's disclosure guidelines. Southwestern Energy had asserted substantial implementation of a political contributions disclosure proposal that followed a similar model to the current Proposal, including accounting of direct and indirect expenditures. However, Southwestern Energy only disclosed direct expenditures and therefore the SEC Staff found that the proposal was not excludable. Similarly, in the present case, the Company's reporting does not fulfill the request of the proposal to create an annual report "...explaining instances of incongruent expenditures and stating whether the identified incongruencies have led to a change in future expenditures or contributions."

Failure of the Company to provide a coordinated and comprehensive disclosure is a basis for finding lack of substantial implementation. The Company's current reporting model requires anyone who wishes to obtain information on the Company's lobbying expenditures to search out the information on various websites on the Internet, and thereby gather the information that would be contained in a report requested by the Proposal.

The Company cites *General Electric* (February 24, 2011) in support of exclusion, but in that case the company had addressed the essential objective of each guideline of the proposal regarding lobbying activities through public disclosures on its own website. General Electric successfully argued for reconsideration, because it was able to go through each of the points in the proposal and show how it had been essentially implemented. This is not the case with the current Proposal, where the Company has not provided the information on its website for at least two of the four elements of the Proposal. Thus, the present matter is more like *Nike, Inc.* (July 5, 2012) where Nike's failure to provide a breakdown of itemized political contributions, as was requested in that proposal, led the SEC Staff to find that the company had not substantially implemented the proposal.

Many other Staff precedents demonstrate the need for a company to do more than report on its policies or expenditures where the guidelines of the proposal and essential purpose require more.

For instance, in *McDonalds Corp.* (March 14, 2012) the proposal requested the board issue a report assessing the company's policy responses to growing evidence of linkages between fast food and childhood obesity, diet related diseases and other impacts on children's health. The proposal also specified that the report should include an assessment of the potential impacts of public concerns and evolving public policy on the company's finances and operations. The company's substantial implementation argument was rejected, even though the company may have internally or implicitly conducted some of the assessments requested by the Proposal. Its reporting to shareholders did not fulfill the guidelines of the Proposal in disclosure of an assessment.

Another example shows that publishing related information from which shareholders might undertake their own analysis is not equivalent to publishing the requested analysis. In *Verizon Communications, Inc.* (February 5, 2013) the proposal requested that the company's board of directors' report on how Verizon is responding to regulatory, competitive, legislative and public pressure to ensure that its network management policies and

practices support network neutrality, an Open Internet and the social values described in the proposal. Even though the company was able to cite a variety of internal management policies located on its website regarding net neutrality, the actions reported did not include the requested analysis by the board directed to shareholders.

Similarly, in *Alpha Natural Resources, Inc.* (March 19, 2013) the proposal requested that the company prepare a report on the company's goals and plans to address global concerns regarding fossil fuels and their contribution to climate change, including analysis of long- and short-term financial and operational risks to the company and society. The Staff did not find substantial implementation where the company had failed to disclose any analysis of long and short term financial and operational risks to the company and society.

In addition, numerous other companies' attempts to exclude proposals under Rule 14a-8(i)(10) have failed where the companies have provided public disclosure of some, but not all, of the elements of reporting requested. See for instance *Marathon Oil Corporation* (January 22, 2013); *Dominion Resources, Inc.* (February 28, 2014), and *NIKE, Inc.* (July 5, 2012) (requesting reports on lobbying or political contributions and expenditures).

The Company Letter cites a series of precedents for finding substantial implementation of a proposal that addresses the issues in a proposal but in a manner that fall short of what is requested by the proposal. Examination of the most relevant of precedents cited by the company demonstrates that they are inapposite, due to the facts of the cases.

Notably, the Company cites a Staff decision from 2020 in which it was allowed to exclude a proposal on substantial implementation grounds. In *Pfizer Inc.* (Jan 31, 2020) the Staff allowed exclusion (without issuing a written decision) of a proposal requesting that Pfizer Inc.'s Board adopt a disclosure policy that provides a description of the specific minimum qualifications that the Board's nominating committee believes must be met by a nominee to be on the Board of Directors and discloses each nominee's skills, ideological perspectives, and experience presented in a chart or a matrix form.

In that prior ruling, the company's argument that the proposal was substantially implemented was based on the Company's Corporate Governance Principles ("the Principles") and a definitive proxy statement listed on their website. The materials included a description of the specific minimum qualifications that the Board committee believed must be met by a nominee – thereby satisfying the first prong. Secondly, Section 6 of the Principles, known as Selection Criteria, expressed the Board's view that the selection should ensure that the Board, "maintains its diverse composition, with diversity reflecting gender, age, race, ethnicity, background, professional experience and perspectives." Further, the Proxy statement discloses in chart and graphical form information regarding each nominee's skill set and experience. These attributes include experiences in government and public policy – satisfying the second prong.

Thus, the company in that instance had fulfilled the guidelines and essential purpose of the proposal to provide particular and descriptive materials regarding criteria for diversity and background on its board members.

In contrast, here, the Company has not fulfilled the guidelines constituting the essential purpose of the current proposal for an annual congruency assessment.¹²

¹² Similarly, in *Johnson & Johnson*. (Jan 31, 2020) the Staff allowed exclusion (without a written decision) of the same proposal on essentially the same basis. Company's Principles of Corporate Governance and definitive proxy statement listed on their website. These materials state:

1. General Criteria for Nomination to the Board of Directors of Johnson & Johnson - This satisfies the first prong.
2. The Proxy statement discloses information about the Board's current composition in graphical representations disclosing certain elements of diversity and disclosing director skills and experiences, including, "International business

Rule 14a-8(i)(11)

The proponent concedes that the previously submitted proposal can be viewed as duplicative with the current proposal. To the extent that the prior proposal will appear on the proxy, the proponent agrees that the current proposal need not also appear on the proxy.

CONCLUSION

The Company has not met its burden that the Proposal is excludable under Rule 14a-8(i)(10). Therefore, we request that the Staff inform the Company that the SEC proxy rules require denial of the Company's no-action request unless the previously submitted proposal appears on the proxy.

Please call me at (413) 549-7333 with respect to any questions in connection with this matter, or if the Staff wishes any further information.

Sincerely,


Sanford Lewis

cc: Margaret M. Madden

APPENDIX

THE PROPOSAL POLITICAL CONTRIBUTIONS MISALIGNMENT

Whereas:

Pfizer policy states that “political contributions are made to support the election of candidates, political parties and committees that support public policies important to the industry, such as innovation and access to medicines.”

However, Pfizer's political expenditures appear to be misaligned with the company's values and interests.

- In January 2021, an internal Pfizer memo communicated that the company would not donate for at least 6 months to the 147 members of Congress who voted against certifying the election results. Following that period, Pfizer PAC has donated to at least six, none of whom has repudiated claims of election fraud.
- Pfizer has stated that “Expanded access to health insurance coverage will help ensure that patients with under-diagnosed and undertreated conditions are able to address them; and that those who will benefit from Pfizer medicines are better able to have access to them.” Yet in 2018, Pfizer was a top contributor to a 527 organization leading efforts to strike down the Affordable Care Act, which has made prescription drugs more accessible for millions, and contributes to PhRMA, which donates to numerous organizations opposing congressional efforts to reform drug pricing.
- Pfizer manufactures contraceptives and a drug commonly prescribed as an
 - abortifacient. Yet Pfizer has been a top contributor to a 527 organization that funds state legislators’ efforts to implement extreme anti-abortion measures. The proponent estimates that in the 2016-2020 election cycles, Pfizer and its employee PACs have donated at least \$8.4 million to politicians and political organizations working to weaken women’s access to reproductive health care.
- Pfizer has set science-based greenhouse gas reduction targets yet is a member of the U.S. Chamber of Commerce, which has consistently lobbied to roll back specific US climate regulations and promote regulatory frameworks that would slow the transition towards a lower-carbon economy. This raises questions about whether Pfizer is also supporting electioneering efforts that conflict with its environmental commitments.

Proponents believe that Pfizer should establish policies and reporting systems that minimize risk to the firm's reputation and brand by addressing possible missteps in corporate electioneering and political spending that contrast with its stated healthcare and environmental objectives.

Resolved:

Pfizer publish an annual report, at reasonable expense, analyzing the congruency of political, lobbying, and

electioneering expenditures during the preceding year against publicly stated company values and policies, listing and explaining any instances of incongruent expenditures, and stating whether the identified incongruencies have led to a change in future expenditures or contributions.

Supporting Statement:

Proponents recommend that such report also contain management's analysis of risks to our company's brand, reputation, or shareholder value of expenditures in conflict with publicly stated company values. "Expenditures for electioneering communications" means spending, from the corporate treasury and from the PACs, directly or through a third party, at any time during the year, on printed, internet or broadcast communications, which are reasonably susceptible to interpretation as in support of or opposition to a specific candidate.